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Introduction. COL5A1 encodes the α1 chain of type V collagen, a minor fibrillar 
collagen that is an important regulator of collagen fibril assembly. A polymorphism 
(rs12722, C/T) within the 3’-untranslated region (UTR) of COL5A1 is associated with 
chronic Achilles tendinopathy (TEN) and other soft tissue injuries as well as 
exercise-related phenotypes. These phenotypes are directly or indirectly associated 
with the mechanical properties of musculoskeletal soft tissue. It has therefore been 
hypothesised that variants in the COL5A1 gene, specifically the 3’-UTR, regulate 
synthesis of the α1(V) chain and type V collagen production. Type V collagen levels 
in turn regulate fibril architecture and structure and, thereby, mechanical properties 
of musculoskeletal soft tissues. Although the 3’-UTR of many eukaryotic genes have 
been shown to play an important regulatory role, the function of the COL5A1 3’-UTR 
is currently unknown.  
 
Aim. The primary aim of this thesis was therefore to determine whether the COL5A1 
3’-UTR was functional and to identify functional differences between the COL5A1 3’-
UTR cloned from participants with TEN and healthy asymptomatic control 
individuals. The secondary aim was to start mapping the functional regions within the 
3’-UTR, focusing on regions which are potentially responsible for contributing to the 
tendinopathic phenotype.  
 
Methods. The entire 2.5 kb COL5A1 3’-UTR from 5 TEN, with a ‘severe’ TEN 
phenotype, and 5 control participants were cloned downstream of a luciferase 
reporter gene. These constructs were sequenced and co-transfected into HT1080 
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cells together with an internal control. Luciferase activity was measured as an 
indication of mRNA stability. To map the region(s) involved with the tendinopathic 
phenotype, deletion constructs were generated and assayed. In addition, 160 
Caucasian TEN and 342 control participants were genotyped for newly annotated 
COL5A1 3’-UTR markers rs71746744, rs16399 and rs1134170 within the functional 
region identified. Site-directed mutagenesis of rs71746744 and rs12722 was used to 
further map the area potentially responsible for the tendinopathic phenotype. 
Moreover, skin biopsies were taken from participants having a known genotype at 
rs12722. Primary fibroblast cell lines were cultured, RNA extracted and cDNA 
obtained for Q-RT-PCR in order to quantify COL5A1and COL1A1 expression levels. 
Lastly, in preliminary RNA electrophoretic mobility shift assays (EMSAs), biotinylated 
C- and T-allelic RNA probes for a specific 57bp functional region were incubated with
either nuclear or cytoplasmic protein extracts from HT1080 cells in order to 
investigate putative distinguishing RNA:RBP complex formation. 
Results. When all the cloned COL5A1 3’-UTRs were sequenced, two major forms 
were identified. One form (termed the C-allelic form) was predominantly identified in 
the controls and the other (the T-allelic form) in tendinopathic participants. The C- 
and T-allelic forms were distinguished by the previously associated rs12722 (C/T) 
and an additional six polymorphisms which spanned the 3’-UTR namely, rs13946 
(C/T), rs3196378 (C/A), rs71746744 (-/AGGG), rs16399 (ATCT/-), rs1134170 (A/T) 
and rs3128575 (T/C). Although the 3’-UTR of both the C- and T-allelic forms were 
functional, the luciferase activity of the C-allelic form (69.0 ± 22.0%, N=24) was 
significantly lower (p<0.001) than the T-allelic form (90.6 ± 13.7%, N=30). This 
suggests an overall increase in mRNA stability for the T-allelic form of COL5A1 3’-
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UTR. Furthermore, an overall increased relative mRNA expression of both COL5A1 
(1.58 ± 0.89 arbitrary units, p<0.001, N=14) and COL1A1 (1.88 ± 1.10 arbitrary units, 
p=0.0015, N=13) were observed in primary skin fibroblasts donated from participants 
having a COL5A1 TT genotype at rs12722 compared with those with the CC 
genotype (COL5A1: 0.57 ± 0.19, N=12 and COL1A1: 0.67 ± 0.29, N=12). 
Furthermore, using deletion constructs, additional elements which may regulate 
COL5A1 mRNA stability were identified. Specifically the analysis of constructs 
containing a 57bp deletion within the 3’-UTR, where rs71746744 (-/AGGG) was 
removed, revealed that there was no significant difference (p = 0.440) in the relative 
luciferase activity of the C-allele (144.2 ± 28.1%, N=9) and the T-allele (156.5 ± 
42.5%, N=18). This suggests that this region was, at least in part, responsible for the 
observed difference in mRNA stability between the C- and T-allelic forms. In addition 
to rs71746744 (-/AGGG), this region contained several putative RNA protein binding 
sites and the downstream flanking sequence contained rs16399 (ATCT/-) and 
rs1134170 (A/T). All three genetic markers were independently associated with 
chronic Achilles tendinopathy and in linkage disequilibrium (D’ ≥ 0.871). Specifically 
the AGGG/AGGG (p=0.008, odds ratio (OR)=2.0, 95% confidence interval (CI)=1.2-
3.3), -/- (p=0.015, OR=1.7, 95% CI=1.1- 2.7) and TT (p=0.011, OR=1.8, 95% CI=1.2-
2.9) genotypes of rs71746744, rs16399 and rs1134170, respectively, were 
associated with increased risk of TEN. Although both the rs71746744 and rs12722 
variants appeared to be functional, they did not independently contribute to the 
tendinopathic phenotype. However, a putative RNA-binding protein complex was 
identified within the 57bp deleted region of the C-allelic, but not the T-allelic, form.  
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Conclusion. Two major functional forms of the COL5A1 3’-UTR were identified. The 
T-allelic form, which has a high mRNA stability, was predominately associated with
the tendinopathic individuals, while the C-allelic form was associated with the 
asymptomatic controls. A region responsible for differences in the mRNA stability 
between the C- and T-allelic forms was mapped to a 57bp region. Three 
polymorphisms within and downstream of this region were shown to be 
independently associated with chronic Achilles tendinopathy. A putative RNA-binding 
protein complex was identified within the 57bp region of the C-allelic form. These 
novel results have important implications for our understanding of the molecular 
basis of musculoskeletal soft tissue injuries and other exercise-related phenotypes. 
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CHAPTER 1 LITERATURE REVIEW 
1.1 Introduction 
The COL5A1 gene encodes for the α1 chain of type V collagen, a quantitatively 
minor fibrillar collagen which plays an important role in fibril assembly and lateral 
growth in skin, tendons, ligaments and other connective tissues (Birk et al., 
1990;Wenstrup et al., 2004). Type V collagen also plays an important role in tendon 
development (Roulet et al., 2007;Wenstrup et al., 2004). Although very little is 
currently known about its regulation, COL5A1 is essential for life and its altered 
expression has a critical impact on both embryonic development and disease 
(Lincoln et al., 2006;Roulet et al., 2007;Segev et al., 2006). This is further 
demonstrated by observations that Col5a1 null mice die in utero (Wenstrup et al., 
2004;Wenstrup et al., 2006), since it is involved in the formation of a number of vital 
tissues and organs including, but not limited to, the heart, skin, bones, vertebral 
column, tendons, ligaments and the cornea of the eye (reviewed by Gelse et al., 
2003;Kadler et al., 2007).  
Moreover, rare mutations within COL5A1 cause the classic form (types 1 and 2) of 
the Ehlers-Danlos syndrome (EDS) which is a severe heritable autosomal dominant 
connective tissue disorder characterised, amongst other clinical symptoms, by joint 
hypermobility and major skin and musculoskeletal soft tissue defects (Beighton et al., 
1998;Malfait et al., 2010;Wenstrup and De Paepe, 1993). In a murine model, 
haploinsufficiency of Col5a1 causes features of the severe EDS phenotype such as 





al., 2006). Given that having only one functional copy of this gene can drastically 
alter the phenotype of these connective tissues, it has been postulated that 
polymorphisms within regulatory regions, such as the 3'-untranslated region (UTR) of 
COL5A1 may alter type V collagen production, fibrillogenesis and the mechanical 
properties of musculoskeletal soft tissues such as tendons (Collins and Posthumus, 
2011). This “normal” biological variation within the mechanical properties of these 
tissues have been proposed, at least in part, to explain the inter-individual variation 
in susceptibility to occupational and physical activity associated musculoskeletal soft 
tissues injuries and other related multifactorial phenotypes (Collins and Posthumus, 
2011).  
 
Indeed, a common polymorphism (rs12722, C/T) within the 3'-UTR of COL5A1 have 
been associated with several musculoskeletal soft tissue injuries (Abrahams et al., 
2013;Burger et al., 2014;Mokone et al., 2006;Posthumus et al., 2009;September et 
al., 2009), exercise-associated muscle cramps (O'Connell et al., 2013), range of 
motion measurements (Abrahams et al., 2014;Brown et al., 2011;Collins et al., 2009) 
and endurance running performance (Abrahams et al., 2014;Brown et al., 
2011;Posthumus et al., 2010). The 3’-UTR of eukaryotic genes is described as a 
zone rich in diverse translational control mechanisms (reviewed by Mazumder et al., 
2003) and is an area where polymorphisms can influence the mRNA stability and 
gene expression (Akai et al., 1999;Conne et al., 2000;Wang et al., 2008). Mazumder 
et al. (2003) described this region of a gene as holding promises for the future 






This thesis will examine the proposed function of polymorphisms within the COL5A1 
3’-UTR on the aetiology of musculoskeletal soft tissue injuries, specifically chronic 
Achilles tendon overuse injuries (tendinopathy), and other exercise-associated 
phenotypes at the molecular, as well as cellular levels. This review will focus on key 
areas relevant to this thesis. 
 
1.2 Musculoskeletal Soft Tissue Injuries 
 
Musculoskeletal soft tissues (tendons, ligaments and skeletal muscle) are common 
structures that can be injured as a result of participating in competitive and 
recreational physically activities (reviewed by Collins and Raleigh, 2009;Kannus, 
1997), as well as, activities in the workplace; especially where cumulative and 
repetitive motion is involved (reviewed by Barr and Barbe, 2002;Yassi, 2000). 
Chronic overuse injuries can occur in the tendons of both the lower and upper limbs 
(tendinopathy) and are characterized by a painful tendon less capable of sustaining 
repeated tensile load, a decreased exercise tolerance of the tissue and a reduction 
in its function (Cook and Purdam, 2009). As much as 50% of all sporting injuries 
involve tendons and a fifth of these affects the Achilles tendon (reviewed by Jarvinen 
et al., 2005;Kujala et al., 2005;Rees et al., 2006). Among running-related 
musculoskeletal injuries (reviewed by Lopes et al., 2012), Achilles tendinopathy is 
one the three most frequently reported injuries (incidence ranging from 9.1% to 
10.9%; prevalence ranging from 6.2% to 9.5%), together with medial tibial stress 
syndrome, commonly known as shin splints, and plantar fasciosis (jogger’s heel). 
Together with patellofemoral syndrome (runner’s knee), Achilles tendinopathy is also 





(prevalence ranging from 2.0% to 18.5%). The prevalence of Achilles tendon injuries 
appears to be increasing globally, with nearly 825 000 runners in the United States 
alone estimated to present with Achilles tendon injuries during 2004 (Albers and 
Hoke, 2003).  
 
In addition, chronic Achilles tendinopathy is not limited to physically active 
populations but also experienced by sedentary individuals (Jarvinen et al., 
2005;Rees et al., 2006). This observation is conceivably linked to the higher 
prevalence of overweight, obesity and metabolic diseases (World Health 
Organisation, 2014) within the sedentary population. Body composition and several 
systemic diseases are risk factors for Achilles tendinopathy (Gaida et al., 2009;Gaida 
et al., 2010;Magnan et al., 2014). These may operate by causing structural changes 
in the tendon matrix (Geyer, 2005;Wearing et al., 2013). In addition, although not 
ascertained in Achilles tendinopathy, changes in tendon properties as a result of 
periods of inactivity (Kubo et al., 2004), e.g. stress-shielded during periods of bed 
rest or spaceflight, suggest that sedentary behaviour may compromise the inherent 
ability of the tendon to sustain a normal or unaccustomed load. 
 
Acute and chronic musculoskeletal soft tissue injuries often result in reduced 
functional capacity in the workplace and significant loss of athletic performance 
amongst affected individuals (Ljungqvist et al., 2008). This is because these injuries 
(1) are often resistant to treatment, (2) recur and/or (3) are risk factors for other 
orthopedic injuries (reviewed by Collins and Raleigh, 2009;Rees et al., 2006). 
Although increasing population-wide participation in physical activity is a major 
health priority to reduce the increasing burden of non-communicable diseases on 
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society (Bangsbo et al., 2014;Matheson et al., 2013), musculoskeletal soft tissue 
injuries are a recognised adverse effect of being physically active (Abate et al., 
2009;Verhagen, 2012). Prevention of these injuries therefore appears to be a 
reasonable long-term strategy which will require an understanding of the molecular 
mechanisms underpinning them. Although they have been described at the clinical 
level, the biological and molecular mechanisms causing these injuries are however 
currently poorly understood. An understanding of the basic structure of the Achilles 
tendon is necessary to understand molecular mechanisms and will be summarised in 
the following section, followed by a brief summary of the common pathologies that 
affect this tendon and surrounding tissues. 
1.3 Structure of the Achilles tendon 
The Achilles (or calcaneal) tendon is the largest and strongest tendon within the 
human body (Jarvinen et al., 2001). It attaches the gastrocnemius as well as the 
soleus muscles, commonly known as the calf muscles, to the calcaneus bone 
posteriorly (the heel bone) (Figure 1.1). The Achilles tendon is responsible for 
transmitting forces generated in the calf muscles to the calcaneus permitting walking, 
running and jumping, as well as stabilizing the ankle-joint and maintaining balance 
(reviewed by Wang, 2006). The point of union of the tendon with the bone is referred 
to as the enthesis or osteotendinous junction and its attachment to the muscle is 
termed the myotendinous junction as described by Kannus (2000). This tendon is 
able to resist extreme forces since it can experience up to 12.5 times of the body 
weight during bouts of running (reviewed by Wang, 2006). Unlike other tendons, the 
Achilles tendon does not have a true synovial sheath but it is covered by a paratenon 
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(reviewed by Asplund and Best, 2013). The paratenon is essentially a loose fibrillar 
tissue, consisting mainly of types I and III collagen, as well as elastin fibres, which 
acts as an elastic sleeve and serves the same role as a tendon sheath to reduce 
friction and facilitate tendon gliding.  
Lastly, there is the presence of a protective fibrous sac, the bursa, cushioning in 
areas where bony protrusions might compress or damage the sliding tendon. The 
bursa has a synovial membrane that secretes synovial fluid (reviewed by Kannus, 
2000). The Achilles tendon has a subtendinous, also known as the retrocalcaneal 
bursa, and a subcutaneous bursa. Its subtendinous bursa is located between the 
Achilles tendon and the calcaneus (heel bone), whereas the subcutaneous bursa is 
positioned between the skin and the posterior aspect of the Achilles tendon, by the 
enthesis (Figure 1.1) (reviewed by Asplund and Best, 2013). The Achilles tendon is 
innervated by nerves attached to the nearby muscles or cutaneous nerves such as 
the sural nerve (Bjur et al., 2005). The insertions and mid-section of the Achilles 
tendon receive blood through the well vascularised paratenon and the attached 
muscles. It is unclear whether the blood supply is uniformly distributed throughout 
the tendon; however the mid-section is believed to have the least vascularisation 
(reviewed by Theobald et al., 2005).  
Tendon tissue is a dynamic structure which is capable of responding to mechanical 
forces by changing its metabolism as well as its structural and mechanical 
properties. The structure and physiology of tendons have been extensively reviewed 
(Kannus, 2000;O'Brien, 1997;Silver et al., 2003;Wang, 2006) and will be briefly 
described in the following paragraphs.  
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Figure 1.1 Lateral and posterior view of the lower leg, indicating the position of the Achilles 
tendon (bold) modified from Asplund and Best (2013). The Achilles tendon attaches to the 
gastrocnemius and the soleus muscles (the calf muscles) and the calcaneus bone (the heel 
bone). The position of the bursae associated with the tendon is also indicated. 
The midsubstance of the tendon is composed predominately of collagen and elastin 
fibres which make up 65-80% and about 2% of the dry mass of the tendon 
respectively as well as non-fibre forming proteins embedded in a gel-like medium 
known as the ground substance (Kannus, 2000). The ground substance is a complex 
mixture of glycoproteins, proteoglycans, water and mineral salts (O'Brien, 1997). The 
collagen fibres are made up of collagen fibrils, which are the smallest functional unit 
of the tendon (O'Brien, 1997), and they in turn consist predominately of type I 
collagen and other quantitatively minor collagen types (Figure 1.2). The collagen and 
elastin fibres, as well as the ground substance and non-fibre forming proteins, are 
produced by tenoblasts (younger cells, highly metabolically active) and tenocytes 





between the fibre bundles, are elongated fibroblasts and fibrocytes responsible for 
the secretion and maintenance of all the components of the extracellular matrix 
(ECM).  
 
Each collagen fibre is surrounded by a thin connective tissue sheath called the 
endotenon. The individual fibres form primary (subfascicle), secondary (fascicle) and 
tertiary bundles each delineated by the endotenon. The tendon, which is surrounded 
by a layer of connective tissue called the epitenon, is a collection of tertiary bundles 
(Figure 1.2). The endotenon is a thin reticular network of connective tissue while the 
epitenon is comprised of relatively dense fibrillar network of collagen. Both of these 
tissues provide a vascular, lymphatic and nerve supply to the tendon (Wang, 2006). 
 
There are a number of acute or chronic pathologies that can affect the insertional or 
non-insertional (mid-substance or mid-portion) regions of the Achilles tendon as well 
as its surrounding tissues and these have been extensively reviewed (Asplund and 
Best, 2013;Cook et al., 2002;Jarvinen et al., 2005;Magnan et al., 2014). In summary, 
acute injuries include partial and complete ruptures of the tendon (Jarvinen et al., 
2005;Kannus and Natri, 1997) while inflammation of the surrounding tissues includes 
paratenonitis and bursitis (Jarvinen et al., 2001;Kannus, 1997;Schepsis et al., 
2002;Weinfeld, 2014). Chronic degeneration of the tendon (Kannus, 1997) is 
referred to as tendinosis and can be detected by ultrasonography or magnetic 
resonance imaging (Asplund and Best, 2013). Because of the different pathologies 
within and around the tendon, a clinical diagnosis of pain, swelling, stiffness and/or 
weakness of the Achilles tendon is generally referred to as Achilles tendinopathy 





tendinopathy (TEN) has been used and implies a painful chronic condition of the 





Figure 1.2 A schematic diagram representing the hierarchical structure of the tendon unit 
(modified from Wang, 2006). The collagen fibrils, made up of highly organised and packed 
tropocollagen molecules (about 280 nm in size with a D-period of about 67 nm – see section 
1.5), are assembled into collagen fibres. These in turn will be grouped into primary fibre 
bundles called subfascicles, and those into secondary fibre bundles called fascicles. 
Collections of these fascicles will make tertiary bundles a component of the tendon unit. The 
subfascicle, fascicle and tertiary bundle will each be enveloped by the endotenon, and the 
final tendon unit wrapped with the epitenon. The relative size of each component of this 
organisation is indicated in the diagram. 
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1.4 Risk factors and Models of Pathology for Tendinopathy 
The exact biological mechanisms that cause tendinopathies are poorly understood 
but the following theories have been proposed: the mechanical theory, vascular 
theory, the ‘neurogenic’ hypothesis, the iceberg theory and the pathology continuum 
theory. While the mechanical theory argues that repetitive mechanical loading within 
the normal thresholds in the tendon may cause fatigue, damage to the fibres and 
ultimately tendon failure (Arnoczky et al., 2007;Rees et al., 2006;Wren et al., 2003), 
the vascular theory puts forward that a compromised vascular supply to the tendon 
impacts negatively on the metabolism of the tendon cells (Fenwick et al., 
2002;Langberg et al., 1998). The ‘neurogenic’ hypothesis asserts that several 
neurotransmitters and mediators in the tendon play an important role in the aetiology 
of tendinopathy (Alfredson et al., 1999;Alfredson et al., 2000;Alfredson et al., 
2001;Andersson et al., 2008;Bjur et al., 2005). 
In the iceberg theory, overload and prolonged repetitive strain of the tendon induce 
the production of pro-inflammatory mediators such as cytokines, prostaglandins, 
nitric oxide, growth factors and neuropeptides which in turn induce apoptosis, pain 
mediators and matrix remodelling agents resulting in a weakened tendon with an 
increased risk of injuries (Fredberg and Stengaard-Pedersen, 2008). Finally, the 
continuum model is a unifying model divided into three main states: (1) the ‘reactive 
tendinopathy’ which is a temporary adaptive and localised thickening of the tendon, 
(2) a ‘tendon dysrepair’ state reminiscent of a failed-healing process and (3) the
‘degenerative tendinopathy’, incorporating clinical, histological and imaging 





Several intrinsic and extrinsic (environmental) risk factors have been shown  to, or 
suggested to, associate with tendon injuries which are therefore considered to be 
multi-factorial (Kannus, 1997;Wren et al., 2001). Although the level of evidence and 
certainty varies, extrinsic risk factors for Achilles tendinopathy include physical 
activity, occupation, training errors, training or playing surfaces, footwear, 
environmental conditions, smoking, medication use (e.g. corticosteroids, 
fluoroquinolone antibiotics), nutrition and psychological factors (Figure 1.3). Intrinsic 
risk factors include gender, age, body mass and size, a previous Achilles tendon 
injury, reduced blood supply to the tendon, tendon temperature, lower limb 
malalignment, joint laxity and specific systemic diseases ( reviewed by Jarvinen et 
al., 2001;Magnan et al., 2014;Mokone et al., 2005) (Figure 1.3). Genetic 
polymorphisms have recently been identified as additional intrinsic risk factors for 
chronic Achilles tendinopathy and other musculoskeletal soft tissue injuries 
(reviewed by Ribbans and Collins, 2013). 
 
The intrinsic risk factors are believed to predispose individuals to injuries (Figure 1.3) 
(Bahr and Holme, 2003;Bahr and Krosshaug, 2005;Meeuwisse, 1994). It is argued 
that the susceptibility to an injury within the predisposed individual is determined by 
exposure to extrinsic risk factors. Through an inciting event, the susceptible 
individual may then sustain an injury or become symptomatic. Furthermore, many of 
the intrinsic risk factors are also in their own right multifactorial phenotypes, which 
are determined by an interaction of both genetic and non-genetic/environmental 
factors. As mentioned above and summarized in table 1.1, variants within several 
genes have been reported to be associated with chronic Achilles tendinopathy.   
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Figure 1.3 Model representing the role of the intrinsic factors in predisposing the individual 
to become susceptible to Achilles tendinopathy, modified from Meeuwisse (1994) and 
Ribbans and Collins (2014). Once an individual is predisposed by intrinsic factors, the 
susceptibility to Achilles tendinopathy is determined by exposure to extrinsic risk factors. 
Upon experiencing an inciting event, the susceptible individual may then sustain an injury. 
The intrinsic factors involved are multifactorial phenotypes determined by an interaction of 
both genetic (G, grey box) with or without environmental factors (E, clear box). 
Polymorphisms within COL5A1 (Abrahams et al., 2013;Mokone et al., 
2006;September et al., 2009), MIR608 (Abrahams et al., 2013), TNC (Mokone et al., 
2005;Saunders et al., 2013), FBN2 (El Khoury et al., In Press), MMP3 (Raleigh et al., 
2008), TIMP2 (El Khoury et al., 2013), GDF5 (Posthumus et al., 2010) and CASP8 
(Nell et al., 2012) have been reported to independently associate with chronic 
Achilles tendinopathy. The association of COL5A1 and MIR608 variants with chronic 
Achilles tendinopathy, other injuries and exercise-associated phenotypes will be 
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reviewed in detail in Section 1.7. The TNC gene, which is located 19.6Mbp upstream 
of COL5A1 on chromosome 9, encodes for the hexameric glycoprotein tenascin C. 
Tenascin C plays an important morphoregulatory role during development, tissue 
remodeling, and in disease by regulating cell adhesion as well as signaling (Jones 
and Jones, 2000). The protein is predominately expressed in regions responsible for 
transmitting high levels of mechanical force in healthy adult tendons (Chiquet and 
Fambrough, 1984;Chiquet et al., 2003;Jarvinen et al., 1999) and the expression of 
the TNC gene in tendons is regulated in a dose-dependent manner by mechanical 
loading (Jarvinen et al., 1999;Jarvinen et al., 2003). The protein is also expressed 
around the collagen fibres and cells of the Achilles tendon (Jarvinen et al., 2003). 
Functionally distinct isoforms of the protein are expressed in degenerate tendons 
(Riley et al., 1996). Increases in tenascin C expression have also been reported in 
chronic Achilles tendinopathy biopsy samples (Alfredson et al., 2003). A GT 
dinucleotide tandem repeat polymorphism within intron 17 of TNC (Mokone et al., 
2005) as well as two SNPs, rs1330363 (A/G) and rs2104772 (A/T) (Saunders et al., 
2013), are also associated with chronic Achilles tendinopathy. The single nucleotide 
base change at rs2104772 (T/A) causes an amino acid change (Leu1677Ile) and has 
been associated with both adult asthma (Matsuda et al., 2005) and childhood 
rhinoconjunctivitis (Orsmark-Pietras et al., 2008), while rs1330363 (A/G), found in 
intron 15, has only been associated with childhood rhinoconjunctivitis (Orsmark-
Pietras et al., 2008).  
Similarly, the GG genotype of rs331079 (C/G) within FBN2 was recently associated 
with increased risk of chronic Achilles tendinopathy (El Khoury et al., In Press). 
FBN2 encodes for fibrillin-2, a member of a multi-domain protein family. These 
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proteins are large, cysteine-rich glycoproteins present in the extracellular matrix of 
extensible tissues (Baldwin et al., 2013;Sakai et al., 1986). Fibrillin-2 may be 
important for the formation of microfibril filaments, providing strength and flexibility to 
tendons (Zhang et al., 1994). Mutations within the FBN2 gene is linked to congenital 
contractural arachnodactyly, a rare congenital connective tissue disorder 
characterised by, among other complications, the manifestation of contractures and 
abnormally slender digits (Baldwin et al., 2013;Sabatier et al., 2014). 
During normal tissue homeostasis, matrix remodelling and in disease the turnover of 
the ECM is regulated by a number of protein families, such as the matrix 
metalloproteases (MMPs), tissue inhibitors of MMPs (TIMPs), growth factors and 
other signaling molecules (Ribbans and Collins, 2013). The GG, CC and AA 
genotypes of the MMP3 rs679620 (A/G), rs591058 (C/T) and rs650108 (A/G) SNPs, 
respectively, are all independently associated with increased risk of chronic Achilles 
tendinopathy (Raleigh et al., 2008). The MMP3 gene encodes for matrix 
metalloprotease-3 which can catalytically degrade multiple ECM substrates 
including: types II, IV, V, IX, X collagens, laminin, fibronectin, proteoglycan, decorin, 
aggrecan as well as activate other MMPs via propeptide removal (Birkedal-Hansen 
et al., 1993;Somerville et al., 2003;Visse and Nagase, 2003). The SNP rs679620 
(A/G) which is in strong linkage disequilibrium with the other two SNPs, is a non-
synonymous polymorphism (Raleigh et al., 2008). Specifically, the A/G changes a 
positively charged lysine residue to a negatively charged glutamate residue, which 
may have implications for the enzyme formed.  
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With respect to the tissue inhibitor of MMP-2 (TIMP2), the CC and CT genotypes of 
the rs4789932 (C/T) promoter SNP was under- and over-represented with chronic 
Achilles tendinopathy respectively (El Khoury et al., 2013). Deregulated expression 
of TIMP2 RNA (Jones et al., 2006;Karousou et al., 2008) and serum TIMP2 protein 
(Pasternak et al., 2010) have been implicated in Achilles tendon rupture samples. 
Furthermore, the TT genotype of the GDF5 rs143383 (T/C) variant was significantly 
associated with increased risk of Achilles tendinopathy in two populations 
(Posthumus et al., 2010). This functional SNP, where the T allele was correlated with 
reduced expression (Dodd et al., 2013;Miyamoto et al., 2007;Southam et al., 
2007;Syddall et al., 2013) is found in the 5’-UTR of the gene and has also been 
associated with lumbar disc degeneration (Williams et al., 2011), osteoarthritis 
(Chapman et al., 2008), congenital hip dysplasia (Dai et al., 2008;Rouault et al., 
2010) as well as a range of phenotypic measures such as height, hip axis length and 
fracture risk (Vaes et al., 2009). GDF5 is a member of the TGF-β superfamily which 
plays an essential role in tissue growth and differentiation as well as homeostasis 
(Benke et al., 2013). The Achilles tendons from mutant GDF-5 deficient mice are 
weaker and contained 40% less collagen (Mikic et al., 2001). 
Caspases are another class of matrix remodelling cysteine proteases (Nunez et al., 
1998). Caspase-8 (CASP8) is one of the key executioners of apoptosis 
(programmed cell death) which is responsible for the proteolytic cleavage of key 
substrates and other caspases in the pathway (Cohen, 1997). The expression of 
CASP8 was found to be elevated in tendinopathy (Millar et al., 2008). An 
independent association of CASP8 rs3834129 and rs1045485 with chronic Achilles 
tendinopathy was recently reported (Nell et al., 2012). Specifically the del/del 
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genotype of rs3834129 (insertion/deletion of CTTACT) increases the risk of Achilles 
tendinopathy by a factor of 1.6 while the C allele at the rs1045485 locus reduces the 
odds of TEN by a factor of 0.6 (Nell et al., 2012).  
Lastly, gene-gene interactions have also been reported to modulate the risk for 
Achilles tendinopathy. For example, interactions between polymorphisms within the 
3’-UTR of COL5A1 and the type XI collagen genes, namely COL11A1 and 
COL11A2, modulate risk (Hay et al., 2013). In addition, within the COL27A1-TNC 
gene cluster, a genomic region containing both genes has been implicated in 
influencing risk of chronic Achilles tendinopathy through haplotype analysis 
(Saunders et al., 2013). Lastly, variants within the interleukin genes, IL-6, IL-1RN 
and IL-1β, which are inflammatory and matrix remodeling signaling molecules, also 





Table 1.1 Genetic polymorphisms shown to be independently associated with chronic 
Achilles tendinopathy.  
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1.5 The Collagen Family and Fibril Forming Collagens  
 
The collagens are a family of twenty-eight structurally and functionally diverse 
proteins. Many are important structural components of, or are associated with, the 
building blocks of tendons, ligaments and other musculoskeletal tissues as reviewed 
by Gelse et al., 2003. All collagens consist of three polypeptides, known as the α 
chains, wound in a characteristic uninterrupted or interrupted right handed triple helix 
(reviewed by Kadler et al., 2007;Mienaltowski and Birk, 2014). Repeating Gly-X-Y 
triplet amino acids within each of the three α-chains, in which every third residue is a 
glycine and the X and Y amino acids are often proline and hydroxyproline 
respectively, are responsible for forming the collagen triple helix (reviewed by Gelse 
et al., 2003;Kadler et al., 2007).  
 
The collagen family is commonly divided into the fibril-forming (fibrillar) and non-fibril-
forming (non-fibrillar) collagens (Table 1.2) as reviewed in Gelse et al. (2003). The 
“classical” fibril-forming collagens are further sub-divided into the major (types I, II 
and III) and minor (types V and XI) fibril-forming collagens. Although not usually 
included as classical fibrillar collagens, the more recently identified non-abundant 
types XXIV and XXVII collagen are nevertheless also fibrillar collagens (Boot-
Handford et al., 2003;Koch et al., 2003;Matsuo et al., 2006;Matsuo et al., 2008). The 
non-fibril-forming collagens, which are beyond the scope of this review, are divided 
into several groups including fibril-associated collagens (FACIT), FACIT-like 
collagens, network-forming collagens, transmembrane collagens, multiplexins and 
other molecules bearing collagenous domains (reviewed by Gelse et al., 2003;Kadler 





Type V collagen, together within types I, II, III and XI, are the “classical” members of 
the fibril-forming collagen family, which all have a long uninterrupted triple-helical 
(COL) domain (Figure 1.4). As the designation indicates, the fibrillar collagen family 
participates in the formation of highly ordered fibrils (reviewed by Kadler et al., 
2007;Mienaltowski and Birk, 2014). Type I, II and III are the most abundant collagen 
species within the fibril structure, where type I collagen is the predominant 
macromolecule of connective tissues, including the tendon mid-substance (reviewed 
by Kannus, 2000). Type II collagen is the predominant protein found within cartilage, 
but it is also an important structural component of fibrocartilaginous zones of 
connective tissue and the osteotendinous junction (Fukuta et al., 1998). Type III 
collagen is also a major fibrillar collagen which forms heterotypic fibrils together with 
type I collagen, and is important in healing processes and during fibrillogenesis 
(Banos et al., 2008;Liu et al., 1995). Tissues with elastic properties, such as skin and 
arteries, also have higher type III collagen content than less elastic tissue as 
reviewed in Gelse et al. (2003). Type III collagen also form fine supporting meshwork 
of reticular fibres, also known as the reticulin (Ushiki, 2002).   
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Table 1.2 Classification of collagen types modified from Mienaltowski and Birk (2014) 
Classification Collagen types Supramolecular structure 
Fibril-forming collagen 
Classical 
Major I, II, III Striated fibrils 
Minor V, XI Striated fibrils, retain N-terminal regulatory domains 
Non-classical XXIV, XXVII Unknown 
Non-fibril forming collagen 
FACITa collagens IX, XII, XIV Associated with fibrils, other interactions 




Chicken wire network with 
lateral association 
Beaded filament-
forming VI Beaded filaments, networks 
Anchoring fibrils VII Laterally associated anti-parallel dimers 
Hexagonal networks VIII, X Hexagonal lattices 
Transmembrane collagens 




(Endostatins) XV, XVIII 
Basement membranes, cleaved 
C-terminal domains influence
angiogenesis
Other molecules with 
collagenous domains 
XXVI, XXVIII 
Collagenous domains in  
primarily non-collagenous 
molecules Acetylcholinesterase, adiponectin, C1q, collectins, 
surfactant protein, others 
a Fibril-associated collagen with interrupted triple helix 
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Types II and III collagen are both homotrimers consisting of α1(II) and α1(III) 
collagen chains respectively while type I is a heterotrimer consisting of two α1(I) and 
one α2(I) chains (reviewed by Gelse et al., 2003). Homotrimers of the α1(I) chains 
can also be formed (Han et al., 2010). Each collagen pro-α chain namely the pro-
α1(I), -α2(I), -α1(II) and -α1(III) is encoded by the COL1A1, COL1A2, COL2A1 and 
COL3A1 genes respectively. 
The biosynthesis of the fibril-forming collagens is reviewed by Gelse et al. (2003) 
and Mienaltowski and Birk (2014) as a complex multi-step process from gene 
transcription in the nucleus to aggregation into supramolecular structures. 
Transcription of the collagen genes may be regulated by the cell type, numerous 
growth factors and cytokines (Rossert et al., 2000). Many collagen genes have been 
shown to undergo alternative splicing (Matsuo et al., 2006;McAlinden et al., 
2007;Mitchell et al., 2012) and their pre-mRNA undergoes capping at the 5’-end and 
polyadenylation at the 3’-end.  
The mature mRNA is transported out of the nucleus and translated into precursor α 
chains (reviewed by Mienaltowski and Birk, 2014). In the rough endoplasmic 
reticulum, a signal peptidase catalyzes the removal of the signal peptide and three 
pro-α chains trimerise to form the procollagen molecule (Figure 1.4). The fibrillar 
procollagen molecules, which contain amino-terminal globular (N), triple helical 
(COL) and carboxy-terminal globular domains (C), are post-translationally modified. 
Specifically, certain proline and lysine residues are hydroxylated to produce 
hydroxyproline and hydroxylysine respectively. In addition, procollagen is also 
glucosylated and galactosylated at specific residues. Furthermore, the globular 
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structure of the N-terminal and C-terminal domains are stabilised and the 
procollagens secreted into the extracellular space through the Golgi apparatus. The 
precursor molecules will be further modified extracellularly, e.g. both globular 
domains of the procollagen molecule are cleaved outside of the cell and the collagen 
triple helix is incorporated into the collagen fibril as reviewed by Mienaltowski and 
Birk (2014). 
In contrast, the amino globular domains of the quantitatively minor types V and XI 
collagens, which form heterotypic fibrils with the major fibrillar collagens, are not 
removed (reviewed by Fichard et al., 1994). The uncleaved N-terminal extension of 
type V collagen contributes mainly to a large flexible globular domain (Birk et al., 
1990). When incorporated in the forming fibril, this globular domain can fit in the 
staggered array of molecules protruding through the fibril gaps and the fibril surface, 
thus thought to regulate fibril growth by sterically preventing the addition of new 
molecules (Linsenmayer et al., 1993).  
Due to structural homologies and similarities between types V and XI collagen, it has 
been proposed that type XI collagen regulates fibrillogenesis of the type II collagen 
containing cartilage fibrils in a similar way as previously described for type V 
collagen (reviewed by Fichard et al., 1994). Although traditionally classified as two 
distinct proteins, types V and XI collagen are now considered a single collagen type 
with multiple tissue-specific isoforms or sub-types, including a hybrid isoform (Table 
1.3) (Wenstrup et al., 2011). Both collagen types V and XI play a crucial and similar, 
if not coordinated, role in the regulation of collagen fibrillogenesis during early tendon 





fibril number and integrity was observed in a mouse model with a compound 
heterozygous genotype for Col5a1 and Col11a1 (Wenstrup et al.,2011). When 
compared to the mice with a reduction of type V collagen alone, the phenotype was 
more severe with a reduction in type XI collagen but it was worst with the absence of 
type XI collagen and a reduction in type V collagen. Moreover, in a mouse study, it 
was observed that both collagens shared a similar pattern of expression. However, 
while type V collagen continues to be steadily expressed past early tendon 
development, type XI appears to be transiently expressed during the early 
developmental stages (Wenstrup et al., 2011). 
 
The newly identified types XXIV and XXVII collagen have shorter interrupted helical 
regions than the other typical fibril-forming collagens. They resemble the invertebrate 
collagens and while they are involved in bone development, to date they have not 
been linked to tendon biology (Boot-Handford et al., 2003;Koch et al., 2003;Matsuo 






Table 1.3 Isoforms of type V and XI collagen as well as the genes encoding the α chains. 
Collagen type Isoform Genes encoding the α chains and  
chromosomal location (Chr) 
Type V collagen α1(V)2α2(V) COL5A1 (Chr9q34.2-q34.3), 
COL5A2 (Chr2q14-q32) 
 
 α1(V)3 COL5A1 
 




Type XI collagen α1(XI)α2(XI)α1(IIB)* COL11A1 (Chr1p21),  
COL11A2 (Chr6p21.3),  
COL2A1 (Chr12q13.11) 
 









Collagen fibrillogenesis is the process by which fibrils are made and assembled to 
form the highly organised structures such as the tendon tissue (Birk et al., 
1990;Fichard et al., 1994). The assembly and deposition of collagen fibrils, mostly 
heterotypic, with tissue-specific structures and organisation involves a sequence of 
events that occur in both intracellular and extracellular compartments (reviewed by 
Mienaltowski and Birk, 2014). The authors further describe the collagen fibrils as 
composites of different matrix molecules and they note that the control of hetero-
polymeric mixing and trimer type stoichiometry begins within the intracellular 
compartments. It involves regulation by processing enzymes as well as interaction 
with these in a spatial and temporal manner during secretion (reviewed by 
Mienaltowski and Birk, 2014).  
 
As previously mentioned the collagen fibril in tendons and other non-cartilaginous 
connective tissue consists predominately of type I collagen. Fibril assembly begins in 
the cell-surface crypts, at the surface of the fibroblast surface (Birk and Trelstad, 
1986). As the propeptides are removed by procollagen proteinases, some degree of 
spontaneous self-assembly of the collagen molecules into protofibrils occurs as 
reviewed in Mienaltowski and Birk (2014). While the cleavage of the C-propeptides is 
an essential step for regulating fibril formation, the presence of uncleaved N-terminal 
propeptides projecting outwards between the gaps of the adjacent type I collagen 
molecules in the fibril, as in the case with type V collagen, may regulate the diameter 
of the forming fibrils (Wenstrup et al., 2004). Non-reducible covalent crosslinks will 
further stabilise the fibrils together (Fichard et al., 1994;Gelse et al., 2003). 
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Figure 1.4 Schematic representation of fibril-forming collagen biosynthesis from transcription 
through mRNA processing, ribosomal protein synthesis followed by post-translational 
modifications and secretion to fibril formation (modified from Gelse et al. 2003). COL: the 
collagenous domain; NC: the non-collagenous domain; N: amino globular domain and C: 
carboxyl domain. Typical enzymes involved in the process are indicated. SP: signal peptidase; 
GT: hydroxylysyl galactosyltransferase and galactosylhydroxylysyl glucosyltransferase; LH: lysyl 
hydroxylase; PH: prolyl hydroxylase; OTC: oligosaccharyl transferase complex; PDI: protein 
disulphide isomerase; PPI: peptidyl-prolyl cis-trans-isomerase; NP: procollagen N-proteinase; CP: 
procollagen C-proteinase; LO: lysyl oxidase; HSP47: heat shock protein 47, colligin1. 
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1.6 Type V Collagen and the COL5A1 Gene 
The major isoform and most ubiquitous form of type V collagen is a heterotrimer 
consisting of two α1(V) chains and one α2(V) chain (Roulet et al.,2007; Wenstrup et 
al.,2011). The pro-α1(V) chain is encoded by the COL5A1 gene on human 
chromosome 9q34.2-q34.3. The pro-α2(V) and pro-α3(V) chain are encoded by the 
COL5A2 gene (Chromosome 2q14-q32) and COL5A3 gene (Chromosome 19p13.2) 
respectively. Except in the case of the type V-type XI collagen isoform (Table 1.3), 
the α1(V) chain is common to all isoforms of type V collagen and therefore important 
for the study of expression or regulation of that collagen (Roulet et al., 2007). The 
α2(V) chains form heterotypic molecules with α1(XI) chains, α1(XI)2α2(V), but the 
distribution and functional roles of these less common isoforms are not well 
described (Birk, 2001;Wenstrup et al., 2011;reviewed in Fichard et al., 1994). 
Throughout this thesis, for ease of reading, the term ‘type V collagen’ will refer to its 
major isoform, α1(V)2α2(V), unless stated otherwise.  
During murine development, Col5a1 expression, which coincided with the pro-α1(I) 
chain developmental expression, was detected using in situ hybridization in the 
heart, dorsal aorta wall, branchial arches, mesonephrotic tubules and intestinal 
mesenchyme (Roulet et al., 2007). Increased expression was detected in discrete 
regions during later stages of development including tendons, skin, cornea, bones, 
vertebral column and ligaments, highlighting the important contribution of type V 





Collagen types I and V interact in heterotypic fibrils within tendons (Figure 1.5) and 
are co-expressed during embryonic development. The triple helical domain of type V 
collagen is buried within the heterotypic fibril while, as mentioned previously, the 
uncleaved N-terminal extension of type V collagen is exposed at the surface. Type V 
collagen is a dominant regulator of collagen fibrillogenesis (Sun et al., 
2011;Wenstrup et al., 2011), specifically, it nucleates fibril assembly, controlling fibril 
number and initial diameter of the fibril. The protruding N-globular domain is believed 
to have a regulatory function in this assembly process (reviewed in Birk, 2001). 
 
 
Figure 1.5 A schematic diagram modified from Raleigh and Collins (2009) representing the 
basic structural unit of the collagen fibril which consists predominately of type I collagen (not 
drawn to scale). The fibril also contains trace amounts of types III and V collagen. Types I 
and III collagen are major fibrillar collagens, while type V collagen is a part of the minor 
fibrillar collagen sub-family. Types XII and XIV collagen are associated with the surface of 
the fibril and belong to the sub-family of fibril-associated collagens with interrupted triple 
helices (FACITs). Tenascin C and MMP3 are also shown in this diagram. Other collagen 
types, proteoglycans and glycoproteins, associated with or structural components of the fibril 
are not depicted in this diagram. The genes that have been shown to be independently 





Rare mutations within COL5A1 as well as mutations within COL5A2 cause the 
classic form (types 1 and 2) of Ehlers-Danlos syndrome (EDS), where EDS is 
described as a severe heritable connective tissue disorder characterised amongst 
other clinical symptoms, by fragile hyper-extensible skin, joint hypermobility and 
musculoskeletal soft tissue defects (Beighton et al., 1998;Malfait et al., 2010). Most 
patients with classic EDS have been reported to have disease-causing mutations 
within one copy of the COL5A1 gene, which result in a loss of function of the 
mutated gene due to a 50% reduction in the production of type V collagen 
(haploinsufficiency) (Malfait et al., 2010;Wenstrup et al., 2000). In support of this, 
although viable, Col5a1 +/- knockout mice, which only produce half the amount of 
type V collagen, display similar symptoms observed in patients suffering from the 
classic form of EDS (Wenstrup et al., 2006). Comparable with EDS patients, the 
mice had decreased aortic stiffness and tensile strength, as well as hyper-extensible 
skin with decreased tensile strength (Wenstrup et al., 2006). 
 
Transmission electron micrographs (TEMs) of the dermis of these heterozygous 
mice displayed two populations of fibrils, where one was circular in appearance and 
comparable to the wild-type dermis while the other population consisted of large 
structurally aberrant fibrils (Figure 1.6; Panel A). Lateral and linear growth was also 
disrupted as seen in the developing dermis at day 10 postnatal (P10) and more 
severe in the mature dermis (20-weeks) (Wenstrup et al., 2006). Similarly, in the 
tendon of the heterozygous mice at P30, two populations of fibrils were also 
observed (Figure 1.6; Panel B) (Wenstrup et al., 2011). TEMs showed an increased 
amount of small and larger diameter fibrils in the heterozygous mice compared to the 





the heterozygous mice compared to wild-type mice. Investigation of the 
biomechanical properties of the tendons in the heterozygous mice indicated that they 
had decreased tissue stiffness, suggesting increased elasticity reminiscent of the 
joint laxity or hyper-extensibility observed in EDS patients (Wenstrup et al., 2011). 
Moreover, Col5a1 null mutant mice died in utero at approximately embryonic day 10, 
indicating the crucial roles that Col5a1 and type V collagen play in the development 
of the mesenchymal tissue (Wenstrup et al., 2004). Collagen fibril formation was 
absent in the type V collagen deficient mice (Col5a1 -/-).  
 
Type V collagen is critical in the initiation of fibril assembly as displayed by the in 
vivo murine models mentioned above (Wenstrup et al., 2004). In addition, in chick 
and murine animal models examining the corneal tissues, it was shown that this 
minor fibrillar collagen regulates fibrillogenesis (Birk et al., 1990;Segev et al., 
2006;Sun et al., 2011). A reduced fibril diameter was observed when the relative 
level of type V collagen was increased in in vitro experiments (Birk et al., 1990). In 
line with these results, larger fibrils were observed in the stroma of conditional type V 
collagen knockout mice (Figure 1.6; Panel C) (Sun et al., 2011). Recently, genome-
wide association studies (GWAS) uncovered a genetic variant in the relative vicinity 
of the COL5A1 gene on chromosome 9 which associated with central corneal 
thickness (Vitart et al., 2010).  
 
Additional studies using Col5a1 mutant mouse models or targeted deletions of 
Col5a1 have shown the analogous functional role played by type V collagen in the 
fibril assembly of the dermis and tendon tissue (Wenstrup et al., 2006;Wenstrup et 





the soft tissues when Col5a1 expression was either increased or decreased in these 
studies (Wenstrup et al., 2006;Wenstrup et al., 2011). Moreover, in a mouse skin 
model harbouring targeted deletion of the Col5a2 gene, the deposition of α1(V)3 
homotrimers was favoured over the more abundant isoform of type V collagen, 
α1(V)2α2(V) in the skin matrix (Chanut-Delalande et al., 2004). Interestingly, this 
altered secretion/deposition lead to exclusion of the α1(V)3 homotrimers from 
incorporation into the heterotypic collagen fibrils and a severely impaired matrix 
assembly, where disorganised and thin fibrils were observed coupled with a five-fold 
increase in Col5a1 expression compared to the WT mice. A transgenic mouse 
model, with a targeted overexpression of pro-α1(V) chain in the epidermis, displayed 
thin fibrillar material composed of the collagen V homotrimer underneath the 
epidermal basement membrane (Bonod-Bidaud et al., 2012). Although not 
significant, stiffness and rupture stress of the transgenic skin were lower compared 
with the WT. In addition, the experiments showed that the homotrimer differed in its 
interaction with ECM molecules, acting as a bridging molecule at the epidermal-
dermal interface. The authors proposed that distinct molecular forms of a collagen 
type can differentially influence the skin ECM architecture as well as its mechanical 
properties. 
 
Although only trace amounts of type V collagen have been identified in healthy 
tendons (reviewed in Birk, 2001; Silver et al.,2003), increases in type V collagen 
content together with a decrease in fibril diameter and changes in the biomechanical 
properties have been reported with age in the rabbit patellar tendon (Dressler et al., 
2002). In addition, increase in types III and V collagen content together with a 
reduction in the content of type I collagen have been reported in biopsy samples of 
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degenerative tendons from patients with posterior tibial tendon dysfunction syndrome 
(Goncalves-Neto et al., 2002;Satomi et al., 2008). Furthermore, in a damage 
accumulation model using the rat patellar tendon, an upregulation of type I, III and V 
collagen expression was observed as a result of a cyclic fatigue loading protocol 
(Andarawis-Puri et al., 2012;Fung et al., 2010). 
In another study, the effect of a particular chain of type V collagen on fibrillogenesis 
was investigated using specific siRNA and primary rat Achilles tenocytes (Lu et al., 
2011). This investigation showed that the pro-α1 and pro-α2 chains of type V 
collagen had, to a certain extent, a different effect on the regulation of the tendon 
matrix and that an optimal level of the pro-α1 chain in particular was pivotal in 
regulating fibrillogenesis. Whereas siRNA specific to Col5a1 decreased the ratios of 
Col5a1, Col3a1 and decorin gene (DCN) to Col1a1, siRNA to Col5a2 increased the 
ratios of Col5a1, Col3a1 and DCN to Col1a1 (Lu et al., 2011). Importantly, the 
authors observed that a tissue-engineered tendon treated with Col5a1 siRNA had 
abnormal collagen fibril morphology while a tendon treated with Col5a2 siRNA had 







Figure 1.6 Transmission electron micrographs (TEMs) modified from Wenstrup et al. 2011, 
Wenstrup et al. 2006 and Sun et al. 2011 showing the effect of haploinsufficiency of mice 
Col5a1 in (Panel A) dermis and (Panel B) tendon. Panel C, the corneal-stroma-specific 
Col5a1-null mouse model showing the fibril implications in the stroma of the mice. Panel A 
shows the cross-sections (A, C, E, G) next to the longitudinal sections (B, D, F, H) at day 10 
and week 20 postnatal. The +/+ or WT indicate presence of both copies of Col5a1 in the 
mice while +/- indicate heterozygous mice. The arrowheads show cylindrical fibrils (similar to 
the WT profile) whereas the asterix indicate aberrant fibrils and the small arrows indicate 
disruption of the fibril organisation and growth. Panel B shows the WT Col5a1 +/+ mice 
tendon (left, A) and the haploinsufficient mice, +/- (right, B) at day 30 postnatal. Two 
populations of fibrils can be observed in the heterozygous mice together with irregular cross-
sections (white arrow in B), where a mixture of small and larger fibrils can be seen in 
comparison to normal circular fibrils of the WT (white arrow in A). Panel C shows the 
increase in size of the fibrils of the stroma when the Col5a1 gene is knocked out (KO) in a 






1.7 COL5A1 and MIR608 are associated with musculoskeletal soft 
tissue injuries and/or other phenotypes 
 
Initial evidence for the involvement of genes in the aetiology of musculoskeletal soft 
tissue injuries arose from reports of an association between the ABO blood group, 
specifically blood group O, and increased risk of Achilles and other tendon injuries 
(reviewed in September et al., 2009). Because the ABO blood group is determined 
by an enzyme encoded by a single gene located on human chromosome 9q34, a 
mere 1.4Mb upstream from the COL5A1 gene, the possible association between 
COL5A1 polymorphisms and the risk of Achilles tendon injuries was investigated 
(Mokone et al., 2006). Of particular interest to the current study are reports that 
variants within the COL5A1 3’-UTR associate independently with several 
recreational and occupational musculoskeletal soft tissue injuries (Abrahams et al., 
2013;Burger et al., 2014;Mokone et al., 2006;Posthumus et al., 2009;September et 
al., 2009) and other exercise-associated phenotypes (Abrahams et al., 2014;Brown 
et al., 2011;Brown et al., 2011;Collins et al., 2009;O'Connell et al., 2013;Posthumus 
et al., 2010).  
 
The terminal exon (exon 66) of the COL5A1 gene encodes for the last 47 amino 
acids (141bp) of the carboxy-terminal domain of the α1(V) chain, the stop codon and 
2.5kb 3’-UTR (Figure 1.7). Variants, which span the entire 3’-UTR, have previously 
been investigated for association with chronic Achilles tendinopathy. Although 
rs13946 (C/T, DpnII RFLP, nucleotide 230 within exon 66) and rs11103544 (C/T, 
MboII RFLP, nucleotide 1041) were not independently associated, rs12722 (C/T), 





associated with chronic Achilles tendinopathy in a self-reported Caucasian South 
African and Australian population (Mokone et al., 2006;September et al., 2009) 
(Figures 1.7 and 1.8). Specifically, individuals with a CC genotype for rs12722 had a 
significantly decreased risk of developing chronic Achilles tendinopathy compared 
with those with a T allele (TC or TT genotype) in both the Australian (OR 0.42, 95% 
CI 0.20 to 0.86, p=0.017) and South African (OR 0.38, 95% CI 0.18 to 0.77, p=0.008) 
participants. Interestingly, individuals in only the Australian group with the 
heterozygous TC genotype for rs3196378 (C/A, AciI RFLP, nucleotide 880) had a 
significantly increased risk of developing chronic Achilles tendinopathy compared 
with those with homozygous TT or CC genotypes (September et al., 2009).  
 
Polymorphisms rs3196378 and rs11103544 were selected because they are located 
within putative polymorphic miRNA recognition sequences, 5’-CCACCCCA-3’ and 5’-
TTTTCTAC-3’ (polymorphic nucleotides underlined), respectively, and therefore may 
potentially be functionally significant (September et al., 2009). Although the miRNA 
that bind to the putative 5’-TTTTCTAC-3’ sequence is currently unknown, the 5’-
CCACCCCA-3’ sequence binds Hsa-miR-608. Two forms of the 25bp mature Hsa-
miR-608, which are produced from the polymorphic (SNP rs4919510, C/G) MIR608 
gene on chromosome 10q24, can potentially bind this miRNA binding site 
(http://www.ncbi.nlm.nih.gov). The CC genotype of rs4919510 (C/G) within the 
MIR608 gene is associated with increased risk of chronic Achilles tendinopathy in 
the South African and Australian cohorts (Abrahams et al., 2013). The upstream 
polymorphism rs10858286 (C/T), within intron 65, and the distal 3’-UTR 
polymorphisms, rs4504708 (G/T) and rs3128575 (A/G) located 2129 and 2135bp 
downstream of rs12722, respectively, were not significantly associated with Achilles 
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tendinopathy in the Australian cohort and were therefore not evaluated in the South 
African cohort (September et al., 2009).  
A single study has also investigated a variant, COL5A1_01 G/A, within intron 65 of 
the equine COL5A1 gene for an association with superficial digital flexor (SDF) 
tendinopathy and reported that the AA genotype was significantly associated with 
SDF tendinopathy (Tully et al., 2014). Other equine COL5A1 variants which were 
located upstream of the associated polymorphism were however not independently 
associated with SDF. Polymorphisms within the 3’-UTR of the equine COL5A1 gene 
have not been investigated. Both the investigated human and equine associated 
variants are nevertheless located within the 3’-end of the gene suggesting that this 
region of the COL5A1 gene within both species could contain important elements 
directly involved in the aetiology of tendinopathy. 
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A
ACCAAGAAAG GCTACCAGAA GACGGTTCTG GAGATCGACA CCCCCAAAGT 50 
GGAGCAGGTG CCCATCGTGG ACATCATGTT CAATGACTTC GGTGAAGCGT 100 
CACAGAAATT TGGATTTGAA GTGGGGCCGG CTTGCTTCAT GGGCTAGGAG 150 
CCGCCGAGCC CGGGCTCCCG AGAGCAACCT CGTGACCTCA GCATGCCATT 200 
CGTTCGTGAG TGTCCCGTGC ACGTCCTGAY CCTGGACAGT GAAGGCTTCT 250 
rs13946 (DpnII RFLP) 
CCCTCCCCTC CCACCTGACT TCATCTACGC CTCGGCACCA CGGGGTGTGG 300 
GACCCCAGCC CGGAGAGAAC AGAGGGAAGG AGCCGCGCCC CCACCTGGAG 350 
CTGAATCACA TGACCTAGCT GCACCCCAGC GCCTGGGCCC GCCCCACGCT 400 
CTGTCCACAC CCAYGCGCCC CGGGAGCGGG GCCATGCCTC CAGCCCCCCA 450 
rs12722 (BstUI RFLP) 
GCTCGCCYGA CCCATCCTGT TCGTGAATAG GTCTCAGGGG TTGGGGGAGG 500 
rs1134114 
GACTGCCAGA TTTGGACACT ATATTTTTTT CTAAATTCAA CTTGAAGATG 550 
TGTATTTCCC CTGACCTTCA AAAAATGTTC CAAGGTAAGC CTCGTAAAGG 600 
TCATCCCACC ATCACCAAAG CCTCCGTTTT TAACAACCTC CAACACGATC 650 
CATTTAGAGG CCAAATGTCA TTCTGCAGGT GCCTTCCCGA TGGATTAAAG 700 
GTGCTTATGT TTTTGTGAGT TTTAAGTAAA TATTTGTATT GTATTGTTAT 750 
AAATGTTAAG TGTGCCTGGC TTTCAATCAT GCACGGAAAC CCAGTCTCAG 800 
TCCCACGGAC AGAATGGGCG AGGCATGGAT TCTGGGTTGC AGTACCGTTC 850 
TGATTAGAAA TAGGAAGTCT CCCCACCCCM GCCCTGGCCA AGAACGTGCA 900 
rs3196378 (AciI RFLP) 
ATAAATTGGA AGTTTGCCCC GGGGCAGCAA GAATTTATGC TGCCATTGAA 950 
AAGCAGGTAC CAGTGCCCCT TTTCAGACAG TTTTTGATTC GCTCTAGACT   1000 
TTTTTTTTTT TTAATAGGGA AAAAATTTGA TAATTTTCTT YTTTCTACAT   1050 
rs11103544 (MboII RFLP) 
GCACTTAAGA CTAAAACACA GGTTTGGATT AATTTTATTT GCTTCCTTTT   1100 
B
AAAAAGAAAA AAATGGTAAG CAAAAAACCC AAGATAAAGT TTCGAGGACA   2500 
TCAGGCCTTT TGAAATACAA TGTCAAATGA CACATTGTAC GKTTTCAAAA   2550 
rs4504708 
AATCCGCTAG ACATGTCATA AGTTTTAACT GTAATGCCCA GGAAAGGATA   2600 
TCTTAAAATA TTCTAAACTT GTGTAACAAA GGAATAATTA ACTGTAAYAG   2650 
rs3128575 
TTTTTCAATA AATCGAGTTG GGTGTTTCCA CCGT 2684 
Figure 1.7 Nucleotide sequence of COL5A1 exon 66 containing the first 5 sequence variants 
(Panel A) and the latter 2 sequence variants (Panel B) (September et al., 2009). The 
positions of the SNPs are annotated in bold (Y: C or T; M: A or C and K: G or T). Their 
accession numbers are given with the name of the RFLPs in brackets. The nucleotide 
position of exon 66 is indicated on the right. The shaded sequences represent the translated 
region of the COL5A1 exon 66 (nucleotides 1–147) and exon 1 of an expressed sequence 
tag (EST) (nucleotides 433–604). The stop codon of exon 66 and the translation start codon 
of exon 1 are underlined. The dotted line indicates the untranslated region of the EST. The 






Figure 1.8 Representation of the 3’-UTR of the COL5A1 gene (9q34) at its terminal end 
showing exons 65 and 66 with the intronic region in between (intron 65), and the MIR608 
gene(10q24) modified from September et al. (2009). The rectangles represent the exons 
while the straight lines correspond to introns. The shaded rectangles are the translated 
regions while the clear ones represent the untranslated regions within the exons. The 
accession number and nucleotide change of each polymorphism described in section 1.7 is 
annotated on the diagram. The common restriction fragment length polymorphism (RFLP) 
associated with them is indicated below. SNPs rs3196378 and rs11103544 are each within 
putative miRNA binding sites.  
 
 
Exercise-associated muscle cramping (EAMC), which is a common medical 
condition amongst participants of endurance events, is defined as “painful, 
spasmodic and involuntary contraction of skeletal muscle that occurs during or 
immediately after exercise” (Schwellnus et al., 1997). Although a number of 
hypotheses have been proposed to explain the aetiology of EAMC, pre-race serum 





athletes who developed EAMC during participation in a 56 km ultra-endurance road 
race when compared with 29 non-crampers (Schwellnus, 2009;Schwellnus et al., 
2011). This suggests that muscle damage, including the connective tissue 
components of skeletal muscle, may play a role in the aetiology of EAMC. In support 
of this, the CC genotype of COL5A1 rs12722 was significantly over-represented in 
150 Caucasian male ultra-endurance athletes (ultra-marathon and Ironman 
triathletes) with no self-reported history of previous (lifelong) EAMC when compared 
to 116 Caucasian male ultra-endurance athletes with self-reported history of EAMC 
within the past 12 months (O'Connell et al., 2013). 
 
Altered musculotendinous flexibility, which is defined as ‘‘the ability to move a joint 
through its complete range of motion (ROM)” (Whaley, 2006), is an intrinsic risk 
factor for several musculoskeletal soft tissue injuries, including Achilles tendinopathy 
(Kaufman et al., 1999) and ACL rupture (Uhorchak et al., 2003). Although ROM is a 
complex phenotype, it has been estimated, using classical twin studies, that up to 
70% is determined by inherited components (Maes et al., 1996). As previously 
mentioned, rare COL5A1 mutations cause classical forms of EDS, which is 
characterised by generalised joint hypermobility (Malfait et al., 2010). Furthermore, it 
has also been proposed that COL5A1 is associated with benign joint hypermobility 
syndrome, also an inherited condition (Grahame, 1999;Zweers et al., 2005). Based 
on these collective reports, it was proposed that variants within the COL5A1 3’-UTR 
were associated with normal joint range of motion (Collins et al., 2009). In support of 
this hypothesis COL5A1 rs12722 has been associated with lower limb range of 
motion, namely sit and reach (SR) measurements (Brown et al., 2011;Brown et al., 





apparently healthy physically active participants with a CC genotype for rs12722, 
while there was no correlation in the other two genotypes (Brown et al., 2011). 
Furthermore, the COL5A1 rs12722 genotype was associated with SR ROM in older 
(≥35 years) participants (TT 225 ± 96 mm, TC 245 ± 100 mm, CC 32 ± 108 mm, 
P=0.017), but not younger participants. Sex and the COL5A1 genotype accounted 
for 22.8% of the variance in SR ROM in the older group (Brown et al., 2011). 
Similarly, a recent study reported that the rs12722 genotype was not associated with 
sit and reach ROM measurements in a young (25.2 ± 4.0 years) Brazilian cohort 
(Bertuzzi et al., 2014).  
 
A previous study consisting of a mixed cohort of older participants, with and without 
a history of chronic Achilles tendinopathy and/or Achilles tendon rupture, reported 
that the homozygote individuals (TT and CC genotypes) were associated with 
greater lower limb ROM measurements (Collins et al., 2009). The difference in age 
and injury profile of the two cohorts could possibly explain this inconsistency 
between the studies. Similar relationships between the COL5A1 genotype groups 
and sit and reach measurements were observed when only the uninjured 
participants from the mixed cohort were analysed separately (Brown et al., 2011). 
COL5A1 rs13946, rs3196378 and rs11103544 were however not associated with the 
lower limb ROM measurements (Collins et al., 2009). In addition, the CC genotype of 
rs12722 was also associated with a decreased joint laxity (Bell et al., 2012) in a 
gender-specific manner consistent with female-specific associations with ACL injury 
(Posthumus et al., 2009;Posthumus et al., 2010). 
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Endurance running performance is also a multifactorial phenotype that is strongly 
associated with range of motion (Craib et al., 1996;Jones, 2002) which has been 
proposed to affect running economy (Gleim et al., 1990). A relationship between 
running performance and rs12722 has therefore been investigated (Posthumus et 
al., 2010). Individuals with the TT genotype had a better running performance when 
completing the road running stage (42.2km) of the Ironman Triathlon compared to 
those with the CC and TC genotype (p=0.019, TT= 294.2 ± 52.1 mins, CC= 307.4 ± 
48.6 mins, N= 313) (Posthumus et al., 2010). Similarly, athletes with a TT genotype 
(341 ± 41 min) completed a 56 km road running ultra-marathon significantly faster 
(p=0.014) than athletes with either a TC or CC genotype (365 ± 39 min). The 
COL5A1 genotype and age accounted for 19% of performance variance in these 
athletes (Brown et al., 2011). Although no direct association between pre-race sit 
and reach ROM measurements (flexibility) and time to complete the 56-km ultra-
marathon race was reported, the COL5A1 T and C alleles were significantly over-
represented in the ‘‘inflexible-fast’’ and ‘‘flexible-slow’’ athletes respectively (Brown et 
al., 2011). However, a recent study reported no significant differences between the 
COL5A1 genotypes and running economy measurements at 10 km/hr (p=0.232) and 
12 km/hr (p=0.259) in a physically active young male Brazilian cohort (Bertuzzi et al., 
2014).  
Although seemingly unrelated, all four phenotypes (Figure 1.9) are directly or 
indirectly related to the mechanical properties of musculoskeletal soft tissues (Collins 
and Posthumus, 2011). Collins and Posthumus (2011) have therefore hypothesised 
that variants within regulatory regions, such as the 3’-UTR, of the COL5A1 gene alter 
collagen fibril architecture and structure and by implications the mechanical 
42 
properties of soft tissues. In brief, this hypothesis suggests that since the pro-α1(V) 
chain is essential to the formation of type V procollagen assembly (Roulet et al., 
2007), changes in COL5A1 expression associated with polymorphisms in regulatory 
regions may have a direct effect on the amount of type V collagen incorporated into 
the collagen heterofibril. The authors propose that if this amount is increased it may 
reduce the average fibril diameter and increase the total numbers of fibres present 
as indicated in figure 1.10. The smaller, densely packed and organised collagen 
fibrils may result in reduced ROM and improved endurance running performance but 
can cause an increased risk for musculoskeletal soft tissue injuries.  
Figure 1.9 Diagram illustrating the common association of the T or C allele of the rs12722 in 
the context of injury risk, EAMC, flexibility and endurance performance as presented in the 
genetic association studies, where green depicts a positive effect on the phenotype while red 
depicts a negative effect. All four phenotypes are directly or indirectly related to the 








Figure 1.10 Integral model of the relationship between COL5A1 genotype (black boxes), 
connective tissue biochemical and mechanical properties (white boxes), flexibility, disease or 
injury risk as well as physical activity, modified from Collins and Posthumus (2011). Left 
panel: The effects of disease causing COL5A1 mutations on decreased type V collagen 
production: abnormal fibrillogenesis (large and small irregular fibrils) and generalized joint 
hypermobility. These mutations cause Ehlers-Danlos syndrome (EDS) which has a 
detrimental effect on the habitual level of physical activity. Middle panel: The wild type 
COL5A1 gene and phenotypes. It is proposed that larger, regularly shaped, stronger and 
more compliant fibrils are produced from the wild type gene. These may be associated with 
increased joint range of motion (ROM) and decreased risk for specific musculoskeletal soft 
tissue injuries but lower endurance running performance. Right panel: The effect of 
functional common polymorphisms within the COL5A1 gene on proposed increased type V 
collagen production. Smaller regularly shaped weaker fibrils are produced during 
fibrillogenesis. These fibrils may have an increased stiffness and/or are creep inhibition, are 
associated with reduced joint ROM, increased risk for musculoskeletal soft tissue injuries 






Interestingly, despite the tendon dimensions being similar between healthy 
participants, large and irregular collagen fibrils were observed in the patellar tendons 
of patients diagnosed with the classic form of Ehlers-Danlos syndrome and having a 
mutation in the COL5A1 gene (Nielsen et al., 2014). Reduced (∼50%) tendon 
stiffness and Young's modulus, which relates inversely to flexibility, was reported in 
these patients compared to healthy participants or individuals suffering from benign 
joint hypermobility syndrome (BJHS). However, no pathology was linked to the 
mechanical properties of the BJHS group indicating that the hypermobility phenotype 
observed in these two conditions may occur through different mechanisms or defects 
(Nielsen et al., 2014).  
 
To further investigate the hypothesis by Collins and Posthumus (2011), Kubo et al. 
(2013) recently examined the association between the COL5A1 rs12722 genotypes 
and knee extensors as well as plantar flexor tendon dimensions and mechanical 
properties in vivo. The authors reported a significantly greater maximal tendon 
elongation (CC: 24.5 ± 5.4 mm versus TT+TC: 21.1 ± 5.4 mm) and strain (CC: 7.61 ± 
1.62 % versus TT+TC: 6.51 ± 1.58 %) as well as lower stiffness (CC: 66.2 ± 19.3 
N/mm versus TT+TC: 78.2 ± 18.5 N/mm) for the knee extensors in Japanese male 
participants with a CC genotype compared to those with a combined TT and CT 
genotype (Kubo et al., 2013).  No differences were however reported for the plantar 
flexor (Kubo et al., 2013). 
 
In contrast, Foster et al. reported no significant differences between the genotypes 
and patellar tendon dimensions (volume) and functional (elastic modulus) properties 





active, non-obese Caucasian, males and females between the ages 18 and 39, with 
no history of injuries to the knee (Foster et al., 2014). Although there were no 
significant differences between the maximal stiffness of genotype groups (p=0.203), 
the median maximal stiffness (range) was however lower in individuals with the CC 
genotype compared to those with a TT genotype (TT: 855.7 N/mm (1,569.1), TC: 
707.6 N/mm (1,729.1) and CC: 555.3 N/mm (1,261.5)). This was also reflected in the 
comparison of the stiffness, elastic modulus and Z-scores (Foster et al., 2014).  
 
Although there have been some contradictory results, there is a growing body of 
evidence that suggests that polymorphisms within the COL5A1 3’-UTR is associated 
with range of motion measurements, endurance running performance and 
musculoskeletal soft tissue properties and injuries. Since these studies suggest that 
the COL5A1 3’-UTR might play an important regulatory role in type V collagen 
production, the main aim of this thesis was therefore to investigate this hypothesis. In 
preparation for the experimental chapters of this thesis the following section will 
briefly review some of the main features and functions of eukaryotic 3’-untranslated 
regions (UTRs), specially focusing on those potentially relevant to the COL5A1 3’-
UTR. 
 
1.8 Eukaryotic 3’-UTRs 
 
Within eukaryotic genes there are non-coding regions, namely the 5’-UTR, introns 
and the 3’-UTR, that contain regulatory elements that impact on gene expression 
(reviewed by Barrett et al., 2012). Interestingly, the average length of the 3'-UTR 





complexity (reviewed by Mazumder et al., 2003;Taft et al., 2007). The 3’-UTR is 
located immediately downstream of the protein coding sequence and determines the 
fate of mRNA because it is involved in numerous post-transcriptional regulatory 
processes, including transcript cleavage, mRNA stability, polyadenylation, translation 
and mRNA localisation as reviewed in Barrett et al.(2012). The 3’-UTR contains 
several elements, such as polyadenylation (poly(A)) signals, microRNA (miRNA) 
binding sites and protein binding sites, which are involved in these regulatory 
processes. In this context, the mRNA secondary structure is also emerging as an 
important feature.  
 
1.8.1 Polyadenylation signals 
 
The poly(A) signal is a highly conserved hexanucleotide consensus sequence, 
AAUAAA (reviewed by Edwalds-Gilbert et al., 1997). The formation of the poly(A) tail 
is the result of the addition of a series of adenosine bases (about 200 residues) to 
the 3’-end of an RNA molecule by the poly(A) polymerase through the interaction of 
numerous factors such as the cleavage and polyadenylation specificity factor (CPSF) 
(reviewed by Glisovic et al., 2008). This addition will occur at a site, about 11 to 23 
nucleotides downstream of the hexanucleotide known as the cleavage site, but 
proximal to a GU- or U-rich region (Figure 1.11A). These structures are essential for 
splicing, transcription termination as well as for initiation and termination of 
translation (reviewed extensively by Barrett et al., 2012;Cooke et al., 1999;Edwalds-
Gilbert et al., 1997;Hilleren and Parker, 1999;Yeung et al., 1998). The presence of 
several polyadenylation sites adds to the versatility of expression from a single gene. 
For example, alternative poly(A) signals may play an important role in the synthesis 
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of different isoforms by differential regulation of mRNA splicing ( reviewed by Barrett 
et al., 2012;Edwalds-Gilbert et al., 1997). The human pro-α2(I) collagen gene 
(COL1A2) uses multiple poly(A) signals present in its 3’-UTR which is thought to 
correlate to tissue specificity (Myers et al., 1983). 
Deadenylation is the initial step in the decay of many mRNAs (reviewed in Ross, 
1995). Poly(A) tails are therefore structural and functional elements of eukaryotic 
mRNA that regulate mRNA stability as well as export to the cytoplasm (Wang et al., 
1999;Zarudnaya et al., 2003). The poly(A) tail also provides the mRNA with a binding 
site for a class of regulatory factors called the poly(A) binding proteins (PABP) () 
(reviewed extensively in Barrett et al., 2012; Brook and Gray, 2012 and Mangus et 
al., 2003). PABPs play an essential role in the regulation of gene expression by for 
example affecting the export, stability, decay and translation of mRNAs (Barrett et 
al., 2012). They regulate the ultimate length of the poly(A) tail and facilitate the 
formation of the ‘closed loop’ structure of mRNAs in the cytoplasm in conjunction 
with the 5’-end of the transcript thereby promoting translation initiation, termination 
as well as stability of the mRNA (Figure 1.11B) (Brook and Gray, 2012;Mangus et 






Figure 1.11 Diagram depicting (A) the three sites important in determining where the poly(A) 
addition will occur in the 3’-UTR, namely the hexanucleotide poly(A) signal, the cleavage site 
(also known as the poly(A) site), and the GU-rich downstream element; (B) the mRNA 
‘closed loop’ structure formed from cooperation of the 5’-cap and the 3’-UTR through the 
poly(A) tail modified from Huntzinger and Izaurralde (2011). PABP proteins bind to the 
poly(A) tail and are essential for the stability of this structure in conjunction with proteins of 






1.8.2 The secondary RNA structure 
 
The secondary structure of mRNA refers to a complex two-dimensional conformation 
resulting from the folding of the single-stranded RNA molecule (Nebel and Scheid, 
2011). It is emerging as an important determinant of translation efficiency. Indeed, 
polymorphisms that cause alterations in the mRNA secondary structure may disrupt 
gene expression through affecting accessibility of important trans-acting factors to 
regulatory elements in the mRNA (reviewed by Barrett et al., 2012).  
 
The secondary structure is determined by stem-loops (hairpins), pseudoknots and 
tetraloops (four-base hairpin loop motifs) (Laing and Schlick, 2010). ‘Stems’ are 
formed by complementary canonical Watson and Crick base pairs GC and AU, along 
with GU wobble base-pairing while the ‘hairpin’ is a single-stranded region that folds 
back on itself via regions of complementary base pairs (Laing and Schlick, 2010). 
The ‘internal loop’ is the single-stranded region between two stems and a ‘junction’ is 
the point of connection between three or more helical stems. Finally, ‘pseudoknots’ 
are defined as base pairs that intertwine in single stranded regions (Laing and 
Schlick, 2010). Dynamic folding is guided by the free energy landscape generated by 
these base pairing interactions within the primary sequence of the mRNA molecule 
as well as interactions of the mRNA molecule with the polymerase enzyme, other 
proteins, solvent and metabolites (Laing and Schlick, 2010;Zhang and Chen, 
2002;Zuker et al., 1999). Several computational and experimental approaches are 
used to predict RNA secondary structures, where prediction software such as Mfold 
(Zuker, 2003) and Sfold (Ding et al., 2004) have been developed to elucidate RNA 





as RNA crystallography and fluorescence resonance energy transfer (FRET) (Laing 
and Schlick, 2010).  
 
1.8.3 MicroRNA binding sites  
 
MicroRNAs are a large family of endogenous, evolutionary conserved and non-
coding RNAs (19-25 nucleotides long) which are implicated in the regulation of 
nearly every biological process by modulating gene expression at the post-
transcriptional level (reviewed by Ambros, 2004). They may induce gene silencing by 
binding sites within target genes resulting in mRNA cleavage or repression of protein 
translation (Lau and Lai, 2005;Matzke and Birchler, 2005). MicroRNAs function 
through perfect or imperfect base-pairing at the miRNA binding sites mostly located 
in the 3'-UTR of their target genes (Meola et al., 2009;Rutnam et al., 2013). 
Importantly, the ‘seed region’, which is composed of 6-7 nucleotides, plays a critical 
role in the recognition of the target mRNA by displaying a perfect or partial 
complementarity between the miRNA and its target (Meola et al., 2009;Rutnam et 
al., 2013). Numerous miRNA target site prediction tools and databases such as 
miRanda (http://www.microrna.org) or TargetScan (http://targetscan.org) have been 
developed to determine the presence of a putative binding site within a gene (Bartel, 
2009). In addition, it appears that miRNAs may cooperate in complex networks to 
regulate target genes. For example, one miRNA can act on several genes while 
many mRNA have ‘seed’ matches allowing the binding of multiple miRNA in their 3’-
UTRs (Peter, 2010) (Figure 1.12). In effect, miRNAs are functionally unique and 





regulation of the timing of cellular events as well as via the collaborative inhibition or 






Figure 1.12 Diagram illustrating (A) the ability of miRNAs to target multiple genes; (B) many 
gene targets have several seed matches for multiple miRNA binding in their 3’-UTRs and (C) 
a complex network of mutual interactions exist between miRNA and their targets (modified 
from Peter, 2010). 
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A miRNA may be transcribed from one miRNA gene code and expressed under the 
control of its own promoter and regulatory sequences, or may be arranged in 
clusters of miRNAs and their expression co-regulated in tandem (reviewed by 
Baskerville and Bartel, 2005). The miRNA can be highly tissue-specific or expressed 
in a pervasive manner even though at differing levels (Graves and Zeng, 2012). The 
miRNAs are transcribed in the nucleus as long transcripts, known as primary miRNA 
transcripts (pri-miRNAs), or may contain multiple miRNAs transcripts (Altuvia et al., 
2005). The biogenesis of miRNA and its regulation is beyond the scope of this thesis 
and has been extensively reviewed (Bartel, 2004;Finnegan and Pasquinelli, 
2013;Kim and Nam, 2006). In brief, several proteins are involved in this process, 
namely members of the Argonaute family, Pol II-dependent transcription and the two 
RNase III proteins, Drosha and Dicer (Kim and Nam, 2006) (Figure 1.13). The 
Drosha RNase III protein forms a complex with the double-stranded RNA-binding 
protein DGCR8 (Gregory et al., 2004). The pri-miRNAs are then processed by this 
complex into a smaller stem-loop miRNA precursor of about 70 nucleotides called 
pre-miRNAs (Denli et al., 2004). The pre-miRNAs are then exported across into the 
cytoplasm by the Exportin-5 complex (Bohnsack et al., 2004;Lund et al., 2004). 
These pre-miRNAs undergo additional cleaving by Dicer, another RNase III protein, 
thus producing a 19-25 nucleotide long RNA duplex. These duplexes then enter a 
complex containing the ribonucleoprotein (RNP) and Argonaute-2 (Ago2) called the 
miRNA-induced silencing (miRISC) complex (Schwarz and Zamore, 2002;Tang, 
2005). Only one strand of the miRNA-duplex termed the mature miRNA is 
incorporated into the complex, while the other strand, denoted as miRNA*, is 
removed (Bartel, 2004). Within this complex, miRNAs will bind to their targets and 






Figure 1.13 The biogenesis of miRNA modified from Rutnam et al. (2013). The miRNA 
genes are transcribed by RNA Pol II/III to make pri-miRNA. The pri-miRNA is cleaved by 
Drosha complexed with DGCR8 generating pre-miRNA. In turn pre-miRNA is exported by 
the Exportin-5 complex into the cytoplasm. The Dicer complex processes it to create the 
miRNA:miRNA* duplex. The RNP complex separates the duplex to create the mature 






Relevant to musculoskeletal soft tissue biology, there is mounting evidence that 
miRNAs contribute to the formation, maintenance and remodelling of the ECM 
(extensively reviewed by Edeleva and Shcherbata, 2013;Guller and Russell, 
2010;Neves et al., 2014;Piccinini and Midwood, 2014). Piccinini et al. (2014) argued 
that miRNAs influences the ECM either directly, by targeting the mRNA of ECM 
molecules, or indirectly, by modulating the expression of genes that regulate the 
synthesis or the degradation of the ECM. This regulation is further mediated through 
cross-talk between the ECM and the cell adhesion and signalling mediators in the 
presence of the cell sensory apparatus (Edeleva and Shcherbata, 2013). To date, 
several members of the ECM have had their mRNA regulated by miRNAs, including 
the structural components such as the soluble multi-adhesive molecules (e.g. 
fibronectin), proteoglycans (e.g. versican), and the collagens as well as the 
enzymatic components such as MMPs (Edeleva and Shcherbata, 2013;Piccinini and 
Midwood, 2014). Recently, Piccinini et al. (2014) generated a comprehensive list of 
ECM encoding genes that are directly or indirectly regulated by miRNA. Among them 
were several collagen genes, namely COL1A1, COL1A2, COL2A1, COL3A1, 
COL4A1, COL4A2, COL5A1, COL5A2 and COL15A1. 
 
Cancer researchers have reported that miRNA let-7g inhibits cell migration 
expression and colony formation by down-regulating the 3’-UTR of COL1A2; thereby 
suppressing hepatocellular carcinoma metastasis (Ji et al., 2010). Moreover, the 
over-expression of a different miRNA, miR-301, up-regulated human breast cancer 
cell migration and invasion through its down-regulation of COL2A1 while exerting 
additional pressure through repressing tumour suppressors (Shi et al., 2011). 





nasopharyngeal carcinomas compared to healthy tissue (Sengupta et al., 2008). The 
authors further observed that miR-29c was able to target multiple collagens, 
including COL1A1, COL1A2, COL3A1, COL4A1, COL4A2 and COL15A1. 
Decreased levels of miRNA in these tumours could correspond to an increased 
expression of these ECM molecules and likely increase their invasiveness and 
metastatic potential (Sengupta et al., 2008). 
 
In cartilage and bone development, miR-145 suppresses chondrogenic 
differentiation of murine embryonic mesenchymal cells by directly targeting SOX9 
mRNA, a positive master regulator of chondrogenesis. At early stages of 
chondrogenic differentiation, miR-145 expression decreases which correlates with an 
increased expression of COL2A1, COL9A2 and COL11A1 among other ECM 
molecules (Martinez-Sanchez et al., 2012;Yang et al., 2011). As expected, miR-145 
overexpression results in a reduction in the levels of these ECM molecules (Yang et 
al., 2011). Similarly, miR-675 and miR-1247 show an interaction with SOX9 and 
regulated the expression of COL2A1 (Dudek et al., 2010;Martinez-Sanchez and 
Murphy, 2013). Lastly, miR-29b was shown to be a negative regulator of the 
COL1A1 gene in liver fibrogenesis (Ogawa et al., 2010) while miR-133a (Castoldi et 
al., 2012;Matkovich et al., 2010) and miR-29b (Castoldi et al., 2012;van Rooij et al., 
2008) showed an important role in myocardial fibrosis by targeting COL1A1 among 
others.  
 
With respect to disease-causing polymorphisms (mutations) and genetic variants, 
mechanisms affecting miRNA function in human genetic disorders have been 
proposed (Meola et al., 2009), mainly through: (1) variations in the miRNA nucleotide 
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sequences; (2) nucleotide changes in miRNA binding sites; and (3) changes in the 
nucleotide sequence of genes that participate in the general processes of miRNA 
processing, regulation and function (Figure 1.14). Of significance to this thesis, Hsa-
miR-608 has a binding site in the COL5A1 3’-UTR at the polymorphic site rs3196378 
(C/A), where the A nucleotide at that locus was preferred for repression compared to 
the C nucleotide (Abrahams, 2013;Laguette et al., 2011). In addition, as mentioned 
in section 1.7, the MIR608 gene is also polymorphic (rs4919510, C/G) and is one of 
the many variants reported to be independently associated with chronic Achilles 
tendinopathy (Abrahams et al., 2013). 
Figure 1.14 Schematic diagram representing the main types of miRNA genetic variations 
with a potential role in disorders (adapted from Meola et al. 2009). 
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1.8.4 Protein binding sites 
Protein binding sites within the 3’-UTR allow the binding of trans-acting factors such 
as RNA binding proteins (RBP) to the mRNA. RBPs are involved in RNA 
modification and processing, stabilisation and destabilisation, shuttling and cellular 
localisation of the mRNA (Extensively reviewed in Glisovic et al., 2008;Hogan et al., 
2008;Ross, 1995). The members of this vast and diverse protein family are nuclear 
and cytoplasmic proteins and they bind one or more RNA binding motif or domain in 
order to control and regulate gene expression (Glisovic et al., 2008).  
Several RNA binding motifs have been characterised and used to screen for new 
RBPs, namely the (1) RNA-binding domain (RBD), also known as the RNA 
recognition motif (RRM), (2) the K-homology (KH) domain (type I and type II), (3) the 
RGG (Arg-Gly-Gly) box, (4) the Sm domain, (5) the DEAD/DEAH box, (6) the zinc 
finger (ZnF), (7) the double stranded RNA-binding domain (dsRBD), (8) the cold-
shock domain; (9) the Pumilio/FBF (PUF or Pum-HD) domain, and lastly, (10) the 
Piwi/Argonaute/Zwille (PAZ) domain (reviewed in Chen and Varani, 2005;Lunde et 
al., 2007). The diversity of this class of proteins is mostly achieved via the presence 
of multiple combination of domains, presence of auxiliary functional domains, splice 
variants, post-translational modifications such as, but not limited to, phosphorylation 
and methylation and/or spatiotemporal-specific expression (Glisovic et al., 2008).  
In addition, RBPs function in numerous cellular processes, but the focus of this 
thesis is their role in the regulation of post-transcriptional gene expression. Figure 





events and RNA processing. For example, they play an essential role in miRNA 
biogenesis, e.g. Dicer, as described in section 1.8.3. Furthermore, specific RBPs are 
responsible for polyadenylation of the mRNA as described in section 1.8.1. Mainly, 
the CPSF complex together with PAPB proteins, drive the activity of the poly(A) 
polymerase (Bienroth et al., 1991). Export of the mRNA is also crucial and a three 
step process mediated by RBPs have been described by Glisovic et al (2008) as 
follows: (1) the generation of a cargo-carrier complex in the nucleus, followed by (2) 
translocation of the complex through the nuclear pore complex, and lastly, (3) 
release of the cargo in the cytoplasm with subsequent recycling of the carrier (Figure 
1.15). For example, the RBP TAP (ATP-binding cassette transporter/ sub-family B) is 
a constitutive transport element binding protein, that is involved in the mRNA export 
process, in conjunction with other adaptor proteins mediating the affinity to the 
mRNA (Gruter et al., 1998;Stutz et al., 2000). Moreover, mRNA localisation, 
translation and mRNA turnover are key processes in the regulation of gene 
expression where RBPs play a critical role (Glisovic et al., 2008). For example, the 
RBP zipcode-binding protein-1 (ZBP1) binds the β-actin 3’-UTR and moves with the 
mRNA into the cytoplasm, blocking the initiation of its translation (Huttelmaier et al., 
2005) until the cell lamella in polarised cells, such as in fibroblasts, is reached 








Figure 1.15 A diagram illustrating the role of RBPs in the regulation of post-transcriptional 
gene expression, modified from Glisovic et al. (2008). Many different classes of RBPs 
interact with various small non-coding RNAs to form ribonucleoprotein (RNP) complexes 
which take part in various cellular processes. In the presence of heterogeneous nuclear 
ribonucleoproteins (hnRNPs), the pre-mRNAs are first transcribed by the RNA polymerase II 
in the nucleus. These then go through several processing steps that will determine the fate 
of the transcript. During splicing, modifications of the exon-junction complex (EJC) occurs 
specifically on spliced mRNAs, and this affects the fate of the messenger ribonucleoproteins 
(mRNPs) in the next steps, for e.g. recruitment of ribosomal subunits for translation initiation, 
or surveillance of mRNA for nonsense-mediated mRNA decay (NMD). Relevant to this 
thesis, RBPs bound to the 3’-UTR of an mRNA can repress the initiation of translation and 
direct the subcellular localisation of the mRNAs. Some mRNAs, upon transport to the 
cytoplasm, are further modified by the cytoplasmic polyadenylation ribonucleoprotein, CPEB. 
PTC stands for premature stop codon. PYM is a protein that binds to the EJC. 
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Importantly, RBPs regulate mRNA turnover and stability. The following cis-elements 
in the 3’-UTR are recognised by trans-acting elements such as the RBPs: poly(A), 
iron-responsive elements, specific protein recognition sites, long range stem loops 
and AU-rich elements (Ross, 1995). The RBPs are able to bind these motifs through 
interactions with other partners influencing the stabilisation or destabilisation of the 
mRNA (Glisovic et al., 2008). The following examples demonstrate that the collagen 
genes are also regulated by RBPs. Namely, the RBP αCP was shown to bind to the 
COL1A1 3’-UTR in a C-rich region and mRNA decay experiments indicated that it 
stabilised the mRNA (Lindquist et al., 2004). In addition, the three RBPs, 
heterogeneous nuclear ribonucleoprotein (hnRNP) A1, E1, and K, are positive 
regulators of collagen synthesis acting on the 3’-UTRs of COL1A1, COL1A2, and 
COL3A1 mRNAs (Thiele et al., 2004).  
1.8.5 Characteristics of the COL5A1 3’-UTR 
The 3’-UTR of the COL5A1 gene, encoded by exon 66, contains several features 
that suggest an important role in the regulation of its gene. To the best of my 
knowledge, there are however no published reports describing a role for the 3’-UTR 
in COL5A1 gene expression and indeed, although an essential gene, the regulation 
of COL5A1 is poorly understood. In addition to the numerous genetically associated 
polymorphisms, with unexplored functions (Mokone et al., 2006;September et al., 
2009), the following features, which may play important regulatory roles in the 
expression of COL5A1 gene, have been identified within its 3’-UTR (Figure 1.16):  
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(i) Three putative polymorphic (rs1134114, C/T; rs3196378, C/A and
rs11103544, T/C) miRNA binding sites, 5’-CCGACCCA-3’, 5’- CCACCCCA -3’
and 5’-TTTTCTAC-3’ for Hsa-miR886-5p, Hsa-miR-608 and an unknown
miRNA, respectively (Abrahams, 2013;September et al., 2009).
(ii) Three poly(A) signals (AAUAAA) within the distal 3’-UTR.
(iii) The first exon of an expressed sequence tag (EST; ENSESTG00000033016)
which is transcribed in the antisense direction with its second and last exon at
the start of COL5A1. To date, it is unknown if it encodes for a functional
protein or not.









Figure 1.16 Schematic representation of COL5A1 3’-UTR on exon 66 (the open rectangle), 
showing the numerous variants investigated in genetic association studies (boxed below with 
arrows). The BstUI RFLP (C/T, rs12722) is shown here (yellow) together with the generated 
genotypes from its allele combinations (CC, CT or TT). The area underlined depicts the zone 
strongly associated with Achilles tendinopathy and other musculoskeletal soft-tissues 
injuries. The putative miRNA binding sites and poly(A) signals (shown as A, bold) as well as 






1.9 Aim of the study 
 
The hypothesis of this thesis is that the COL5A1 3’-UTR is functional and that 
common polymorphisms within it may result in alterations in type V collagen 
production which is predicted to affect fibrillogenesis and by implication the 
mechanical properties of musculoskeletal soft tissues. Therefore the aim of this 
thesis was to determine whether the 3’-UTR of COL5A1 was functional and whether 
polymorphisms within the 3’-UTR generate functional differences.  
 
The specific objectives of this thesis were therefore: 
(i) To determine whether the COL5A1 3’-UTR was functional and to identify 
functional differences between the 3′-UTR from patients with chronic Achilles 
tendinopathy having the ‘at risk’ TT rs12722 genotype (BstUI RFLP) and 
asymptomatic controls having the ‘protective’ CC genotype at the same locus.  
(ii) To identify additional polymorphisms within the 3’-UTR that are associated 
with chronic Achilles tendinopathy.   
(iii) To map the functional regions of the COL5A1 3’-UTR, focussing on those 
regions which are potentially responsible for contributing to the tendinopathic 
phenotype. 
(iv) To measure COL5A1 (Type V collagen) and COL1A1 (Type I collagen) gene 
expression in primary skin biopsies from individuals with a known ‘at risk’ or 
‘protective’ genotype at rs12722. 
(v) Identify any putative regulatory motifs within the functional regions and 
determine whether there are any binding differences between the control and 
tendinopathic phenotypes.   
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CHAPTER 2 MATERIAL AND METHODS 
2.1 Participants used for the Cloning of the 3’-UTR 
For the purpose of this study, five de-identified individuals diagnosed with chronic 
Achilles tendinopathy (TEN) within the mid-portion of the tendon, as well as five 
healthy and physically active de-identified asymptomatic individuals with no self-
reported history of tendon injuries (CON) were chosen from the participants included 
in a previous study (Mokone et al., 2006). By design, the five selected TEN 
participants all had a TT genotype at COL5A1 rs12722, the genotype associated 
with an increased risk of Achilles tendinopathy (Table 2.1). In contrast, the five 
selected CON participants all had the “protective” CC genotype at this 
polymorphism. In addition, the TEN participants all had a TT genotype at rs13946 
(also known as the DpnII RFLP) which was also examined in the study but not 
associated with the disease, whereas the CON subjects were either CC (n=3) or TC 
(n=2) at this polymorphism (Table 2.1). The use of the participants’ previously 
extracted total genomic DNA samples (Mokone et al., 2006) was approved for this 
study by the Human Research Ethics Committee of the Faculty of Health Sciences at 
the University of Cape Town (Appendix A). 
The two groups were matched for sex (TEN 4 males vs. CON 2 males, p=0.524), 
age (initial injury, TEN 38.4 ± 16.1 years vs. recruitment, CON 39.7±11.5 years, 
p=0.910), weight (TEN 75.8±9.7 kg vs. CON 65.0±12.4 kg, p=0.198), height (TEN 
178±6 cm vs. CON 175±8 cm, p=0.471) and BMI (TEN 23.8±2.0 kg.m-2 vs. CON 
21.1±2.2 kg.m-2, p=0.099) (Table 2.2). 
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Table 2.1 The COL5A1 3’-UTR single nucleotide polymorphisms rs12722 (C/T) and rs13946 
(C/T) genotypes of the individual Achilles tendinopathy (TEN) and asymptomatic control 
(CON) participants included in this study, as well as the consensus genotypes. 
Genotype 
Participant rs12722 rs13946 
TEN-1 TT TT 
TEN-2 TT TT 
TEN-3 TT TT 
TEN-4 TT TT 
TEN-5 TT TT 
Consensus TT TT 
CON-1 CC CC 
CON-2 CC CC 
CON-3 CC CC 
CON-4 TC CC 
CON-5 TC CC 






Table 2.2 General characteristics of the individual Achilles tendinopathy (TEN) and 















TEN-1 49 31 Male 186 87 25.1 
TEN-2 27 20 Female Unknown Unknown Unknown 
TEN-3 62 61 Male 175 64 20.8 
TEN-4 47 32 Male 173 73 24.4 
TEN-5 49 48 Male 179 79 24.7 
Ave ± SD. 46.8 ± 12.6 38.4 ± 16.1 80%* 178 ± 6 75.8 ± 9.7 23.8 ± 2.0 
CON-1 Unknown - Female 167 54 19.4 
CON-2 28 - Male 183 78 23.3 
CON-3 51 - Female 171 56 19.1 
CON-4 40 - Female 170 58 20.1 
CON-5 Unknown - Male 183 79 23.6 
Ave ± SD. 39.7 ± 11.5 - 40%* 175 ± 8 65 ± 12.4 21.1 ± 2.2 
 
BMI - Body mass index; Ave – average; SD. - Standard Deviation; cm - centimetres; kg – 
kilograms; m - metres.  







Moreover, a “severe” phenotype was an inclusion criterion for the TEN subjects and 
was determined by most of the following criteria: 
 Early age of onset of initial symptoms (3 of 5 were ≤32 years of age at the 
initial injury) 
 Multiple Achilles tendon injuries (2 of 5) 
 Bilateral chronic Achilles tendinopathy (3 of 5) 
 
 
Table 2.3. Characteristics of the Achilles tendinopathy (TEN) participants as well as features 
of their pathology. 
 
Participants 






Number of “Severe” 
Phenotype a 
TEN-1 31 1 Bilateral 2 
TEN-2 20 1 Unknown 1 
TEN-3 61 2 Bilateral 2 
TEN-4 32 2 Right 2 
TEN-5 48 1 Bilateral 1 
 
a Age at initial injury < 40 years, multiple injuries and bilateral Achilles tendon injury.  






2.2 Cloning the COL5A1 3’-UTR Reporter Gene Constructs 
 
The 2546 bp COL5A1 3′-UTR was amplified from previously extracted total genomic 
DNA (Mokone et al., 2006) from the TEN and CON participants included in this study 
(section 2.1) using a nested polymerase chain reaction (PCR) and cloned into the 
pGL3-Promoter vector (Promega Corporation, Madison, WI, USA), substituting the 
SV40 (Simian virus 40) late poly (A) signal of the firefly luc+ reporter gene (Appendix 




Figure 2.1 Schematic drawing representing the cloning strategy of the human COL5A1 3’-
UTR (left, in red) into the pGL3-Promoter vector (right, in black), substituting the SV40 late 
poly (A) signal (blue box) of the firefly Luc+ reporter gene (yellow box).  
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The COL5A1 3′-UTR was PCR amplified using an external set of primers (forward: 
5′-GAT CAG CTT CAA TCC TGT GTG TGC-3′, and reverse: 5′-GTT ATC TCC AGA 
GCT CCT AGC GTC CT-3′) and an internal set of primers in which restriction 
enzyme (RE) sites were created for cloning (forward: 5′- GCT TGC TTC ATG GGC 
TAG CAG CCG C-3′ with the NheI RE site (underlined and bold) producing 
complementary sticky ends to an XbaI RE digest, reverse: 5′-GAG TCA CTC GGA 
TCC GTT TAC GGT GG-3′ with the BamHI RE site (underlined and bold). The 
secondary PCR products were digested with NheI (Promega Corporation, Madison, 
WI, USA) and BamHI (New England Biolabs, Ipswich, MA, USA). The digested 
fragment was purified using QIAEX®II Gel Extraction kit (QIAGEN GmbH, Hilden, 
Germany) and then ligated using the T4 DNA Ligase enzyme (Promega Corporation, 
Madison, WI, USA) into the prepared pGL3-Promoter vector. The later was digested 
using XbaI (New England Biolabs, Ipswich, MA, USA) and BamHI enzymes as 
shown in figure 2.2. 
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GTGGGGCCGG CTTGCTTCAT GGGCTAGgAG CCGCCGAGCC CGGGCTCCCG AGAGCAACCT 180  
NheI 
CGTGACCTCA GCATGCCATT CGTTCGTGAG TGTCCCGTGC ACGTCCTGAC CCTGGACAGT 240 
DpnII (rs13946) 
GAAGGCTTCT CCCTCCCCTC CCACCTGACT TCATCTACGC CTCGGCACCA CGGGGTGTGG 300  
GACCCCAGCC CGGAGAGAAC AGAGGGAAGG AGCCGCGCCC CCACCTGGAG CTGAATCACA 360  
TGACCTAGCT GCACCCCAGC GCCTGGGCCC GCCCCACGCT CTGTCCACAC CCACGCGCCC 420 
BstUI (rs12722) 
CGGGAGCGGG GCCATGCCTC CAGCCCCCCA GCTCGCCCGA CCCATCCTGT TCGTGAATAG 480 
  rs1134114 
GTCTCAGGGG TTGGGGGAGG GACTGCCAGA TTTGGACACT ATATTTTTTT CTAAATTCAA 540  
CTTGAAGATG TGTATTTCCC CTGACCTTCA AAAAATGTTC CAAGGTAAGC CTCGTAAAGG 600  
TCATCCCACC ATCACCAAAG CCTCCGTTTT TAACAACCTC CAACACGATC CATTTAGAGG 660  
CCAAATGTCA TTCTGCAGGT GCCTTCCCGA TGGATTAAAG GTGCTTATGT TTTTGTGAGT 720  
TTTAAGTAAA TATTTGTATT GTATTGTTAT AAATGTTAAG TGTGCCTGGC TTTCAATCAT 780  
GCACGGAAAC CCAGTCTCAG TCCCACGGAC AGAATGGGCG AGGCATGGAT TCTGGGTTGC 840  
AGTACCGTTC TGATTAGAAA TAGGAAGTCT CCCCACCCCC GCCCTGGCCA AGAACGTGCA 900 
hsa-miR-608
AciI (rs3196378) 
ATAAATTGGA AGTTTGCCCC GGGGCAGCAA GAATTTATGC TGCCATTGAA AAGCAGGTAC 960  
CAGTGCCCCT TTTCAGACAG TTTTTGATTC GCTCTAGACT TTTTTTTTTT TTAATAGGGA 1020 
XbaI    rs71698207   rs71746744 
AAAAATTTGA TAATTTTCTT TTTTCTACAT GCACTTAAGA CTAAAACACA GGTTTGGATT 1080 
MboII (rs11103544) AflII 
AATTTTATTT GCTTCCTTTT TCCGCTTTTC TTCCCGCAGA GCCTGATGGG AGAATGTCCA 1140 
GGGCAGGGAA ACCACATTTT TTGTAGGTGA TAACTCAATG AAAATTGGTG CTTATTTTTT 1200 
ACACTTCTCT CTTGTGGCTC TCTTGTGGTG CTATCTATCT GTTTTAAGGT CTCCTTGAAG 1260 
GCGCACTGGG GACCCTGGCC ATGCCTCGTT CTCCCTGCTT TCTTTATCCT GTTATTGCCT 1320 
CCACAGTCTG TTGCCAAGGA CTCTAAGATC AATGCACGTC ACTTTCCTTT CCACTGGGCA 1380 
GGATAGCCAA GCACACTCCC TCCTGCGCTC TCCCGCCCCG GTGCGTCCAC TCCCGAGGGC 1440 
TGTTATGAGG ACTGGGTTGT GCCTACTTGA TTTGAAAACA CACACAAGCa ataaaaaGCC 1500 
TCTTCCTGCA TTGTCTGTGG TGTGACCATA GCAGATTATA TTTGGTTCCT GAaTGTTTGT 1560 
GGTGCTAATT TCTGTGTTTG TTCCAAGCCG TTCAGTCATG CCATGCGCTG CCTCGGTAGA 1620 
TGGAGTAATG TACAATGAAC TCCATGAGTC TCTCCAGGGC TGCCTGCAGC ACGTCTTTTC 1680 
CAAGTAGCCT ATTTGGATTC CCATCTCAAA TGTCCTGGAT GCGAGCGTCA GCGGCTCCAG 1740 
AGCTCGGGGC GGGTGAGGTC CCCTTTGGGG AACCCTTTCC TGGCCATCGA GGTCGGGGGG 1800 
CTGCCGTCTG TGGGCAGGAG GACCCGAGGG GCAGCCAGGA AAGGCGATCT CTTCACTGTG 1860 
AAAAGTTGCC CGGGTGCAGC GCCTTTTCCT TCTACCATGG GAAATGCAGG CTGGGCCCTT 1920 
GGGGTGAGCC TGCGGGGCTC TGGTGCTGTC CCCGACCCCC ACCACCACCA GAATGCAGTT 1980 
CCAGCTTAGG AAGCCACAAA CAAGCCACCC AGGAGGAACA AAACACCGCC AGCGTGGATT 2040 
TTCCAAATTT CCCTGGAAAG TAAGTCTCGC TCTTGCCAAA GAAAAGTCTG GCTTGGAGAG 2100 
TCTCTGGAGC CCAGGATGCC AGCATGTGCC AATGACTGTC ACCTTCATCT CTTCAAAAGA 2160 
AAAGCCATAG CCGAGGACTG TCCCGCGACC CCCGTGGACT GCGTCTAGGT CATGTGATTC 2220 
TthIII 
TGTTTTCATT TCTCATCCCA TCCAATTTGT CCTTTTCTCC TGTCATTTTC TTCCTCTGTG 2280 
GTCCCTTCAA AGTTGTTATA ATTTGTACTG AACTTCAAAA TGTGTCCCGT TCTCCCCAGA 2340 
CCACTCTAGC CACAGTATAT TGCaataaaa TTACTTCTTA TATTTGCAGA AaTTCTTTTG 2400 
GTGTAATTTT ATTTTTTCCT CTCAATATAT ATAATTGGAC AAACGCTGGC AAAAAGAAAA 2460 
AAATGGTAAG CAAAAAACCC AAGATAAAGT TTCGAGGACA TCAGGCCTTT TGAAATACAA 2520 
TGTCAAATGA CACATTGTAC GGTTTCAAAA AATCCGCTAG ACATGTCATA AGTTTTAACT 2580 
GTAATGCCCA GGAAAGGATA TCTTAAAATA TTCTAAACTT GTGTAACAAA GGAATAATTA 2640 
ACTGTAATAG TTTTTCaata aaTCGAGTTG GGTGTTTCCA CCGTAAaCgG ATccGAGTGA 2700 
BamHI 





Figure 2.2 Nucleotide sequence of COL5A1 exon 66 (PubMed accession no. NM_000093) 
containing the 3’-untranslated region (UTR) (nucleotides 148 to 2688). The sequences 
highlighted in grey represent the last 27 nucleotides of the translated region of exon 66 
(nucleotides 121-147). The stop codon (TAG) within the exon is double underlined. 
Nucleotide numbers of exon 66 are annotated on the right side of the sequence. The 
positions of key polymorphisms within the 3’-UTR are highlighted in black with the text in 
white. The sequence contains the wild-type nucleotides of the polymorphic sites. The 
accession numbers of selected polymorphisms are given, including, when appropriate, the 
name of the restriction fragment length polymorphism. The four unlabelled polymorphic sites 
are the (i) ATCT at position 1237, rs16399; (ii) A at position 1272, rs1134170; (iii) G at 
position 2542, rs4504708; and (iv) T at position 2648, rs3128575. The putative recognition 
sequences of the two micro RNAs are highlighted in grey, while the three putative 
polyadenylation signals are in white lower case and highlighted in black. Key restriction sites 
are annotated on the sequences. Mutations generated in the sequences of the 3’-UTR are 







2.3 Generation of Deletion Constructs of the COL5A1 3’-UTR 
 
Two deletion constructs (Figure 2.3) pGL3-COL5A1-3′UTR (Δ488) using RE Tth111I 
(Promega Corporation, Madison, WI, USA) and BamHI, and pGL3-COL5A1-3′UTR 
(Δ57) using XbaI and AflII (New England Biolabs, Ipswich, MA, USA) were 
generated from the parental constructs (pGL3-COL5A1-3’UTR) cloned from the TEN 
and CON participants. The parental constructs were digested using the respective 
restriction enzyme pairs sequentially before being visualized on a 0.7% agarose gel. 
The DNA fragment generated was gel purified or re-precipitated as described before. 
The digested constructs were blunt-ended using the DNA Polymerase I Large 
(Klenow) Fragment (Promega Corporation, Madison, WI, USA) according to the 
manufacturer’s recommendations. This was followed by gel purification or re-
precipitation before ligation using the T4 DNA Ligase enzyme. The ligation products 





Figure 2.3 Construction of two deletion constructs of the COL5A1 3’-UTR. The parental 
constructs (pGL3-COL5A1-3′UTR, on top) cloned from the TEN and CON participants were 
digested using the annotated respective enzymes to remove the indicated sequences of the 
parental COL5A1-3’UTR to generate deletion constructs pGL3-COL5A1-3′UTR (Δ488) and 





2.4 Generation of Site-Directed Mutants within the COL5A1 3’-UTR 
 
Site-directed mutagenesis (SDM) of rs12722 (C/T) within the COL5A1 3’-UTR 
(Figure 2.2) of the parental constructs (pGL3-COL5A1-3’UTR) cloned from the TEN 
and CON participants was performed using the QuikChange™ Site-Directed 
Mutagenesis guidelines (Stratagene, La Jolla, CA, USA). Table 2.4 lists the primers 
(IDT, Coralville, IA, USA) used to generate the SDM mutants, which were designed 
as recommended by the QuikChange™ Site-Directed Mutagenesis manual. The 
PCR reaction was optimized and performed in a total volume of 50 μl containing 50 
ng of circular plasmid DNA (pGL3-COL5A1-3’UTR), 20 μM of each of the forward 
and reverse primers, 1X reaction buffer (20mM Tris-HCl, pH 8.8; 10mM KCl; 10mM 
(NH4)2SO4; 2mM MgSO4; 0.1% Triton® X-100 and 0.1mg/ml nuclease-free BSA), 10 
mM of each dNTPs, 4 μl of Dimethyl Sulphoxide (DMSO) (Sigma-Aldrich, Munich, 
Germany) and 1 μl of Pfu DNA polymerase (Promega Corporation, Madison, WI, 
USA). The cycling conditions included an initial denaturing step at 95°C for 1 min 
followed by 17 cycles of denaturing at 95°C for 45 s, annealing at 55°C for 1 min and 
extension at 73°C for 14 mins using an Applied Biosystems 2720 Thermal cycler 
(Applied Biosystems, Foster City, CA, USA). Two mutants were generated: (i) TEN 
rs12722_T>C, where the T polymorphic nucleotide of rs12722 was mutated to a C 
nucleotide within the parental constructs (pGL3-COL5A1-3’UTR) cloned from the 
TEN participants and (ii) CON rs12722_C>T, where the C polymorphic nucleotide of 
rs12722 was mutated to a T nucleotide within the parental constructs (pGL3-
COL5A1-3’UTR) cloned from the CON participants, as illustrated in figure 2.4. 
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Table 2.4 Primers designed for the site-directed mutagenesis of rs12722 (C/T) within the 
COL5A1 3’-UTR (figure 2.2) of the parental constructs (pGL3-COL5A1-3’UTR) cloned from 
the TEN and CON participants. 
Primer Name 5’- Position 
exon 66 a 
Primer Sequence (5'-3') 
FWD TEN rs12722_T>C 400 TCT GTC CAC ACC CAC GCG CCC CGG GAG 
REV TEN rs12722_T>C 425 TCC CGG GGC GCG TGG GTG TGG ACA GAG b 
FWD CON rs12722_C>T 400 TCT GTC CAC ACC CAT GCG CCC CGG GAG 
REV CON rs12722_C>T 425 TCC CGG GGC GCA TGG GTG TGG ACA GAG b 
The mutated nucleotides within the primers are highlighted in bold and underlined. 
a Refer to figure 2.2 
b reverse complement 
For variant rs71746744 (-/AGGG), within the COL5A1 3’-UTR (Figure 2.2) of the 
parental constructs (pGL3-COL5A1-3’UTR) cloned from the TEN and CON 
participants, mutants were generated using the KAPAHiFi™ DNA Polymerase (Kapa 
Biosystems, MA, USA) and phosphorylated primers as recommended by the 
manufacturer (Table 2.5).  
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Table 2.5 Primers designed for the site-directed mutagenesis of rs71746744 (-/AGGG) 
within the COL5A1 3’-UTR (figure 2.2) of the parental constructs (pGL3-COL5A1-3’UTR) 
cloned from the TEN and CON participants. 
Primer Name 5’- 
Position 
exon 66 a 
Primer Sequence (5'-3') 
FWD CON rs71746744_C>T 1016 /5Phos/AGG GAA AAA ATT TGA TAA TTT TCT TTT TTC TAC ATG CAC 
FWD TEN rs71746744_T>C 1020 /5Phos/AAA AAA TTT GAT AAT TTT CTT TTT TCT ACA TGC AC 
REV CON rs71746744 986 /5Phos/CCC TAT TAA AAA AAA AAA AAA AAG TCT AGA GCG AAT C b
The mutated nucleotides within the primers are highlighted in bold and underlined. 5Phos 
denotes the 5’ position of the phosphorylated nucleotide. 
a Refer to figure 2.2 
b reverse complement 
For the deletion mutagenesis, the primers were designed with a gap between them 
(FWD TEN rs71746744_T>C and REV CON rs71746744), while for the insertion, the 
extra nucleotides were added at the 5’- position of the forward primer (FWD CON 
rs71746744_C>T and REV CON rs71746744). The PCR reaction was performed in 
a total volume of 25 μl containing 5 ng of circular plasmid DNA, 0.3 μM of each of the 
forward and reverse primers, and 12.5 μl of 2x KAPAHiFi™ HotStart ReadyMix (1x 
concentration containing 0.3 mM of each dNTP, 2.5 mM MgCl2 and 1 U of KAPA 
HiFi HotStart DNA Polymerase in a proprietary reaction buffer) (Kapa Biosystems, 
MA, USA). The cycling conditions included an initial denaturing step at 95◦C for 2 
mins followed by 16 cycles of denaturing at 98°C for 20 s, annealing at 60°C for 15 s, 





using an Applied Biosystems 2720 Thermal cycler (Applied Biosystems, Foster City, 
CA, USA).  
 
As illustrated in figure 2.4, the generation of two mutants were attempted: (i) CON 
rs71746744_ins AGGG, where a second AGGG tetranucleotide was inserted into 
rs71746744 of the parental constructs (pGL3-COL5A1-3’UTR) cloned from the CON 
participants and (ii) TEN rs71746744_del AGGG, where the second AGGG 
tetranucleotide was deleted from rs71746744 of the parental constructs (pGL3-
COL5A1-3’UTR) cloned from the TEN participants. 
 
Following the SDM PCR reactions, the mutants were subjected to a digestion by the 
DpnI enzyme (Promega Corporation, Madison, WI, USA) in order to remove the 
residual methylated parental templates and any hemi-methylated DNA following the 
manufacturer’s recommendations for 1hr at 37°C and heat inactivated at 65°C for 20 
mins. Mutants for rs71746744 required an extra ligation step after the above 
digestion. This was done as described previously. Finally, all the mutants generated 
were transformed into competent E. coli bacteria (DH05α strain) as described in 
section 2.5. Maxi preparations of the constructs were then made and purified as 












Figure 2.4  Schematic diagram representing the site-directed mutations (Grey boxes) that 
were generated in the COL5A1 3’-UTR cloned from the TEN and CON participants. Top 
Panel: CON rs12772_C>T, where the C polymorphic nucleotide of rs12722 was mutated to 
a T nucleotide within the parental constructs (pGL3-COL5A1-3’UTR) cloned from the CON 
participants (C-allelic form). CON rs71746744_ins AGGG, where a second AGGG 
tetranucleotide was inserted into rs71746744 of the parental constructs (pGL3-COL5A1-
3’UTR) cloned from the CON participants. Bottom Panel: TEN rs12722_T>C, where the T 
polymorphic nucleotide of rs12722 was mutated to a C nucleotide within the parental 
constructs (pGL3-COL5A1-3’UTR) cloned from the TEN participants (T-allelic form). TEN 
rs71746744_del AGGG, where the second AGGG tetranucleotide was deleted from 







2.5 Production of Competent Cells and Transformation 
 
The method described below was initially developed to optimize bacterial 
transformation efficiency, transformation being the uptake of naked DNA by bacterial 
cells (Hanahan, 1983). A single E. coli colony (DH5α strain) from a freshly streaked 
SOB (Super Optimal Broth) agar plate (Appendix B) was resuspended in 5 ml of 
Transformation broth (TFB) (Appendix B) and shaken overnight at 37ºC. This starter 
culture was then inoculated into 100 ml of pre-warmed TFB broth in a 1 L conical 
flask, and shaken at 37ºC until the log phase growth (an Optical Density of 0.35 at 
600 nm) was reached. This culture was transferred to an ice-cold centrifuge tube and 
chilled on ice for at least 15 mins. It was pelleted by centrifugation at 3000 rpm for 10 
mins at 4ºC using the rotor JA-14 in the J2-21 centrifuge (Beckman, USA). The 
supernatant was discarded and the pellet gently resuspended in 21 ml of 
Transformation buffer 1 (TFB1) solution (Appendix B). The resuspended cells were 
incubated on ice for 90 mins and centrifuged as described before. The supernatant 
was decanted once more and the cells resuspended in 4 ml of ice-cold TFB2 
solution containing glycerol (Appendix B). Finally, 100 μl aliquots of the above 
resuspension were stored in the -70ºC until needed. 
 
During transformation, a 100 μl aliquot of competent cells was mixed with 10-50 ng 
of plasmid DNA by gentle flicking and left on ice for 30 mins. The mixture was moved 
to a 42ºC pre-heated water bath for 1 min and then put back on ice for 2 mins. Nine 
hundred microlitres of pre-warmed SOC (Super Optimal broth with Catabolite 
repression) medium (Appendix B) was added and recovery, as well as expression of 





Typically 50, 100 and 200 μl aliquots of the transformation mixture were plated onto 
SOB agar plates, containing 100 μg/ml of Ampicillin (Sigma-Aldrich, Munich, 
Germany) where appropriate. The plates were inverted and left overnight at 37ºC. 
 
2.6 Maxi Preparation of Plasmid DNA by Caesium Chloride and 
Ethidium Bromide Gradient Centrifugation 
 
Following an adapted protocol (Sambrook et al., 1989), 50 ul of glycerol stock of 
DH5α competent cells, transformed with DNA plasmids, was grown overnight in 5 ml 
of SOC medium and 100 μg/ml Ampicillin. From this starter culture, 1ul was 
inoculated into 400 ml of SOC medium with 100 μg/ml Ampicillin and grown 
overnight at 37ºC at 200 revolutions per minute (rpm). The overnight culture was 
spun at 7000 rpm for 10 mins at 4ºC using the JA-20 rotor in the J-21B centrifuge 
(Beckman, USA). The supernatant was removed and the pellet was resuspended in 
10 ml of Solution I (Appendix B), followed by the addition of 80 ml of Solution II 
(Appendix B). After several inversions, 45 ml of ice-cold Solution III (Appendix B) 
was added. The resulting white precipitated solution was spun as described above. 
The supernatant was removed and filtered into a clean centrifuge tube containing 90 
ml of isopropanol (Merck (Pty) Ltd, South Africa). The precipitated DNA was spun 
down at 7000 rpm for 10 mins using the above centrifuge. The supernatant was 
discarded and the pellet air-dried briefly. The DNA was resuspended in 2 ml of sterile 
double distilled water, transferred to 10 ml tubes containing 4.8 g of caesium chloride 
(CsCl) (Roche Diagnostics, Mannheim, Germany) in 2.1 ml of sterile distilled water. 
At that point, 200 μl of ethidium bromide (10 mg/ml, Promega Corporation, Madison, 
WI, USA) was added to each tube. The solution was spun for 10 mins at room 
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temperature at 3000 rpm using the Labofuge 400R centrifuge (Heraeus, Germany). 
The top clear red solution was transferred into an ultracentrifuge tube (Beckman 
Quick-Seal Ultracentrifuge tubes, USA) using a 2 ml syringe fitted with a 21-gauge 
needle. The tubes were heat-sealed following the manufacturer’s instructions and 
centrifuged for 16 hrs at 53,000 rpm at 20ºC using the VTI 65.2 HR rotor in the L8-
79M Ultracentrifuge (Beckman, USA). 
On the following day, the lower band representing plasmid DNA was extracted using 
a syringe fitted with a 21-gauge needle and the extracted band released into a 10 ml 
tube. The subsequent plasmid DNA was purified using the following protocol (Heilig 
et al., 1998). Briefly, the ethidium bromide and any RNA contamination was 
extracted from the plasmid DNA solution using organic solvent isobutanol (Sigma-
Aldrich, Munich, Germany) and digested 10 mg/ml RNase A (Sigma-Aldrich, Munich, 
Germany) respectively. The solution (1 ml) was transferred into a dialysis cassette 
(Pierce, thermo scientific, MA, USA) and immersed in a beaker containing TE buffer 
pH 7.5 (see appendix B) and the process of dialysis was allowed to take place 
overnight at room temperature for the removal of CsCl. Proteinase K (Promega 
Corporation, Madison, WI, USA) was dissolved in 0.2% Sodium dodecyl sulphate 
(SDS) (Sigma-Aldrich, Munich, Germany) and added to the DNA solution for an hour 
at 37ºC followed by a phenol:chloroform (1:1) extraction to remove any protein 
contamination.  
Finally, the plasmid DNA was concentrated by ethanol precipitation (Sambrook et al., 





analysis using the NanoDrop® ND-1000 spectrophotometer NanoDrop (Coleman 




Different primer pairs were created to PCR amplify selected regions of the cloned 
COL5A1 3′-UTR (section 2.2) and deletion constructs (section 2.3) (Table 2.5). All 
primers were manufactured by IDT (Coralville, IA, USA). The PCR reactions were 
performed in a total volume of 60 μl containing at least 50 ng of plasmid DNA, 20 
pmol of each of the forward and reverse primers, 1X reaction buffer, 200 μM of each 
dNTPs and 1 unit of Taq DNA polymerase (New England Biolabs, Ipswich, MA, 
USA). The cycling conditions included an initial denaturing step at 94°C for 3 mins 
followed by 35 cycles of denaturing at 94°C for 1 min, annealing between 60-65°C 
depending on primer pairs used for 1 min, extension at 72°C for 1.5 mins and a final 
extension step at 72°C for 5 mins using the XP Thermal Cycler Block (Bioer 
Technology, Tokyo, Japan). The PCR products were then gel purified using the 
QIAEX®II Gel Extraction kit (QIAGEN, Hilden, Germany) as described by the 
manufacturer and sequenced at the Central Analytical Facility (University of 
Stellenbosch, Stellenbosch, South Africa) using the appropriate primers. 
 
Furthermore, the insert and vector of all the site-directed mutant clones (section 2.4) 
were completely sequenced by Inqaba Biotec (Pretoria, South Africa) following maxi-
preparation purification. An independent set of primers (Inqaba Biotec, Pretoria, 





below. BioEdit version 7.0.5.2 software (www.mbio.ncsu.edu/bioedit/bioedit.html) 









exon 66 a Primer Sequence (5’-3’) 
FWD1 1850 b AAG GTC TTA CCG GAA AAC TCG ACG 
REV1 488 CCT GAG ACC TAT TCA CGA AC c 
FWD2 667 GTC ATT CTG CAG GTG CCT TC 
REV2 774 GAA AGC CAG GCA CAC TTA AC c 
FWD3 1058 AGA CTA AAA ACA CAG GTT TGG 
REV3 1230 CAC CAC AAG AGA GCC ACA AG c 
REV4 1468 AAG TAG GCA CAA CCC AGT CC c 
FWD4 1546 TTC CTG AAT TGT GGT GC 
REV5 1912 AGC CTG CAT TTC CCA TGG c 
FWD5 2087 TCT GGC TTG GAG AGT CTC TGG 
REV6 2278 CAG AGG AAG AAA ATG ACA GG c 
FWD6 2483 GAT AAA GTT TCG AGG ACA TC 
REV7   2284 a CAT AAG TGC GGC GAC GAT AGT CAT GC c 
 
a Refer to figure 2.2 
b 5’-position in the pGL3-Promoter vector (Accession no. U47298.2) 








Table 2.7 Primers designed to sequence the entire plasmids containing the site-directed 





 Construct a 
Primer Sequence (5’-3’) 
SEQ1 640 GAA CGT GAA TTG CTC AAC AG 
SEQ2 1280 TGC CAA GAG GTT CCAT CTG C 
SEQ3 5040 TGT AGG TCG TTC GCT CCA AG 
SEQ4 5680 TCC ATA GTT GCC TGA CTC CC 
SEQ5 6240 AGA TGC TTT TCT GTG ACT GG 
SEQ6 6880 TTC GCC CTT TGA CGT TGG AG 
SEQ7 7235 CTA GCA AAA TAG GCT GTC CC 
 
a 5’-Position in the pGL3-Promoter vector sequence (Accession no. U47298.2) with inserted 
3’-UTR at position 1938. 
 
 
2.8 Annotation of the Template Sequence 
 
The NCBI website (http://www.ncbi.nlm.nih.gov/nuccore/89276750) was used to 
annotate the multiple poly (A) signals present on the 3’-UTR of COL5A1. Several 
miRNA databases (Patrocles, www.patrocles.org) (Hiard et al., 2010), miRBase 
(www.mirbase.org) (Griffiths-Jones, 2004;Griffiths-Jones et al., 2006) and 
MicroCosm Targets (www.ebi.ac.uk/enright-srv/microcosm) were used to annotate 






2.9 Cell Culture 
 
HT1080 fibrosarcoma cells (ATCC® no. CCL-121) (Rasheed et al., 1974), SVWI-38 
cells (ATCC® no. CCL-75) (de Haan et al., 1986) as well as primary skin fibroblast 
cell lines (section 2.17) were maintained in Dulbecco's modified Eagle's medium 
(DMEM) (Highveld Biological, South Africa) containing 10% foetal bovine serum 
(FBS) (Highveld Biological, South Africa), 200 units/ml penicillin and 100 μg/ml 
streptomycin (Complete DMEM). The HT1080 human fibroblast cell line is derived 
from a fibrosarcoma arising adjacent to the acetabulum, at the hip joint, of a 35 years 
old Caucasian male individual (Rasheed et al., 1974) while the SVWI-38 is a human 
embryonic lung fibroblast cell line (WI-38) transformed with the Simian virus 40 
(SV40) (de Haan et al., 1986). The lines were incubated at 37°C (95% air, 5% CO2, 
65% humidity). The cells were regularly monitored for mycoplasma and infections. 
 
2.10 Mycoplasma Testing 
 
The cells were grown on a sterile coverslip in a 35 mm culture dish in antibiotic-free 
medium (DMEM with 10% FBS) for a minimum of 24 hrs. On testing day, the cells 
were fixed using a mixture of glacial acetic acid and methanol (ratio 1:3) for a few 
seconds and washed gently with water to remove the fixing solution. Once the 
coverslip had air-dried for a few minutes, the DNA was stained with 500 µl of 
Hoechst no. 33258 (0.5 μg/ml) for not more than 30 sec and washed off with water to 
prevent excessive staining. The coverslip was then mounted on a slide with a drop of 
mounting fluid (0.02M citric acid, 0.06M Na2HPO4.H2O and 50% glycerol, pH 5.5). 
The cells were viewed shortly after setting of the slide by fluorescence microscopy. 
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Mycoplasma positive cells will have staining in the nucleus as well as in the 
cytoplasm and around the cells. 
2.11 Transient Co-Transfections and Luciferase Assays 
Transient co-transfections were performed using FuGENE HD (Roche Diagnostics, 
Mannheim, Germany) according to the manufacturer's instructions. The HT1080 or 
SVWI-38 cells were plated at 1.0 X 105 cells per well in 12-well plates and 24 h later 
co-transfected with 500 ng of a pGL3-COL5A1-3′UTR vector and 50 ng of the pRL-
TK vector containing the thymidine kinase promoter driving the expression of a 
renilla reporter which was used as an internal control for transfection efficiency. Each 
experiment was done in triplicate and repeated at least twice. In all the transfection 
experiments, cells were cultured for 45 hrs and extracts were assayed for firefly and 
renilla luciferase activity using the dual luciferase assay system (Promega 
Corporation, Madison, WI, USA). Luciferase activities were measured using the 
Luminoskan Ascent luminometer (Thermo Labsystems, Franklin, MA, USA). Firefly 
luciferase values were normalised to the renilla luciferase activity.  
2.12 Messenger RNA Decay Assay 
HT1080 cells were plated at 0.5 X 105 cells per ml in 6 cm dishes in 4 ml of complete 
DMEM (Highveld Biological, South Africa) at 37°C (95% air, 5% CO2, 65% humidity). 
Co-transfections using 1 ug of TEN and CON full constructs (pGL3-COL5A1-3′UTR) 
as well as 100 ng transfection efficiency construct pRL-TK were done using FuGENE 





instructions. After 30 hrs of co-transfection, one experimental subset was treated 
with 5µM Actinomycin D for 1 hr to stop de novo transcription while the other 
experimental set was not treated using this inhibitor.  
 
Thereafter, total RNA was extracted using the High Pure RNA isolation kit (Roche 
Diagnostics, Mannheim, Germany) from the treated and untreated plates at the 
following time intervals (t): 0, 15, 30 mins and 1 hr. The RNA was quantified and 
integrity assessed on a 1 % agarose gel using the RiboRuler™RNA ladder and 2X 
RNA Loading Dye (95% formamide, 0.025% SDS, 0.025% bromophenol blue, 
0.025% xylene cyanol, 0.025% ethidium bromide and 0.5 mM EDTA) (Fermentas, 
thermo scientific, MA, USA) following the manufacturer’s recommendations. It was 
kept at -80°C until cDNA was obtained using the Improm-II™ Reverse Transcriptase 
kit (Promega Corporation, Madison, WI, USA). Finally the transcript abundance was 
quantified in real time using the Power SYBR green PCR master (Applied 
Biosystems, Foster City, CA, USA) and the PCR reactions were carried out in the 
Applied Biosystems StepOnePlus real-time PCR System (Life Technologies, Applied 
Biosystems, Foster City, CA, USA) following the manufacturer’s recommended 
cycling conditions. The threshold cycle (CT) values were used to derive the relative 
transcript abundance using the comparative CT method. Primers for the TEN and 
CON constructs, specific to their genetic differences, were designed as well as 
primers for pRL-TK to gauge transfection efficiency. In addition, β-actin was used as 
a housekeeping gene for this experiment. All primers were manufactured by IDT 







Table 2.8  Primers used for quantifying relative mRNA abundance in the decay assay. 
 
Primer Name Primer Sequence (5'-3') 
FWD for both ALLELIC FORMS GGA AAG ATC GCC GTG TAA TTC 
REV T-ALLELIC FORM AGA AGC CTT CAC TGT CCA GGA 
REV C-ALLELIC FORM AGA AGC CTT CAC TGT CCA GGG 
FWD pRL-TK  GGT AAC GCG GCC TCT TCT TA 
REV pRL-TK GCC AAA CAA GCA CCC CAA TC 
FWD β-ACTIN CGG CAT CGT CAC CAA CTG 




2.13 Nuclear and Cytoplasmic Protein Harvest for an RNA 
Electrophoretic Mobility Shift Assay (EMSA) 
 
A monolayer of HT1080 cells were split into five 10cm dishes and incubated to 90% 
confluency. The medium was aspirated off and the cells in each dish were washed 
twice with 1ml of 0.15M 1X Phosphate-buffered saline (PBS) at room temperature. 
The cells were harvested by scraping in 800µl PBS, pooled in a 12.5ml falcon tube 
and were spun for 4 minutes at 400 x g. The supernatant was discarded and the 
pellet was resuspended in 800µl PBS in a 1.5ml microfuge tube on ice. The samples 
were pulsed in a microfuge at room temperature and the supernatant discarded. The 
pellet was resuspended in 250µl solution I (20mM PIPES pH 6.8, 1mM EGTA pH 
6.8, 1mM magnesium chloride (MgCl2), 10X Protease Inhibitor Cocktail, 1mM Sodium 





minutes. Triton X-100 was added to a final concentration of 0.5% and the cells were 
gently resuspended and incubated on ice for 5 minutes. Thereafter, the lysed cells 
were centrifuged at 900 x g at 4°C for 5 minutes.  
 
The supernatant, containing the cytoplasmic proteins was collected in 100µl aliquots 
and stored at -80°C. The nuclear pellet was resuspended in 250µl of solution I and 
centrifuged at 900 x g at 4°C for 5 minutes. The supernatant was discarded and the 
pellet resuspended in 250µl of solution II (100mM KCl (potassium chloride), 300mM 
sucrose, 10mM PIPES pH6.8, 3mM MgCl2, 1mM EGTA pH6.8, 10X Protease 
Inhibitor Cocktail, 1mM Na3VO4, 1mM NaF) and 10µl DNase was added to the 
extract before it was incubated at 30°C for 45 minutes, with occasional flicking. After 
incubation the extract was centrifuged at 1500 x g for 5 minutes at 4°C. The 
supernatant which contains the nuclear proteins was collected in 100µl aliquots and 
stored at -80°C.  
 
The protein obtained was quantified using the Pierce bicinchoninic acid (BCA) 
Protein Assay Kit (Pierce Biotechnology, Rockford, USA).  Solution I were used as 
diluents respectively and a protein standard curve was established from protein 
standards made up in their diluent using 2mg/ml BSA (bovine serum albumin) in 
0.9% NaCl (Sodium chloride) . Proteins were diluted to concentrations ranging from 
1:20 – 1:200. In a 96-well microplate (Greiner Bio-One GmbH, Frickenhausen, 
Germany) 25µl of each standard and protein sample was added per well in duplicate, 
as well as 200µl of working reagent (15ml of Pierce BCA Protein Assay Reagent A 





manufacturer’s instructions. Readings were obtained at an OD of 595 nm on the RT-
2100C Microplate Reader (Rayto, Shenzhen, China). 
 
2.14 Non-radioactive RNA EMSA 
 
A preliminary RNA EMSA was performed to determine if there are any interactions 
between RNA binding proteins (RBP) and putative sites on the C- and T-allelic forms 
of the COL5A1 mRNA 3'-UTR in the XbaI and AflII 57 bp region deleted in section 
2.3. Single stranded biotin-labelled C- and T-allelic form RNA probes corresponding 
to nucleotides 993 to 1059 and 993 to 1063 of the COL5A1 mRNA 3'-UTR were 
purchased from IDT (Coralville, IA, USA). Both probes were designed with two 
modifications; (1) a 2'O-Methyl RNA base was added to the 5' end of both probes to 
assist in protecting the probes from degradation and (2) a Biotin tag was added to 
the 3' end to bind to the streptavidin-HRP(horseradish peroxidase) conjugate to allow 
for detection. The oligonucleotide sequences are as follows:  
 
C-allelic form: 5' – mUrUrU rUrUrU rUrUrA rArUrA rGrGrG rArArA rArArA rUrUrU 
rGrArU rArArU rUrUrU rCrU/ 3Bio/ - 3' 
T-allelic form: 5' – mUrUrU rUrUrU rUrUrA rArUrA rGrGrG rArGrG rGrArA rArArA 
rArUrU rUrGrA rUrArA rUrUrU rUrCrU /3Bio/ - 3' 
 
All apparatus was washed thoroughly with bleach and DEPC (Diethylpyrocarbonate) 
treated water prior to use to avoid RNase contamination. Between 4 and 100µg of 
protein lysate was added to 1X binding buffer (2M KCl and 1M MgCl2) containing 





or T-allelic biotin-labelled target RNA probes in a final volume of 18µl. The DTT 
assists in reducing the disulphide bonds of the protein and the tRNA acts as a non-
specific competitor. The binding reactions took place for 30 minutes at room 
temperature. After incubation, 2µl of 10X loading dye (0.25% Bromophenol Blue, 
0.25% Xylene Cyanol FF, 15% Ficoll) was added to each sample to a final volume of 
20µl. The reaction mixture was loaded onto a pre-electrophoresed 1.5mm thick 8% 
native polyacrylamide gel (40% Acrylamide, 10X TBE, 10% APS, TEMED) and 
electrophoresed at 200 V in 0.5X TBE buffer for an hour on ice.  
 
Following electrophoresis the protein samples were transferred to positively charged 
Hybond nylon membrane (Amersham, UK) at 380mA for 30min on ice. RNA was 
cross-linked on the membrane for 60 seconds using UV Stratalinker 1800 apparatus 
(Stratagene, CA, USA). The membrane was then blocked whilst shaking for 15 
minutes in blocking buffer (3% BSA in 0.1% (v/v) Tween 20 in 1x PBS (PBS/T)). A 
1:300 dilution of streptavidin-HRP conjugate was made in blocking buffer and the 
membrane was incubated in this solution for 15 minutes whilst shaking.  
 
The membrane was subsequently washed 5X for 5 minutes on a shaker in 1X PBS/T 
washing buffer and thereafter incubated for 5 minutes in a 1X PBS equilibration 
buffer. To detect RNA-protein complexes the membrane was placed in 4ml of equal 
parts chemiluminescent detection reagent component 1 and chemiluminescent 
detection reagent component 2 purchased from Advansta (CA, USA), and the 
chemiluminescent signal was captured using  Biospectrum Imaging system using 
Visionworks LS software (UVP, UK). 
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2.15 Participants for Genetic Association Study 
The reporting of the following case-control genetic association study is in compliance 
with the recommendations drawn by the STREGA (STrengthening the REporting of 
Genetic Association studies) initiative, which is an extension of the STROBE 
(STrengthening the Reporting of OBservational Studies in Epidemiology) statement 
(Little et al., 2009). 
Three hundred and forty-two asymptomatic (342) control participants (CON) and 160 
with diagnosed chronic Achilles tendinopathy (TEN) were included in this study. The 
TEN and CON participants were recruited from South Africa and Australia as 
previously described (Mokone et al., 2005;Mokone et al., 2006;September et al., 
2009;September et al., 2011). All participants were of self-reported European 
Caucasian ancestry. 
All participants were given information about the study (Appendix A) and signed an 
informed consent form (Appendix A) prior to participation in this study, in accordance 
with the Declaration of Helsinki (World Medical Association, 2013). All participants 
completed questionnaires about their medical and sporting participation histories. 
Approval for the study was obtained from the Human Research Ethics Committee at 
the University of Cape Town and the Human Ethics Committee at La Trobe and 





South African Participants 
 
A total of 227 unrelated physically active participants, 149 asymptomatic individuals 
(CON) and 81 diagnosed with chronic Achilles tendinopathy (TEN) were included in 
this study. The participants were recruited from medical practices within Cape Town 
and Johannesburg in South Africa between 2004 and 2012. The TEN participants 
were all physically active prior to the onset of the condition. The clinical diagnosis, 
which was performed as described in Mokone et al (2006) (Mokone et al., 2006), of 
each participant was made and reviewed by experienced sports clinicians.   
 
The stringent clinical diagnostic criteria for TEN included gradual progressive pain 
over the posterior lower limb in the Achilles tendon area for greater than 6 months, 
together with at least one out of the following six criteria: (1) early morning pain over 
the Achilles tendon area, (2) early morning stiffness over the Achilles tendon area, 
(3) a history of swelling over the Achilles tendon area, (4) tenderness to palpation 
over the Achilles tendon, (5) palpable nodular thickening over the affected Achilles, 
or (6) movement of the painful area in the Achilles tendon with plantar-dorsi-flexion 
(positive ‘‘shift’’ test) (Kader et al., 2002;Paavola et al., 2002;Schepsis et al., 2002). 
In addition to these criteria, soft-tissue ultrasound examination was performed in a 
sub-group of subjects to confirm the above diagnosis.  
 
Physically healthy and active control subjects were recruited from various 
recreational sporting clubs. They had no history of chronic Achilles tendinopathy and 





Exclusion criteria included history of current or past fluoroquinolone antibiotic use or 
previous local corticosteroids injection in the Achilles tendon or the area surrounding 
the Achilles tendon prior to the onset of symptoms. Furthermore, participants with 
diagnosed connective tissue disorders or any other systemic diseases believed to be 
associated with TEN, such as, but not limited to, EDS, benign hypermobility joint 
syndrome, rheumatoid arthritis, systemic lupus erythematosus, hyperparathyroidism, 
renal insufficiency, diabetes mellitus and familial hypercholesterolemia were also 




A total of 272 unrelated physically active participants, 193 asymptomatic individuals 
(CON) and 79 diagnosed with chronic Achilles tendinopathy (TEN), were included in 
this study. The participants were recruited at the Musculoskeletal Research Centre 
of La Trobe University, Melbourne, Australia from 2008 to 2010. The clinical 
diagnosis for the TEN participants was performed as described for the South African 
participants (Mokone et al., 2005) and confirmed by soft tissue ultrasound 
examination (September et al., 2009). In addition, apparently healthy participants, 
with no prior history of soft tissue pathology, were recruited from Melbourne, 
Australia. Again, the AUS CON subjects were matched for age of onset and country 
of birth to the AUS TEN group. Exclusion criteria were identical to those of the South 







2.16 DNA Extraction for Genetic Association Study 
 
Blood was collected from all participants by venipuncture of a forearm vein into an 
EDTA vacutainer tube. These samples were stored at 4˚C until DNA extraction. For 
the South African participants, total DNA was extracted from the collected blood 
using a method described by Lahiri and Nurnberger (1991) (Lahiri and Nurnberger, 
1991) with modifications by Mokone et al. (2005) (Mokone et al., 2005) (Appendix 
C). In the case of the Australian participants, the DNA was extracted using the 
FlexiGene DNA kit (Qiagen, Valencia, CA, USA) as per the manufacturer’s 
instructions. The extracted DNA was stored at -20˚C until needed. 
 
2.17 COL5A1 3’-UTR Genotyping 
 
Using the extracted DNA, the participants were genotyped for the rs71746744 (-
/AGGG; 91 TEN and 198 CON), rs16399 (ATCT/-; 120 TEN and 254 CON) and 
rs1134170 (A/T; 107 TEN and 241 CON) polymorphisms within the 3’-UTR of the 
COL5A1 gene. Genotyping was performed using custom-designed Fluorescence-
based Taqman® PCR assays (Applied Biosystems, Foster City, CA, USA). Custom-
made allele specific probes and flanking primer sets (Table 2.9) were used along 
with a pre-made PCR mastermix containing ampliTaq® DNA polymerase Gold 
(Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 8 µl. The 
two-step PCR consisted of a 10 mins heat activation step (95º C) followed by 40 
cycles of 15 sec at 92º C and 1 min at 60º C using the XP Thermal Cycler, Block 
model XP-G (BIOER Technology, Tokyo, Japan). End-point fluorescence using a 
7900 HT Fast Real-Time PCR System and the SDS Software version 2.3 (Applied 
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Biosystems, Foster City, CA, USA) was used to determine the genotypes of each 
polymorphism.  
Table 2.9 Custom-made allele specific probes and flanking primer sets primers used in 
custom designed Fluorescence-based Taqman® PCR assays. 
Primer 
Name
Primer Sequence (5’-3’) Reporter Dye Reporter Sequence (5’-3’) 
rs1134170_F CTT GTG GTG CTA TCT ATC TGT TTT AAG GT VIC TGG CCA GGG TCC CCA 
rs1134170_R GGA TAA AGA AAG CAG GGA GAA CGA FAM TGG CCA GGG ACC CCA 
rs16399_F TTC TCT CTT GTG GCT CTC TTG TG VIC 
CCT TAAA AAC AGA TAG 
ATA GC 
rs16399_R CCC AGT GCG CCT TCA AG FAM AGA CCT TAA AAC AGA TAG C 
rs71746744_F GCC CCT TTT CAG ACA GTTTTT GAT T VIC TTT CCC TCC CTA TTA AAA 
rs71746744_R CAA ACC TGT GTT TTA GTCTTA AGT GCA T FAM 
CAA ATT TTT TCC CTA TTA 
AAA 
In addition, 310 (162 TT and 148 AT) of the 348 (89.1%) DNA samples were 
regenotyped for SNP rs1134170 using the Restriction Fragment Length 
Polymorphism (RFLP) method. Only two of the AT genotypes were reassigned as an 
AA genotype (0.6% genotyping error). The fragments containing rs1134170 were 
amplified using 5’- CAG AGC CTG ATG GGA GAA TGT CCA GGG CA -3’ as the 
forward primer and 5’- GGA TAA AGA AAG CAG GGA GAA CGA GGC ATG ACC 
AG -3’ as the reverse primer.  
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The PCR reactions were performed in a total volume of 50 μl containing at least 100 
ng of total genomic DNA, 20 pmol of each of the forward and reverse primers, 1X 
buffer (10 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl2, pH8.3), 200 μM of each 
dNTPs and 1 unit of Taq DNA polymerase (New England Biolabs, Ipswich, MA, 
USA). The cycling conditions included an initial denaturing step at 95°C for 2 mins 
followed by 30 cycles of denaturing at 95°C for 30 s, annealing at 65°C for 30 s, 
extension at 68°C for 1.5 mins and a final extension step at 68°C for 5 mins using 
the XP Thermal Cycler Block (Bioer Technology, Tokyo, Japan).  
The PCR products were digested with the PShAI restriction enzyme (New England 
Biolabs, Ipswich, MA, USA) following the manufacturers instructions, to produce 159-
bp and 34-bp fragments for the A allele and an uncut 193-bp fragment for the T 
allele. The resultant products were separated on 6% nondenaturing polyacrylamide 
gels (PAGE) and visualized using SYBER Gold staining (Invitrogen Molecular 
Probes, Eugene, Oregon) (Figure 2.5). The gels were photographed under UV light 
using a Uvitec photodocumentation system (Uvitec Limited, Cambridge, UK), and the 








Figure 2.5 A typical image of a 6% PAGE gel discriminating restriction fragments from 
individuals who are homozygous AA ( 159 and 34 bp, lane 3), homozygous TT ( 193, lane 4) 
and heterozygous AT (193, 159 and 34 bp, lane 5) upon digestion of the 193 bp PCR 
products (Uncut: U, lane 2) of rs1134170 with the PShAI restriction enzyme. The size of the 
fragments are indicated on the right while the genotypes are annotated on top. Fragment 
sizes of the 100bp DNA ladder (MW) (lane 1) are also indicated on the left. Electrophoresis 
was performed at 120 Volts for 2 hrs. 
 
 
In addition, high resolution melting (HRM) analysis was performed for rs16399 
(ATCT/-) by the Central Analytical Facility (University of Stellenbosch, Stellenbosch, 
South Africa). The DNA template was quantified using the NanoDrop ND1000 
(NanoDrop Technologies, Wilmington, DE, USA) and adjusted to 5 ng/µl. The 20 ul 
PCR reactions were performed in the ABI Fast 96-well optical plates (Applied 
Biosystems, Foster City, CA, USA) which contained:1X ABI MeltDoctor HRM Master 
Mix (Applied Biosystems, Foster City, CA, USA), 6 pmol of each designed primer 





AAG GAG AC-3’), 20 ng of DNA template a final volume of. The HRM-PCR was 
performed in the StepOne Real-time PCR System (Applied Biosystems, Foster City, 
CA, USA) with the following conditions: an activation step at 95°C for 10 mins 
followed by 40 cycles consisting of a denaturing step at 95°C for 15 sec and an 
annealing step at 60°C for 1 min. This was followed by a melt curve consisting of the 
sequential steps: a denaturing step at 95°C for 10 sec, an annealing step at 60°C for 
1 min, a HRM step at 95°C for 15 sec (ramping rate of 1%) ending with an annealing 
step at 60°C for 15 sec. In each experiment, DNA samples of known genotypes 
(confirmed using Sanger sequencing) were included as reference standards.  
 
Data collection and primary analysis including amplification plots were performed 
using the StepOne Software Version 2.2.1 (Applied Biosystems, Foster City, CA, 
USA). The high-resolution melt analysis was performed using the High Resolution 
Melt Software Version 3.0.1 (Applied Biosystems, Foster City, CA, USA). The 
genotypes of the samples were assigned automatically using the melt curve profiles. 
The pre-melt and post-melt regions were found between 70.9° C to 71.3° C and 
78.0° C to 78.3° C, respectively. Aligned melt curves and difference plots were 
generated as well as silhouette scores for each sample. Any samples with low 
amplification or with outlier melt profiles were removed from the HRM analysis. 
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2.18 Preliminary Gene Expression Study using Skin Biopsy 
Participants 
Individuals of self-reported European Caucasian ancestry were invited to take part in 
a component of the study from 2013 to 2014. All participants were given information 
about the study (Appendix A) and signed an informed consent form (Appendix A) 
prior to participation in accordance with the Declaration of Helsinki (World Medical 
Association, 2013) and guidelines on good clinical laboratory practice (Ezzelle et al., 
2008). Participants completed questionnaires about their medical and injury history 
(Appendix A). Approval for the study was obtained from the Human Research Ethics 
Committee at the University of Cape Town (Appendix A). Participants were included 
strictly with respect to their genotype at the rs12722 locus and exclusion criteria 
described in section 2.13 were applied. Following blood collection and DNA 
extraction, only individuals with the desired genotype were retained and invited to 
donate a skin biopsy sample (table 2.10). Three participants having the COL5A1 
BstUI RFLP (rs12772) TT genotype (“at risk”), 3 asymptomatic active control 
participants having the CC genotype as well as an individual having the TC genotype 
at this locus were recruited. 
Genotyping of Participants 
Approximately 4.5ml of venous blood was collected from all participants by 
venipuncture of a forearm vein into an EDTA vacutainer tube. These samples were 





(Mokone et al., 2005), with minor modifications (section 2.16). Participants were 
genotyped for COL5A1 rs12722 as previously described (Mokone et al., 2006) and 
two investigators independently confirmed the genotypes. Briefly, 667 bp fragments 
containing the COL5A1 BstUI RFLP (rs12722) were amplified by PCR using the 
forward Primer, 5’- GAA GAC GTT TCT GGA GGA TC -3’, and reverse primer, 5’-
GGA GGC ACC TGC AGA ATG AC -3’.   
 
The PCR reactions were performed in a total volume of 60 μl containing at least 100 
ng of total genomic DNA, 20 pmol of each of the forward and reverse primers, 1X 
buffer (10 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl2, pH8.3), 200 μM of each 
dNTPs and 1 unit of Taq DNA polymerase (New England Biolabs, Ipswich, MA, 
USA). The cycling conditions included an initial denaturing step at 94°C for 3 min, 
followed by 35 cycles of denaturing at 94°C for 1 min, annealing at 53°C for 1 min, 
extension at 72°C for 1.5 min, and a final extension step at 72°C for 8 min using the 
XP Thermal Cycler Block (Bioer Technology, Tokyo, Japan).  
 
The PCR products were digested with the BstUI RE enzyme (New England Biolabs, 
Ipswich, MA, USA) to produce 351 and 316bp fragments for the T allele; 316, 271 
and 80bp fragments for the C allele. The resultant fragments were separated, 
together with a 100bp DNA ladder, on 6% non-denaturing polyacrylamide gels and 
visualized by SYBER Gold staining (Invitrogen Molecular ProbesTM, Oregon, USA).  
The gels were photographed under UV light using a Uvitec photodocumentation 
system (Uvitec Limited, Cambridge, UK) and the sizes of the DNA fragments 





other polymorphisms important in distinguishing between the two the allelic forms of 
CON and TEN were also genotyped as described in section 2.17. 
 
 
Table 2.10 Characteristics and genotype of participants who donated a skin biopsy. 
 











SB-1 TT AGGG/AGGG 47 M 173.0 73.1 24.4 
SB-2 TT AGGG/AGGG 25 M 182.0 75.0 22.6 
SB-3 TT AGGG/AGGG 26 M 183 76 22.7 
SB-4 TC -/AGGG 26 F 174 86 28.4 
SB-5 CC -/AGGG 30 F 163 80 30.1 
SB-6 CC -/- 22 F 174.0 65.0 21.5 










Figure 2.6 A typical image of a 6% PAGE gel discriminating restriction fragments from 
individuals who are homozygous CC (316, 271 and 80bp, lane 3), homozygous TT (351 and 
316bp, lane 4) and heterozygous CT (351, 316, 271 and 80 bp, lane 5) upon digestion of the 
667 bp PCR product (Uncut: U, lane 2) of rs12722 with the BstUI restriction enzyme. The 
size of the fragments are indicated on the right while the genotypes are annotated on top. 
Fragment sizes of the 100bp DNA ladder (MW) (lane 1) are also indicated on the left. 
Electrophoresis was performed at 120 Volts for 2 hrs. 
 
Skin Biopsy Procedure 
 
All needle biopsies were performed in a sterile environment by an experienced 
medical practitioner. The area of the forearm to be biopsied was cleaned thoroughly 
with 70% isopropyl alcohol. A 23-gauged needle was used to obtain a 2 mm wide 





scarring for the participant. The biopsy site was dressed and the obtained biopsies 
were transported in sterile vials containing 3ml of Dulbecco's Modified Eagle's 
medium (DMEM) (Gibco) supplemented with 10% foetal calf serum (Gibco), 200 
units/ml penicillin and 100 μg/ml streptomycin (complete medium). Sterile and 
aseptic techniques were used at each stage. All biopsies were kept at 4°C and used 
within 24 hrs. 
 
2.19 Derivation of Participant’s Primary Fibroblast Cell Line from Skin 
Biopsy 
 
Primary fibroblast cell cultures were established from the skin biopsies (Baumgarten, 
1993). While working under a laminar flow hood, the dermis and epidermis were 
dissected from the rest of the skin and washed several times with sterile 1X PBS. 
Baumgarten’s methodology was used to obtain outgrowth of fibroblast cells from the 
explants. Briefly, the tissue was finely sliced into approximately 1mm by 1mm pieces 
while covered in complete medium. The fragments were dispensed into several 
35mm culture dishes and covered with a sterile coverslip placed on top of them to 
keep them in place, allowing their attachment to the dish’s surface. An additional 
2.5ml of complete medium was added and the plates placed in a 37°C humidified 
(95% air/ 5% CO2, 65% humidity) incubator and the culture monitored for infections. 
The culture medium was changed twice weekly until enough cells had grown out of 
the explants.  
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As described by Baumgarten et al. (1993), once a reasonable amount of the 
fibroblast explants had migrated out of the explants, the coverslips were inverted and 
placed cell side up into new 35mm dishes. The original dishes were kept because 
they also contained our cells of interest. When the fibroblasts, outgrown from the 
explants, covered 70 to 90% of the culture area (2-3weeks) the medium was 
removed, the cells were washed twice with PBS, trypsinised (passage one) using 
0.25% trypsin/EDTA solution and seeded into a 50ml culture flask. Mycoplasma 
testing was performed regularly between passages on cells grown in antibiotic-free 
medium containing 10% foetal calf serum. Subcultures involved expansion of the 
fibroblast culture into several flasks in complete medium. Stocks of fibroblasts from 
passage two and three were cryogenically preserved using 10% DMSO (Sigma-
Aldrich, Munich, Germany) and stored in liquid nitrogen for further usage. 
2.20  Expression levels of COL5A1 and COL1A1 in Primary skin 
fibroblast cell lines 
Quantitative Real-Time Reverse Transcription PCR (Q-RT-PCR) was performed to 
look at expression of COL5A1 and COL1A1 in the primary fibroblast cells derived 
from participants with a defined genotype. The primary fibroblast cells at early 
passages (Passages 3-6) were seeded at 2 X 105 cells per ml in two 6 cm dishes per 
samples in 4 ml of complete DMEM (Highveld Biological, South Africa). The cells 
were incubated at 37°C (95% air, 5% CO2, 65% humidity) overnight or until an 80% 
confluency was obtained. Thereafter, total RNA was extracted using the High Pure 
RNA isolation kit (Roche Diagnostics, Mannheim, Germany). The RNA was 





ladder and 2X RNA Loading Dye (Fermentas, thermo scientific, MA, USA) following 
the manufacturer’s recommendations. It was kept at -80 °C until cDNA was obtained 
using the Improm-II™ Reverse Transcriptase kit (Promega Corporation, Madison, 
WI, USA). Finally the transcript abundance was quantified in real time using the 
Power SYBR green PCR master (Applied Biosystems, Foster City, CA, USA) and 
the PCR reactions were carried out in the Applied Biosystems StepOnePlus real-
time PCR System (Life Technologies, Applied Biosystems, Foster City, CA, USA) 
following the manufacturer’s recommended cycling conditions followed by a melting 
curve protocol. The threshold cycle (CT) values were used to derive the relative 
transcript abundance using the comparative CT method. SB-7 is used as a control 
sample and β-actin as the housekeeping gene. The primers used for this experiment, 
COL5A1 and COL1A1 as well as primers for β-actin as a housekeeping gene, have 
been used in the literature in a similar experiment (Luna et al., 2011) (Table 2.6). All 








Table 2.11  Primers extracted from Luna et al. (2011) to quantify relative expression of the 
COL5A1 and COL1A1 genes. 
 
Primer Name Primer Sequence (5'-3') 
FWD COL1A1 AGC CAG CAG ATC GAC AAC A 
REV COL1A1 TCT TGT CCT TGG GGT TCT T 
FWD COL5A1 GGC TGT GCT ACC AAG AAA GG 
REV COL5A1 GAG GTC ACG AGG TTG CTC T 
FWD β-ACTIN CCT CGC CTT TGC CGA TCC G 






Data were analysed using STATISTICA version 10.0 (StatSoft, Tulsa, OK, USA) and 
GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA, 
www.graphpad.com) programs. For the analysis of Luciferase assays and the 
expression studies, normally distributed data were analysed using an independent t-
test or a one-way analysis of variance (ANOVA), followed by, if appropriate a Tukey 
HSD post-hoc analysis. The nonparametric Mann–Whitney U test was performed for 
data deviating from the normal distribution. Data sets are presented as mean ± 






For the genetic association study, a one-way analysis of variance was used to 
determine any significant differences between the characteristics of the TEN and 
CON groups within the AUS and SA cohorts. The Quanto V.1.2 software 
(http://hydra.usc.edu/gxe) was used to determine the statistical power of the sample 
size. Assuming allele frequencies between 0.2 and 0.8 for the “risk” allele of each 
SNP investigated, our sample size of 100 cases to 200 controls would be adequate 
to detect an allelic OR of 2.0 and greater at a power of 80% and a significance level 
of 5%. A Chi2-analysis or Fisher’s exact test was used to analyse any differences in 
the genotype frequencies and other categorical data between the groups. 
Statistically significant differences were accepted when P<0.05; and P<0.025 when 
combined gene-gene interactions and effects were analysed.  
 
Combined genotype frequencies were also analysed using the Monte Carlo test 
(CLUMP program, version 2.0) (Sham and Curtis, 1995). Hardy-Weinberg 
equilibrium (HWE) was established using the program Genepop web version 3.4 
(http://genepop.curtin.edu.au/). Linkage disequilibrium (LD) was calculated using 
CubeX: cubic exact solution (www.oege.org/software/cubex/) (Gaunt et al., 2007). 
Inferred haplotype analysis (Lin et al., 2008) was performed using the Hapstat case-
control haplotype inference software. Statistically significant differences were 







CHAPTER 3 RESULTS 
 
Aspects of the data presented in this chapter have been published in the following 
peer-reviewed articles: 
 
 Mary-Jessica Laguette, Yoonus Abrahams, Sharon Prince and Malcolm 
Collins. Sequence variants within the 3’-UTR of the COL5A1 gene alter 
mRNA stability: Implications for musculoskeletal soft tissue injuries. Matrix 
Biology. 2011 Jun;30(5-6):338-45 
 
 Yoonus Abrahams, Mary-Jessica Laguette, Sharon Prince and Malcolm 
Collins. Polymorphisms within the COL5A1 3'-UTR that alters mRNA structure 
and the MIR608 gene are associated with Achilles tendinopathy. Ann Hum 
Genet. 2013 May;77(3):204-14 
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3.1 Overall Increase in COL5A1 mRNA Stability in the Tendinopathic 
Phenotype 
As mentioned in Chapter 1, the C/T single nucleotide polymorphism (SNP) rs12722, 
also referred to as BstUI RFLP, in the 3’-untranslated region (3’-UTR) of COL5A1 is 
associated with chronic Achilles tendinopathy (TEN) in two independent populations. 
Furthermore, DNA was previously obtained from South African (SA) tendinopathic 
participants with the TT genotype (‘at risk’) for rs12722 and physically active 
asymptomatic individuals (CON) with a CC genotype (‘protective’). To determine 
whether the COL5A1 3’-UTR was functional, the 2.5 kb COL5A1 3’-UTR was 
amplified from the DNA of four TEN (1, 2, 3 and 5) and three CON (2, 3 and 5) 
participants and cloned downstream of a luciferase reporter gene. Two separate 
clones were obtained for CON 2, CON 3, TEN 2 and TEN 3, while only a single 
clone was obtained for CON 5, TEN 1 and TEN 5.  
These constructs were transiently co-transfected into HT1080 cells as described in 
section 2.9 and the relative normalised luciferase activity was used as an indirect 
indication of mRNA stability (Figure 3.1A). On average, the TEN clones showed a 
higher mRNA stability compared with the CON clones (p<0.001, Figure 3.1A). There 
was a 2.1 fold (p<0.001) difference in the average normalised luciferase activity of 
the construct with the lowest activity (CON 5.1: 49.4 ± 12.5%) when compared to the 
one with the highest activity (TEN 2.2: 104.2 ± 13.2%). It is worth noting that the 
luciferase activity of the CON 2.1 construct was more similar to the TEN constructs 
(Figure 3.1A). However, when all the TEN and all the CON constructs were pooled, 





constructs (Figure 3.1B). These results suggest that the Achilles tendinopathic 
phenotype is associated with increased COL5A1 mRNA stability. 
 
3.2 Identification of Two Major Allelic Forms of the COL5A1 3’-UTR 
 
To identify any potential sequence differences between the COL5A1 3’-UTRs cloned 
from the TEN and CON participants, the 2.5 kb 3’-UTR of all the clones were 
sequenced and analyzed. Only 9 polymorphisms were identified within the 3’-UTR 
(Table 3.1) which produced two major allelic forms termed the C- (which 
corresponds to the published wild type sequence) and T-allelic forms. Seven 
(rs13946, rs12722, rs3196378, rs71746744, rs16399, rs1134170 and rs3128575) of 
the 9 polymorphisms within the C- and T-allelic forms were tightly linked (Table 3.1, 
Figure 3.2). Importantly, with the exception of CON 3.1 and TEN 3.1, the C- and T-
allelic forms, corresponded with the CON and TEN clones respectively (Table 3.1). 
Furthermore, when the luciferase activity of the individual clones were divided into 
the allelic groups based on sequence there was a significant increase (p<0.001) in 
the T-form allelic group (TEN 1.1, TEN 2.2, TEN 3.2 and TEN 5.1; 90.6 ± 13.7%) 
compared to the C-form allelic group (CON 2.1; CON 3.2 and CON 5.1; 69.0 ± 








Figure 3.1 Functional analysis of the 2.5 kb COL5A1 3’-untranslated region (UTR) in 
HT1080 cells. (A) The relative luciferase activity of the individual control (CON, black bars) 
and tendinopathic (TEN, grey bars) clones are expressed as averages ± standard 
deviations, with the number of assays (n) indicated above each bar. Clones were obtained 
from 4 TEN (1, 2, 3 and 5) and 3 CON (2, 3 and 5) participants. Two separate clones were 
obtained from CON 2, CON 3, TEN 2 and TEN 3, while only a single clone was obtained 
from CON 5, TEN 1 and TEN 5. The constructs (500 ng) and 50 ng of pRL_TK were co-
transfected into HT1080 fibroblast cells for 45hrs. Firefly luciferase activity for each clone 
was normalised with Renilla luciferase activity and expressed relative to CON 2.1. The 
global p-value as well as the p-values between the highest (TEN 2.2) and lowest (CON 5.1) 
is indicated. The dotted line represents the average activity of CON 2.2. (B) The relative 
luciferase activity of the pooled control (CON, black bars) and tendinopathy (TEN, grey bars) 
clones. Values are expressed as averages ± standard deviations, with the number of assays 





Table 3.1 Summary of the identified sequence differences within the COL5A1 3’-UTR region 
(2.5kb) of each clone. 
POSITION 230 369 414 880 1000 1016 1237 1272 2648 
POLYMORPHISM C/T C C/T C/A (T)n (AGGG)n (ATCT)n A/T T/C 
SNP rs13946 - rs12722 rs3196378 rs71698207b rs71746744b rs16399 rs1134170 rs3128575C 
RFLP DpnII - BstUI AciI - - - - - 
CON 2.1 C C C C 13 1 2 A T 
CON 2.2 C   T f C C 13 1 2 A T 
CON 3.1d T C T A 13 2 1 T C 
CON 3.2 C C C   C a 13 1 2 A T 
CON 5.1 C C C C 13 1 2 A T 
TEN 1.1 T C T A 13 2 1 T C 
TEN 2.1 T C T A 12 2 1 T C 
TEN 2.2 T C T A 13 2 1 T C 
TEN 3.1e C C C C 14 1 2 A T 
TEN 3.2 T C T A 13 2 1 T C 
TEN 5.1 T C T A 13 2 1 T C 
C- allelic form 
(W/T) C  C C  1 2 A T 
T- allelic form T  T A  2 1 T C 
 
Clones were obtained from 3 out of 5 CON participants (2, 3 and 5) and 4 out of 5 TEN participants (1, 2, 3 and 
5). Two different clones were obtained from CON 2, CON 3, TEN 2 and TEN 3, while only a single clone was 
obtained from CON 5, TEN 1 and TEN 5. Position is the nucleotide number of the COL5A1 exon 66 sequence; n, 
the number of T’s or repeats; SNP, single nucleotide polymorphism; RFLP, restriction fragment length 
polymorphism. The C- or wild type (W/T) allelic form is the consensus sequence of the major variant isolated 
from CON constructs, while the T-allelic form is the consensus sequence of the major variant isolated from CON 
constructs. Deviations of the consensus sequences are highlighted in grey. 
 
a Single nucleotide polymorphism (SNP) rs3196378 (AciI RFLP) is an A in CON 3.1 with the 57 bp deletion within 
the COL5A1 3’-UTR. 
b SNPs rs71698207, rs71746744 and rs11103544 (MboII RFLP, T in all the constructs), is deleted within the 57 
bp deletion within the COL5A1 3’-UTR. 
c SNPs rs3128575 and rs4504708 (G in all the constructs), is deleted within the 488 bp deletion within the 
COL5A1 3’-UTR.  
d The genotype of participant from which CON 3.1 was cloned was CC and CC at SNPs rs13946 (DpnII RFLP) 
and rs12722 (BstUI RFLP) respectively. 
e The genotype of participant from which TEN 3.1 was cloned was TT and TT at SNPs rs13946 (DpnII RFLP) and 
rs12722 (BstUI RFLP) respectively. 
f Has not been reported in any public database. Since it was only identified in a single clone, we cannot exclude 
the posibility that this nucleotide substitution was introduced by the polymerase enzyme machinery during 














Figure 3.2 The seven tightly linked polymorphic sites within the COL5A1 3’-untranslated 
region (UTR) are annotated as black boxes. The accession numbers and/or restriction 
fragment length polymorphism (RFLP) associated with the polymorphic sites are indicated 
together with the nucleotide changes. The sequence of the seven polymorphisms for the C- 
(wild type) and T-allelic forms were C-C-C-(AGGG)1-(ATCT)2-A-T and T-T-A-(AGGG)2-




Figure 3.3 The relative luciferase activity of the pooled control (CON, black bars) and 
tendinopathy (TEN, grey bars) clones, containing the COL5A1 3’-UTR C- (CON 2.1, CON 
3.2 and CON 5.1) or T- (TEN 1.1, TEN 2.2, TEN 3.2 and TEN 5.1) allelic form, in HT1080 
cells. Values are expressed as averages ± standard deviations, with the number of assays 
(n) indicated above each bar. Only six CON 2.1 values were included when calculating the
pooled CON luciferase activity to avoid skewing the results by a single clone.
Using a range of bioinformatic tools (section 2.8), two putative polymorphic miRNA 
binding sites, three putative polyadenylation signals and an expressed sequence tag 
(EST) within the COL5A1 3’-UTR were identified (Figure 3.4). The first exon of the 
EST (ENSESTG00000033016) with an unknown function is expressed in the 
opposite orientation to the COL5A1 gene. Each putative miRNA binding site contains 
a single nucleotide polymorphism and is located within the region previously 
associated with the exercise-related phenotypes (Abrahams et al., 2013;Brown et al., 
2011;Brown et al., 2011;Burger et al., 2014;Collins et al., 2009;Mokone et al., 
2006;O'Connell et al., 2013;Posthumus et al., 2009;Posthumus et al., 





and TTTTCTAC and they contain the polymorphisms (underlined) rs3196378 and 
rs11103544 respectively. While the core sequence of CCACCCCA is reported to 
bind Hsa-miR-608, the miRNA that binds TTTTCTAC is still unknown. The binding of 
Hsa-miR-608 to the C- and T-allelic forms of COL5A1 3’-UTR has previously been 




Figure 3.4 Schematic representation of the human COL5A1 3’-untranslated region (UTR). 
Key variants that have been previously investigated (dotted lines) (Abrahams et al., 
2013;Mokone et al., 2006;September et al., 2009) and identified within the two functional 
forms, putative miRNA binding sites (black lines) present within the studied polymorphic 
sites, an expressed sequence tag (EST) (grey shading, ENSESTG00000033016, function 
unknown) as well as three putative polyadenylation signals (A, compound lines) are 
indicated on this diagram. Binding of Has-miR-608 to rs3196378 has been previously 
studied (Abrahams et al., 2013). The nucleotide number within exon 66 of the COL5A1 gene 






3.3 Identification of a Region of the COL5A1 3’-UTR that Confers 
mRNA Stability 
 
Having identified putative regulatory elements within the COL5A1 3’-UTR, two 
deletion constructs, based on the availability of convenient restriction sites, were 
generated to test whether they do indeed contribute to COL5A1 mRNA stability 
(Figure 3.5). The first construct (Δ488) lacks the last 488bp of the COL5A1 3’-UTR 
which contains the two distal polymorphisms (rs4504708 and rs3128575), not 
associated with chronic Achilles tendinopathy (September et al., 2009), and two 
terminal polyadenylation signal sites (Figure 3.5). A 57bp XbaI-AflII fragment, 
containing the putative miRNA binding site harbouring the MboII RFLP (rs11103544) 
(September et al., 2009) as well as polymorphisms rs71698207 and rs71746744, 
were deleted from the second construct (Δ57). 
 
When the Δ488 constructs were assayed, the average relative luciferase activity of 
TEN 1.1 (Δ488), which contains the T allele, was significantly higher (121.3 ± 22.5%, 
p<0.001) than the pooled CON constructs (CON 2.1 and CON 5.1) with a C allele 
(84.0 ± 14.2%) (Figure 3.6A). Although TEN 2.1 (Δ488) yielded similar results 
(p=0.007) (data not shown) it was not included in this analysis because it contains 12 
instead of 13 T’s at rs71698207 (Table 3.1). These results support the finding that 
the regulatory region associated with the tendinopathic phenotype may reside within 







With the exception of CON 2.1, there was a significant increase in the luciferase 
activity when the Δ488 deletion constructs were compared to their parent full length 
3’-UTR constructs (Figure 3.6B). This suggests that the terminal 488bp region of the 
COL5A1 3’-UTR contains novel regulatory elements which however do not 





Figure 3.5 The COL5A1 3’-untranslated region (UTR) deletion constructs in HT1080 cells. 
Schematic representations of the full length COL5A1 3’- UTR cloned upstream of the firefly 
luciferase gene (LUC+), together with Δ488bp and Δ57bp deletion constructs. Key restriction 
enzymes used to generate these clones are indicated. The seven tightly linked polymorphic 
sites within the 3’-UTR are annotated as black boxes. The accession numbers and/or 
restriction fragment length polymorphism (RFLP) associated with the polymorphic sites are 
indicated together with the nucleotide changes. The sequence of the seven polymorphisms 
for the C (wild type) and T alleles were C-C-C-(AGGG)1-(ATCT)2-A-T and T-T-A-(AGGG)2-
(ATCT)1-T-C, respectively. CON 3.2 (Δ57) contains an A (highlighted in the white box) 
instead of a C nucleotide at position 880, while the sequence of the other six polymorphic 










Figure 3.6 Functional analysis of the COL5A1 3’-untranslated region (UTR) Δ488 deletion 
constructs in HT1080 cells. (A) The relative luciferase activity of the pooled control (CON, 
black bars) and tendinopathy (TEN, grey bars) clones, containing the COL5A1 3’-UTR C- or 
T-alleles, respectively. (B) The relative luciferase activity of the individual full length (grey 
bars) and Δ488 (clear bars) clones. The CON constructs containing the C (wild type) 
COL5A1 3’-UTR are labelled with a “C”, while the TEN constructs with the T allele are 
labelled with a “T”. Values are expressed as averages ± standard deviations, with the 
number of assays (n) indicated above each bar. Firefly luciferase activity for each clone was 
normalised with renilla luciferase activity and expressed relative to full length CON 2.1. 
 
 
Analysis with the Δ57 constructs revealed that there was no significant difference in 
the relative luciferase activity of CON 5.1 (Δ57), which contains the C allele, (144.2 ± 
28.1% p=0.440) and the two pooled TEN deletion constructs (TEN 1.1 and TEN 2.1) 
with a T allele (156.5 ± 42.5%) (Figure 3.7A). CON 3.2 (Δ57) was not included in this 
analysis because it contains an A instead of a C nucleotide at position 880 which 
altered its luciferase activity (Figure 3.7B).  
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When the Δ57 constructs (CON 5.1, TEN 1.1 and TEN 2.1) were expressed relative 
to the activity of their respective full length 3’-UTR constructs, they exhibited a 
significant increase in luciferase activity (Figure 3.7B). These results indicate that the 
deleted TTTTCTAC binding site, for which there is currently no identified miRNA, 
may be functional but whether it contributes to the tendinopathic phenotype is as yet 
unclear. 
Figure 3.7 Functional analysis of the COL5A1 3’-untranslated region (UTR) Δ57 deletion 
constructs in HT1080 cells.(A) The relative luciferase activity of the pooled control (CON, 
black bars) and tendinopathy (TEN, grey bars) Δ57 clones, containing the COL5A1 3’-UTR 
C- (CON 5.1) or T- (TEN 1.1 and TEN 2.1) alleles, respectively. CON 3.2., which contains an
A nucleotide at position 880, was not included in the analysis. (B) The relative luciferase
activity of the individual full length (grey bars) and Δ57 (clear bars) clones. The nucleotide (C
or A) at position 880 of the COL5A1 3’-UTR is indicated for each clone. Values are
expressed as averages ± standard deviations, with the number of assays (n) indicated
above each bar. Firefly luciferase activity for each clone was normalised with renilla





3.4 The SVWI-38 cells exhibit No Overall Increase in COL5A1 mRNA 
Stability in the Tendinopathic Phenotype. 
 
Having established the activity of the C- and T-allelic forms in the HT1080 cells, their 
activity was next examined in another fibroblast cell line. To this end, the constructs 
CON 2.1, CON 5.1, TEN 1.1 and TEN 2.2 were transiently co-transfected into the 
SVWI-38 SV40-transformed lung fibroblast cells (Section 2.9) with pRL-TK. Again, 
the normalized luciferase activity generated by each construct was expressed 
relative to CON 2.1, and the resulting activities of constructs representing the C- and 
T-allelic form were pooled as described before. There was no significant difference 
(p=0.135) in the luciferase activities of the two allelic forms (CON 72.3 ± 18.3% vs 
TEN 64.7 ± 12.8%) in the SVWI-38 cells (Figure 3.8).  
 
Figure 3.8 Functional analysis of the 2.5 kb COL5A1 3’-untranslated region (UTR) in SVWI-
38 cells with respect to the C- and T-allelic forms. The graph shows the relative luciferase 
activity of all the control (CON, black bars) and tendinopathy (TEN, grey bars) clones, 
containing only COL5A1 3’-UTR C- or T-alleles. Values are expressed as averages ± 





3.5 The Newly Annotated Variants (rs71746744, rs16399 and 
rs1134170) are also Associated with Achilles Tendinopathy 
 
As previously reported, two major allelic forms, namely the C- and T-alleles of the 
COL5A1 3’-UTR were identified, which show significant differences in mRNA stability 
(Section 3.2). In addition, deletion of a 57 bp region within the 3’-UTR containing the 
putative polymorphic miRNA binding site (rs11103544, MboII RFLP, T/C), as well as 
an AGGG short tandem repeat polymorphism (STRP rs71746744, -/AGGG) was 
sufficient to abolish the difference in mRNA stability between the C- and T-functional 
forms (Section 3.3). Variant rs11103544 was previously shown not to independently 
associate with Achilles tendinopathy (September et al., 2009). However, the 
associations of the variant rs71746744, the downstream rs16399 (ATCT/-) and 
rs1134170 (A/T) variants have not previously been investigated (Figure 3.9). 
 
3.5.1 Characteristics of Participants  
 
In order to examine the genetic association of these three variants with respect to 
soft tissue injuries, 342 control participants (CON) and 160 individuals with 
diagnosed chronic Achilles tendinopathy (TEN) from a South African (SA), as well as 
an Australian (AUS) population group, were included in this study. There were 
significantly more male participants within the combined SA and AUS TEN groups 
when compared to the combined CON groups (Table 3.2). When analysed 
separately, there were no significant differences (p=0.128) in gender between the SA 





significantly more males (p<0.001) within the AUS TEN (73.0 %, N=63) group when 








Figure 3.9 A genetic study investigating the variants rs71746744, rs16399 and rs1134170 
(grey arrows). The seven tightly linked polymorphic sites within the 3’-UTR are annotated as 
black boxes. The accession numbers and/or restriction fragment length polymorphism 
(RFLP) associated with the polymorphic sites are indicated together with the nucleotide 
changes. The sequence of the seven polymorphisms for the C (wild type) and T alleles were 







Table 3.2 Descriptive characteristics of the combined South African and Australian 
Achilles tendinopathic (TEN) and control (CON) participants 




 P-value  
Gender (% Male) 72.7 (143) 52.4 (294) <0.001 N.D. 
Age (yrs) a 40.4 ± 14.5 (136) 37.6 ± 11.8 (286) 0.037 N.D. 
Height (cm) 175.5 ± 8.8 (132) 173.0 ± 9.4 (290) 0.011 0.671 b 
Weight (kg) 79.2 ± 14.2 (137) 72.8 ± 13.2 (294) <0.001 0.057 c 
BMI (kg/m2) 25.6 ± 3.9 (132) 24.3 ± 3.6 (286) <0.001 0.305 c 
 
Except for gender, which is presented as a frequency, values are presented as mean ± 
standard deviations. The number of participants with non-missing data is in parenthesis. 
a Age of the TEN participants is at the time of their initial injury, while the age of the CON 
participants is at the time of recruitment. 
b co-varied for gender. 
c co-varied for gender and age at recruitment. 





There were no significant differences between the age of the initial injury of the AUS 
TEN group (40.4 ± 14.7 yrs, N=62) and the age of recruitment of the AUS CON 
group (38.5 ± 12.6 yrs, N=151). The SA TEN group (age of the initial injury 40.4 ± 
14.4 yrs, N=74) was however significantly older (P=0.036) than the SA CON group 
(36.6 ± 10.8 yrs, N=135). The combined SA and AUS TEN group (age at initial 
injury) was therefore significantly older than the combined CON group (Table 3.2). 
The combined TEN groups were recruited on average 9.2 ± 11.02 yrs (SA TEN 8.6 ± 
10.74 yrs, N=74 and AUS TEN 9.8 ± 11.38 yrs, N=62) after their initial injury.  
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When co-varied for gender, there were no significant differences in height between 
the combined TEN and CON groups (Table 3.2). The SA groups were matched for 
height (TEN: 176.9 ± 8.7 cm, N=71 vs CON: 174.8 ± 9.5 cm, N=137, p=0.110) and 
similarly, there were no significant differences (adjusted p=0.152, unadjusted 
p=0.086) in height between the AUS groups (TEN: 173.8 ± 8.7 cm, N=61 vs CON: 
171.5 ± 9.2 cm, N=153).  
When adjusted for both age at recruitment and gender, there were no significant 
differences in the weight and BMI of the combined SA and AUS TEN and CON 
groups (Table 3.2). Similarly when adjusted for age at recruitment and gender, there 
were no significant differences (weight: adjusted p=0.318, unadjusted p<0.001 and 
BMI: p=0.371, unadjusted p=0.005) in the weight and BMI of the AUS TEN (weight: 
80.6 ± 14.5 kg, N=63; BMI: 26.6 ± 4.1 kg/m2, N=61) and CON (weight: 73.4 ± 14.2 
kg, N=153; BMI: 24.9 ± 4.0, N=153) groups. Although adjusted for age at recruitment 
and gender, the SA TEN group (78.1 ± 14.0 kg, N=74) was significantly (adjusted 
p=0.034 and unadjusted p=0.001) heavier than the CON group (72.1 ± 12.1 kg, 
N=141). The SA groups were nevertheless matched for BMI (TEN: 24.7 ± 3.4, N=71 
kg/m2 vs CON: 23.6 ± 2.8 kg/m2, N=133, adjusted p=0.194, unadjusted p=0.010). In 
terms of the country of birth, 72.1% (N=222) of participants in the SA groups 
reported that they were born in South Africa, and similarly, 78.1% (N=215) of the 
participants in the AUS groups were born in Australia. 
As indicated in section 2.13, stringent clinical diagnostic criteria were used during the 
recruitment of participants by an experienced medical practitioner (Mokone et al., 





in this study had symptoms or signs of EDS (skin hyper extensibility, bruising, 
recurrent joint effusions, subluxations or dislocations, ocular manifestations or 
cardiovascular manifestations), hypermobility or benign hypermobility joint syndrome 
when their medical examinations were reviewed by the medical practitioner (Mokone 
et al., 2005;Mokone et al., 2006;September et al., 2009). 
 
In the SA TEN participants (N=81) included in this study (i) 76.5% (N=62) were 
clinically diagnosed with tenderness to palpation, (ii) 58.0% (N=47) with early 
morning stiffness, (iii) 39.5% (N=31) with a history of swelling, (iv) 35.8% (N=28) with 
early morning pain, (v) 29.6% (N=23) with palpable thickening, (vi) 23.5% (N=19) 
tested positive for the ‘‘shift’’ test, and (vii) 93.8% (N=76) had a gradual progressive 
pain profile. Table 3.3 displays the frequencies of individuals having only one or 
more of the symptoms listed above. In addition, the diagnosis was confirmed in a 
subset of the TEN participants (39.5%) by soft-tissue ultrasound examination of the 
affected Achilles tendon. Among the TEN participants, 41.1% (N=73) had a 
confirmed bilateral Achilles tendinopathy while 24% (N=18) reported multiple injuries 
to the tendon. To confirm the pathology and clinical diagnosis of the AUS TEN 
group, all the subjects were examined using a soft-tissue ultrasound of the affected 
Achilles tendon (September et al., 2009). Together, 93.8% (N=64) were symptomatic 
where 79.7% was either of a gradual onset or acute (20.3%). Within the pathology 
group, 53.1% (N=64) were diagnosed with bilateral chronic Achilles tendinopathy 








Table 3.3 Collection of symptoms present in the South African Achilles tendinopathic (TEN) 
participants where the list includes (i) tenderness to palpation, (ii) early morning stiffness, (iii) 
a history of swelling, (iv) early morning pain, (v) palpable thickening and (vi) a positive ‘‘shift’’ 
test.  
Number of clinical 
symptoms present 
TEN Group  
(81) 
All Six 13.6 (11) 
Five 6.2 (5) 
Four 7.4 (6) 
Three 13.6 (11) 
Two 25.9 (21) 
One 27.2 (22) 
None* 6.2 (5) 
 
*Tendinopathic participants with missing clinical diagnostic data but whose diagnosis was 
confirmed by soft-tissue ultrasound examination. 
 Values are presented as a frequency (%), whereas the number of symptomatic TEN 




Running was the predominant (68.1%, N=69) sporting activity resulting in injury in 
the SA cohort and the groups were matched for the mean number of years 
participating in running (8.5 ± 8.1 yrs, N=107, CON versus TEN 8.6 ± 10.0 yrs, N=65, 
p=0.972). However, there was a significant difference in hours of training between 
the two SA groups (p=0.003, 3.6 ± 3.0 hrs/week (N=103) CON vs. TEN 2.1 ± 2.6 
hrs/week (N=57)), where the SA CON group trained for more hours per week. In 
addition, while the SA TEN group participated in more high impact sports compared 
to the CON group in the past ((p<0.001), 17.0 ± 16.5 yrs (N=107) CON vs. TEN 32.2 





impact training performed over the past two years. Although all AUS participants 
were physically active individuals, the type of sporting activity that they were involved 
in and the frequency of this activity as well as their hours of training were not 
recorded.  
 
3.5.2 COL5A1 3’-UTR Genotype Frequencies 
 
With the exception of significant differences between the weight and BMI within the 
three rs16399 (ATCT/-) genotype groups, there were no significant genetic 
interactions with any of the other physiological variables (age, height, and gender) 
for any of the three COL5A1 3’-UTR variants (Tables 3.4 to 3.6). Participants with an 
ATCT/ATCT genotype were significantly heavier, with a corresponding larger BMI, 
than those with ATCT/- or a -/- genotypes (Table 3.5). Similar results were obtained 
when the pathology and country groups were analyzed separately, except for the 
AUS TEN individuals with the -/- genotype being taller than the ones with the ATCT/- 
.genotype (p=0.03) (Appendix D).  
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Table 3.4 Physiological characteristics of the three rs71746744 (-/AGGG) genotype groups 
of the combined Australian and South African participants 
-/- AGGG/- AGGG/AGGG P-value
Gender (% Male) 60.71 (28) 51.28 (117) 60.99 (141) 0.268 
Age (yrs) a 38.7 ± 12.6 (28) 38.5 ± 13.1 (113) 38.8 ± 12.6 (137) 0.973 
Height (cm) 173.8 ± 7.3 (27) 173 ± 10.0 (115) 174.2 ± 9.1 (133) 0.621 
Weight (kg) 76.5 ± 17.4 (27) 73.3 ± 14.4 (116) 75.8 ± 12.8 (139) 0.306 
BMI (kg/m2) 25.1 ± 4.4 (27) 24.4 ± 4.1 (113) 24.9 ± 3.5 (133) 0.530 
Except for gender, which is presented as a frequency, values are presented as mean ± 
standard deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
Table 3.5 Physiological characteristics of the three rs16399 (ATCT/-) genotype groups of 
the combined Australian and South African participants 
ATCT/ATCT ATCT/- -/- P-value
Gender (% Male) 64.9 (37) 54.54 (154) 64.44 (180) 0.154 
Age (yrs) a 39.6 ± 13.5 (37) 37.9 ± 12.7 (147) 38.1 ± 12.1 (173) 0.774 
Height (cm) 172.9 ± 9.2 (36) 173.5 ± 9.6 (149) 174.7 ± 9.2 (173) 0.410 
Weight (kg) 81.0 ± 18.6 (36) 72.3 ± 12.5 (151) 75.4 ± 13.5 (178) 0.002 
BMI (kg/m2) 27.0 ± 6.1 (35) 24.0 ± 3.2 (147) 24.6 ± 3.4 (172) <0.001 
Except for gender, which is presented as a frequency, values are presented as mean ± 
standard deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
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Table 3.6 Physiological characteristics of the three rs1134170 (A/T) genotype groups of the 
combined Australian and South African participants 
AA AT TT P-value
Gender (% Male) 50.00 (4) 55.25 (181) 62.89 (159) 0.338 
Age (yrs) a 38.8 ± 13.5 (4) 38.4 ± 12.5 (154) 38.8 ± 13.8 (152) 0.971 
Height (cm) 170.5 ± 10.9 (4) 173.1 ± 9.4 (175) 174.9 ± 9.2 (152) 0.164 
Weight (kg) 75.0 ± 12.5 (4) 74.1 ± 13.8 (179) 75.6 ± 13.8 (156) 0.636 
BMI (kg/m2) 25.7 ± 2.7 (4) 24.7± 4.1 (172) 24.6 ± 3.3 (151) 0.815 
Except for gender, which is presented as a frequency, values are presented as mean ± 
standard deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
The genotype distributions of rs71746744, rs16399 and rs1134170 were similar 
within the SA and AUS cohorts (Table 3.8) and were therefore combined for further 
analysis. As illustrated by figure 3.10, the AGGG/AGGG (p=0.008, odds ratio 
(OR)=2.0, 95% confidence interval (CI)=1.2-3.3), -/- ATCT (p=0.015, OR=1.7, 95% 
CI=1.1- 2.7) and TT (p=0.011, OR=1.8, 95% CI=1.2-2.9) genotype frequencies of 
rs71746744, rs16399 and rs1134170 respectively were significantly over-
represented in the combined Achilles tendinopathy cohorts. Except for rs1134170, 
the other two polymorphisms were in Hardy-Weinberg equilibrium (HWE). All three 













Table 3.7 The linkage disequilibrium (LD) between the three newly annotated variants 
rs71746744, rs16399 and rs1134170 as well as with respect to the reported rs12722 variant 
within the combined Australian and South African participants.  
 rs12722 rs71746744 rs16399 
rs71746744 
0.77 















The D′ value between the pairs of variants is in bold for the control (CON) group while in 







Table 3.8 Genotype frequency distributions the COL5A1 3’-untranslated region (UTR) 
polymorphisms, rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T), in control 





CON TEN CON TEN 
rs71746744  N=101 N=51 N=97 N=40 
 -/-  8.9 (9) 2.0 (1) 15.5 (15) 7.5 (3) 
 -/AGGG  48.5 (49) 37.3 (19) 38.1 (37) 30.0 (12) 
 AGGG/AGGG  42.6 (43) 60.8 (31) 46.4 (45) 62.5 (25) 
 HWE  0.503 0.666 0.124 0.374 
 P-value a  0.040 0.095 
rs16399  N=133 N=68 N=121 N=52 
 ATCT/ATCT  9.0 (12) 4.4 (3) 16.5 (20) 3.9 (2) 
 ATCT/-  46.6 (62) 41.2 (28) 38.8 (47) 32.7 (17) 
 -/-  44.4 (59) 54.4 (37) 44.6 (54) 63.5 (33) 
 HWE  0.552 0.536 0.114 1.000 
 P-value b  0.183 0.031 
rs1134170  N=131 N=66 N=110 N=41 
 AA  0.0 (0) 0.0 (0) 3.6 (4) 0.0 (0) 
 AT  56.5 (74) 40.9 (27) 56.4 (62) 46.3 (19) 
 TT  43.5 (57) 59.1 (39) 40.0 (44) 53.7 (22) 
 HWE  <0.001 0.056 0.002 0.087 
 P-value c 0.050 0.144 
 
Genotypes are expressed as percentages with numbers (N) in parenthesis.  
HWE are exact P-values from tests of Hardy-Weinberg equilibrium.  
a AGGG/AGGG genotype vs. the combined -/AGGG and -/- genotypes  
b -/- ATCT genotype vs. the combined ATCT/- and ATCT/ATCT genotypes  









Figure 3.10 Genotype frequency distributions for the COL5A1 3’-untranslated region (UTR) 
polymorphisms, (A) rs71746744 (-/AGGG), (B) rs16399 (ATCT/-) and (C) rs1134170 (A/T), 
in control (CON) and chronic Achilles tendinopathy (TEN) for the combined SA and AUS 
(SA+AUS) cohorts. The genotype frequency for the CON and TEN groups are denoted by 
black and white bars respectively. The P-value for each (A) AGGG/AGGG genotype vs. the 
combined -/AGGG and -/- genotypes, (B) -/- ATCT genotype vs. the combined ATCT/- and 
ATCT/ATCT genotypes, (C) TT genotype vs. the combined AT and TT genotypes is 







3.5.3 Inferred Haplotype Study 
 
As described in section 3.2 two major functional forms of the COL5A1 3’-UTR, 
namely the C- and T-forms were identified after sequencing the 3’-UTR from CON 
and TEN participants respectively. The distinct C- and T-functional forms were 
determined by seven polymorphisms, namely rs13946 (C/T), rs12722 (C/T), 
rs3196378 (C/A), rs71746744 (-/AGGG), rs16399 (ATCT/-), rs1134170 (A/T) and 
rs3128575 (T/C) (Figure 3.2). The nucleotide sequence associated with the C-form 
and T-forms were C-C-C-(AGGG)1-(ATCT)2-A-T and T-T-A-(AGGG)2-(ATCT)1-T-C, 
respectively. With the exception of rs3128575, which had previously been genotyped 
in only the SA cohort (September et al., 2009), rs13946, rs12722, and rs3196378 
have previously been genotyped in most of the participants within the AUS and SA 
cohorts (September et al., 2009). In order to confirm the sequencing results, inferred 
haplotypes were constructed with six of the seven polymorphisms that distinguished 
the two forms of the 3’-UTR. 
 
Eight of the possible 36 inferred haplotypes had a frequency >1% (Figure 3.11). In 
agreement with the sequencing data (section 3.2), the T-T-A-(AGGG)2-(ATCT)1-T 
haplotype was significantly over-represented (p=0.003) in the combined SA and AUS 
TEN group (42.4%,N=76) when compared to the CON group (39.7%, N=150) (Figure 
3.11). In addition, the T-C-C-(AGGG)2-(ATCT)1-T haplotype was also significantly 
over-represented (p=0.015) in the TEN group (15.7%, N=28) compared with the 
CON group (11.1%, N=42), mapping the associated region to rs71746744 (-/AGGG), 
rs16399 (ATCT/-) and rs1134170 (A/T). Four of the possible 8 inferred haplotypes 
constructed from rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T) had 
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a frequency >1% (Figure 3.12). The AGGG)2-(ATCT)1-T haplotype was significantly 
over-represented (p=0.007) in the combined SA and AUS TEN group (72.2%,N=130) 
when compared to the CON group (62.5%, N=236).  
Figure 3.11 The frequency distribution of 8 of the possible 36 inferred haplotypes with a 
frequency >1% constructed from COL5A1 3’-UTR variants rs13946 (C/T), rs12722 (C/T), 
rs3196378 (C/A), rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T) in the 
combined Australian and South African Achilles tendinopathy (TEN, white bars) and control 
(CON, black bars) groups. The P-value of the significantly different haplotypes and the total 







Figure 3.12 The frequency distribution of 4 of the possible 8 inferred haplotypes with a 
frequency >1% constructed from COL5A1 3’-UTR variants rs71746744 (-/AGGG), rs16399 
(ATCT/-) and rs1134170 (A/T) in the combined Australian and South African Achilles 
tendinopathy (TEN, white bars) and control (CON, black bars) groups. The P-value of the 
significantly different haplotypes and the total number (N) of haplotypes within the CON and 
TEN groups are indicated on the graph. 
 
 
3.5.4 Gene-gene Interactions 
 
As previously mentioned in section 3.2, the COL5A1 3’-UTR contains a functional 
polymorphic (rs3196378, C/A) Hsa-miR-608 miRNA binding site (Figure 3.4) 
(Abrahams et al., 2013). Two forms of the mature Hsa-miR-608 are produced from 
the polymorphic (SNP rs4919510, C/G) MIR608 gene on chromosome 10q24 
(Abrahams et al., 2013). Although it was previously reported that there is no 
genotype-genotype association between these two SNPs and chronic Achilles 
tendinopathy, the CC genotype of MIR608 was significantly over-represented in the 
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TEN group (Abrahams et al., 2013). Since, the CC MIR608 rs4919510, 
AGGG/AGGG COL5A1 rs71746744, -/- ATCT COL5A1 rs16399 and TT COL5A1 
rs1134170 genotypes were all independently associated with increased risk of 
chronic Achilles tendinopathy, gene-gene interactions were further investigated. 
Each of the four individual “at risk” genotypes contributed a score of 2 towards a 
participants “genotype risk score”. Participants with all four individual Achilles 
tendinopathy “at risk” genotypes had a total score of 8, while those with none of the 
risk genotypes had a score of 0. When compared to the CON group, the “genotype 
risk score” of 8 was significantly over-represented within the TEN group (p=0.004; 
odds ratio=2.6; 95% confidence interval 1.3 to 4.9), while the “genotype risk score” of 
0 was significantly under-represented (p=0.019; odds ratio=3.1; 95% confidence 
interval 1.2 to 8.5) (Figure 3.13). When the CC MIR608 rs4919510 “at risk” genotype 
was excluded from the analyses, the three COL5A1 3’-UTR “at risk” genotypes were 
also significantly over-represented (p=0.006; odds ratio=2.3; 95% confidence interval 
1.3 to 4.3) within the TEN participants (60.0%, N=36 of 60) when compared to the 
CON participants (39.4%, N=61 of 155) (Figure 3.13). In contrast, participants with 
none of the three “at risk” COL5A1 genotypes were significantly over-represented 
(P=0.002; odds ratio=2.7; 95% confidence interval 1.4 to 5.0) within the CON 
participants (55.5%, N=86 of 155) when compared to the TEN participants (31.7%, 
N=19 of 60).  
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Figure 3.13 Genotype risk score frequency distributions of the Hsa-miR-608 gene (MIR608) 
rs4919510 (C/G) polymorphism and the three COL5A1 3’-untranslated region (UTR) 
polymorphisms, (i) rs71746744 (-/AGGG) polymorphism, (ii) rs16399 (ATCT/-), and (iii) 
rs1134170 (A/T) in the pooled South African and Australian control (CON, clear bars) and 
chronic Achilles tendinopathy (TEN, black bars) groups. The ‘at risk’ genotypes for chronic 
Achilles tendinopathy at each variant contributed 2 points (rs4919510, CC; rs71746744, 
AGGG/AGGG; rs16399, -/- ATCT; rs1134170, TT) towards the genotype risk scores while 
the non-risk genotypes (rs4919510, CG and GG; rs71746744, -/- AGGG and -/AGGG; 
rs16399, ATCT/- and ATCT/ATCT; rs1134170, AT and AA) contributed 0 points. As 
indicated by an asterisks, the genotype risk score of 0 was significantly under-represented in 
the TEN group, p=0.019, OR=3.1 and 95% CI=1.2 to 8.5. The genotype risk score of 8 was 
however significantly over-represented in the TEN group, p=0.004, OR=2.6 and 95% CI=1.3 
to 4.9. The global P-value, which was calculated by combining the 4 and 6 genotype risk 
scores, is indicated. 
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3.6 Independently, the variants rs12722 and rs71746744 are not 
responsible for the tendinopathic phenotype. 
Since the COL5A1 3’-UTR variants rs12722 (C/T) and rs71746744 (-/AGGG) were 
independently associated with chronic Achilles tendinopathy (Abrahams et al., 
2013;September et al., 2009) (section 3.5.2), site directed mutagenesis of these 
sites were attempted on the parental T- and C-allelic constructs as described in 
section 2.4 to determine whether they were functional. In addition since variant 
rs71746744 (-/AGGG) is within the functional Δ57bp deletion region (section 3.3) 
and is also tightly linked to the two other independently associated variants, rs16399 
(ATCT/-) and rs1134170 (A/T), (Table 3.7), it was decided to only mutate 
rs717146744. The mutants generated (insert and vector) were sequenced to confirm 
the desired nucleotide changes. Two mutants were obtained with an altered rs12722 
(T/C) variant while only one was obtained with an altered rs71746744 (-/AGGG) 
variant (Figure 3.14A & 3.15A).  
One rs12722_C>T and one rs12722_T>C construct was generated, where a C to a 
T nucleotide change was introduced at rs12722 in the CON parental construct 
(pGL3-COL5A1-3’UTR) and a T to a C nucleotide change was introduced at rs12722 
in the parental TEN construct as illustrated in figure 3.14A. The site-directed mutants 
as well as their parental constructs were transfected into HT1080 cells and assayed 
as described in section 3.1.  
There was a significant decrease (p=0.022) in the relative luciferase activity of the 
mutated rs12722 CON construct (73.5%, n=17) compared to the CON parental 
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construct (100%, n=17) (Figure 3.14B). In contrast, there was a significant (p=0.021) 
increase in the relative activity of the mutated rs12722 TEN construct (133.6%) when 
compared to the TEN parental construct (Figure 3.14C). Interestingly, when the 
relative luciferase activities of the mutated rs12722 TEN and CON constructs were 
compared (Fold increase of 1.8 ± 0.367,N=17, p<0.001; figure 3.14D), the difference 
in the activity was more pronounced than that reported between the C- and T-allelic 
form. Since the difference in mRNA stability increased rather than decreased, it 
appears that the variant rs12722 T/C on its own is not responsible for the 
tendinopathic phenotype. 
There was no significant difference (p=0.411) in the relative luciferase activity 
between the CON rs71746744 (-/AGGG) construct which contains only one AGGG 
tetranucleotide, (80.0 ± 17.8 %, N=9) and the CON mutant rs71746744 construct 
which contained two AGGG tetranucleotides (72.6 ± 21.2 %, N= 12) (Figure 3.15A 
and B). A comparable experiment using the TEN construct could not be performed 
due to technical difficulties with deleting one of the two AGGG tetranucleotides from 







Figure 3.14 Examination of the effect of the variant rs12722 on the mRNA stability of the 
COL5A1 3’-UTR. (A) Schematic diagram representing the site-directed mutants and their 
parental constructs used in this experiment. The altered sites are shown as grey boxes. (B) 
The relative luciferase activity of rs12722_C>T compared to the C allele construct. (C) The 
relative luciferase activity of rs12722_T>C compared to the T allele construct. (D) The fold 
difference illustrated between rs12722_C>T and rs12722_T>C. The number of assays (n) is 
indicated below the bar. Values are expressed as mean ± standard deviations. Firefly 
luciferase activity for each construct was normalised to renilla luciferase activity and 







Figure 3.15 Examination of the effect of variant rs71746744 on the mRNA stability of the 
COL5A1 3’-UTR (C-allelic form). (A) Schematic diagram representing the site-directed 
mutant and its parental construct. The altered sites are shown as grey boxes. (B) The 
relative luciferase activity (%) of the mutant and its parental construct were plotted. The 
luciferase activity of rs71746744_ins AGGG is shown as the grey bar on the right while that 
of the C-allelic construct is shown in black on the left. The number of assays (n) is indicated 
above the bar. Values are expressed as mean ± standard deviations. Firefly luciferase 
activity for each construct was normalised to renilla luciferase activity and expressed relative 
to full length CON 2.1. 
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3.7 Establishment of Primary Skin Fibroblast Cell Lines 
Since the in vitro experiments and genetic association studies described above 
implicated the 3’-UTR in the regulation of the COL5A1 gene, the next set of 
experiments were performed to determine whether these findings could be replicated 
in vivo. Due to ethical considerations about obtaining tenocytes, especially from 
healthy participants, these experiments were carried out on primary fibroblasts with a 
known COL5A1 genotype derived from skin biopsies. Briefly, primary fibroblast 
cultures were established from a superficial skin sample which was obtained from 
each participant with known COL5A1 3’-UTR genotypes at rs12722, rs71746744, 
rs16399 and, rs1134170 (section 2.16; Table 3.9). Primary fibroblasts could be seen 
migrating out of the skin explants after approximately one week (Figure 3.16). To 
increase the yield of fibroblasts, the explants were placed under coverslips and a 
week later the coverslips were inverted and placed cell-side up in new plates with 
fresh complete DMEM.  
Once a moderate amount of cells were obtained, the explants were removed and the 
fibroblasts were allowed to proliferate until they were dominant in the population of 
cells present in the dish. The fibroblasts appeared predominantly as large, irregular 
and elongated in shape or were typically spindle-shaped. The plates were then 
treated with trypsin/EDTA and passaged for the first time and when they reached 
80% confluence, they were either passaged a second time or frozen down for later 
use. When cultured at higher confluence, the cells aligned in an orderly parallel 
manner. 
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SB-1 TT AGGG/AGGG -/- TT 
SB-2 TT AGGG/AGGG -/- TT 
SB-3 TT AGGG/AGGG -/- TT 
SB-4 TC -/AGGG -/- AT 
SB-5 CC -/AGGG -/- AT 
SB-6 CC -/- ATCT/- AA 










Figure 3.16 (A, B) High-power photomicrographs showing migrating cells (see arrows) out of 







3.8 A Preliminary Study shows an Increase in the Expression Levels of 
COL5A1 and COL1A1 for Individuals with a T allele at rs12722. 
 
Fibrillogenesis requires both Type V and Type I collagen for initiation and elongation 
of the fibril. This raised the question as to whether the levels of COL5A1 and 
COL1A1 were altered in individuals with a T allele at rs12722. To address this, total 
RNA was extracted from the established primary fibroblast cultures and subjected to 
Quantitative Real-Time Reverse Transcription PCR (Q-RT-PCR) (donor’s cells SB-1 
to SB-7). 
 
Figure 3.17A and B respectively shows the relative mRNA abundance of COL5A1 
(clear bars) and COL1A1 (grey bars) with respect to the rs12722 genotype of each 
participant (indicated at the base of the bar graphs). Two independent biological 
replicates were used and each experiment was performed in triplicate. The third 
graph (Figure 3.17C) displays the ratio of the relative mRNA expression of COL1A1 
and COL5A1 (COL1A1/COL5A1). An inter-individual variation was observed for both 
COL5A1 and COL1A1 (global p <0.001, N≥30). 
 
When compared to all donor fibroblasts, the relative mRNA abundance of COL5A1 
was significantly the highest in SB-2 (TT genotype, 2.25 ± 0.85, p<0.024, N=5). 
However, there was no significant difference in the relative mRNA abundance of 
COL5A1 between SB-1 and SB-2, both donor fibroblasts having the TT genotype. 
The COL5A1 transcript abundance was significantly higher for SB-1 (1.75 ± 0.68, 
N=4) compared to SB-3 (p=0.049, N=5), SB-5 (p=0.005, N=6) and SB-6 (p=0.011, 





3.17B) was significantly higher for SB-2 (3.34 ± 0.45, p<0.001, N=4). The mRNA 
expression of COL1A1 was significantly elevated in the SB-1 donor fibroblasts from 
a participant with a TT genotype (1.47 ± 0.48, p<0.001, N=4) compared to SB-5 
donor fibroblasts from a CC genotype (0.45 ± 0.21, N=6). However, there were no 
significant differences in the COL1A1 to COL5A1 ratio (Figure 3.17C) within the 
individual samples except for participant SB-2 (p=0.008, N≥4). 
 
When the relative expression levels of the transcripts was pooled in terms of the 
genotype at the rs12722 locus an interesting pattern was observed (Figure 3.18A, 
B). The TT genotype displayed a higher COL5A1 (1.58 ± 0.89, p<0.001, N=14) and 
COL1A1 (1.88 ± 1.10, p=0.0015, N=13) mRNA abundance compared to that of the 
CC genotype (COL5A1: 0.57 ± 0.19, N=12 and COL1A1: 0.67 ± 0.29, N=12) 
regardless of whether SB-2 was included or excluded from the analysis (p=0.010 for 
COL5A1 and p=0.003 for COL1A1, N=9). No significant differences were observed 




Figure 3.17 Relative mRNA abundance of (A) COL5A1 (clear bars) and (B) COL1A1 (grey 
bars) expressed by the skin fibroblasts cultured from each participant (SB-1 to SB-7). (C) 
The ratio of the relative mRNA abundance of the two genes, COL1A1/COL5A1 (black bars). 
The relative mRNA abundance (2-Δ (ΔCT)) is given in arbitrary units. The genotype at the 
rs12722 locus of each individual is indicated at the base of each bar graph. The number of 
samples included is shown on top of the bars and the significance is indicated on the graphs. 
SB-7 (CC at rs12722) is used as a control sample and β-actin as the housekeeping gene. 
The comparative CT method was used to derive the relative mRNA abundance from the 
threshold cycle (CT) values obtained. 
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Figure 3.18 Relative mRNA abundance of (A) COL5A1 (clear bars) and (B) COL1A1 
expressed (grey bars) in skin fibroblasts pooled with respect to their genotype at the rs12722 
locus. (C) The ratio of the relative mRNA abundance of the two genes, COL1A1/COL5A1 
(black bars). The relative mRNA abundance (2-Δ (ΔCT)) is given in arbitrary units. The number 
of samples included is shown on top of the bars and the significance indicated on the 
graphs. SB-7 (CC at rs12722) is used as a control sample and β-actin as the housekeeping 
gene. The comparative CT method was used to derive the relative mRNA abundance from 





3.9 Differential Binding of RNA Binding Proteins (RBPs) to the C- and 
T-allelic forms. 
 
As reported in section 3.3, a 57bp XbaI-AflII deletion region within the COL5A1 3’-
UTR may contain site(s) responsible for the functional differences between the C- 
and T-allelic forms. Previous work in our laboratory excluded the involvement of two 
polymorphic miRNA binding sites (Abrahams, 2013;Laguette et al., 2011). However, 
when this region was screened using a RNA binding protein (RBP) database 
(http://rbpdb.ccbr.utoronto.ca/) putative sites were identified for NONO, KHDRBS3, 
HNRNPA1, EIF4B, ELAVL1 and PTBP1 in both allelic forms (See Table 3.10 and 
Figure 3.19).  
 
The non-pou domain-containing octamer-binding protein (NONO) is a 54kDa nuclear 
protein involved in RNA biogenesis and DNA repair (Krietsch et al., 2012). The KH 
domain-containing RNA binding signal transduction-associated protein 3 
(KHDRBS3) is a 55kDa nuclear protein which may act as a shuttle between the 
nucleus and cytoplasm (Lei et al., 2011). The heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) is 35kDa which affects mRNA stability during 
collagen synthesis (Thiele et al., 2004) and is involved in numerous cellular 
processes through its ability to bind to both DNA and RNA sequences (Chen et al., 
2010). The eukaryotic translation initiation factor 4B (EIF4B) is an 80kDa protein 
important for mRNA biogenesis (Meyer et al., 1995) and capable of binding targets in 
the cytoplasm thereby directing translation initiation (Shahbazian et al., 2010). The 
(embryonic lethal, abnormal vision, Drosophila)-like 1 (ELAVL1) is a 36kDa protein 
which can increased mRNA stability, resulting in greater translation and gene 
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expression (Viiri et al., 2013). The polypyrimidine tract-binding protein 1 (PTBP1) is 
57KDa in size and is involved in mRNA biogenesis, namely alternative splicing 
(Romanelli et al., 2013).  
Interestingly, compared to the C-allelic form which had 1 binding site for NONO, the 
T-allelic form had two binding sites for this RBP (Figure 3.19B). The current study
investigated the possibility that one or more of the putative RBP sites identified may 
be responsible for the functional differences between the C- and T-allelic forms using 
RNA electromobility shift assays (EMSAs). Briefly, this assay involved incubating 
biotinylated C- and T-allelic RNA probes with either nuclear or cytoplasmic protein 
extracts from HT1080 cells. Protein-RNA complexes and free RNA probe were 
resolved using native polyacrylamide gel electrophoresis and following crosslinking, 
signals were detected using a streptavidin-HRP conjugate and the chemiluminescent 
signal emitted captured. While DNA EMSAs are well established in our laboratory, 
we had not previously performed RNA EMSAs and therefore it had to be optimised, 
as described below. 
Protein-RNA interactions are influenced by the tertiary structure of the protein and in 
RNA EMSAs, both the RNA and protein(s) must be correctly folded to allow proper 
binding (Butcher and Pyle, 2011). In addition, RNA is particularly vulnerable to rapid 
degradation and care must be taken to prevent contamination of the reaction with 
RNases (RNA degrading enzymes). Several strategies were therefore explored to 
harvest protein lysates suitable for RNA EMSAs and the most critical factors are 
described here. Rather than a mechanical lysis, a gentle chemical lysis was 





included 1mM EGTA pH 6.8, phosphatase inhibitors as well as protease inhibitors 
(detailed in section 2.13). Moreover RNase-free techniques were implemented at 
every step of the RNA EMSA protocol. To optimise complex formation in the binding 
assays, a titration with decreasing amounts of tRNA, the non-specific competitor, 
was performed. Based on the results obtained, 10mg/ml tRNA was chosen for all 
future experiments. Lastly, to determine the optimal quantity of protein lysates 
required, the RNA probes were reacted with increasing amounts of protein extracts. 
Based on the results from these experiments, 12 and 24µg nuclear extracts and 13 
and 26µg cytoplasmic extracts were used (detailed in section 2.14).  
 
It is important to note that due to inherent differences the T-allelic probe was 4 
nucleotides longer than the C-allelic form. Furthermore, due to limitations of the size 
of the probes that can be used in these RNA EMSAs, probes were generated that 














Figure 3.19 Putative RBPs binding sites (underlined) within the 57bp deletion region 
(flanking RE sites annotated and sequence underlined) together with the sequence of the 
RNA biotinylated probes (mapped in grey highlight) used in this experiment for the (A) C- 
allelic form and (B) the T-allelic form. The position is the nucleotide number of the COL5A1 









Table 3.10 Summary of the size, putative binding site sequence, localisation and function of 
key RBPs binding putatively within the 57bp deletion region of the 3'-UTR of COL5A1 gene  
 
NONO, Non-pou domain-containing octamer-binding protein; KHDRBS3, KH domain-
containing RNA-binding signal transduction-associated protein 3; HNRNPA1, heterogeneous 
nuclear ribonucleoprotein A1; EIF4B, Eukaryotic translation initiation factor 4B; ELAVL1, 










Localization Key Function 








HNRNPA1 35 UAGGGA Nuclear RNA biogenesis 
EIF4B 80 GGAA Cytoplasmic Translation initiation 
ELAVL1 36 AUUU Nuclear and cytoplasmic 
RNA 
biogenesis 







The results show that the signal for the shorter C-allelic unbound probe was 
consistently more intense and that it migrated faster through the gel than the 
unbound T-allelic probe used at the same concentration. A large complex was 
observed when 13 and 26µg of the cytoplasmic extract was incubated with 0.125µM 
of the C- and T-allelic probe respectively (indicated by * in figures 3.20 and 3.21B). 
This complex was also detected in lanes containing cytoplasmic extract only i.e. in 
the absence of the RNA probes, but not in lanes containing nuclear protein extracts 
with or without probes (Figures 3.20 and 3.21). Together these results suggest that 
the cytoplasm of HT1080 cells contain endogenous biotinylated proteins such as 
carboxylases which is consistent with other reports (Bina, 2006;Wolinsky and 
Driskell, 2005). 
 
Importantly, a signal showing a complex was detected when nuclear extracts were 
incubated with the C-allelic RNA probe (indicated by ** in figure 3.21A). This signal 
was also present when the C-allelic probe was incubated with cytoplasmic extract 
but it was much fainter (Figure 3.21B). This signal (**) was absent in the presence of 
the T-allelic probe. These results indicate that a complex may be forming in the 
presence of the C-allelic probe selectively. Noteworthy, when the T-allelic RNA 
probe was incubated with either nuclear or cytoplasmic protein extracts, a signal was 
detected at the level of the wells (indicated by # in figure 3.20 and 3.21A, B). It is 
tempting to speculate that this represents a true complex because the signal for the 
unbound T-allelic probe was less intense in these lanes. Furthermore, this “complex” 
was also present when the C-allelic probe was incubated with both protein lysates 





for the unbound C-allelic probe. These results suggest that a large complex may be 








Figure 3.20 Blot of a non-radioactive RNA EMSA where 13 and 26µg of the cytoplasmic 
protein extract reacted with 0.125µM of the C- or T-allelic probes spanning the functional 
57bp deletion region as described in the results section. The symbol *, ** and # denoted the 









Figure 3.21 Blot of a non-radioactive RNA EMSA where (A) 12 and 24 µg of the nuclear 
protein extract reacted with 0.125µM of the biotinylated C- or T-allelic probes spanning the 
functional 57bp deletion region (B) Both 12µg of the nuclear and 13µg cytoplasmic protein 
extract respectively were used with the biotinylated probes in a replicated experiment. The 
symbol *, ** and # denoted the position of RNA-Protein complexes on the blot as described 







CHAPTER 4 DISCUSSION 
 
Research in our laboratory has previously reported the association of a common C/T 
polymorphism (SNP rs12722; BstUI RFLP) within the COL5A1 3’-UTR with 
musculoskeletal soft tissue injuries including chronic Achilles tendinopathy (Mokone 
et al., 2006;September et al., 2009), ACL injuries in females (Posthumus et al., 
2009), exercise-associated muscle cramps (O'Connell et al., 2013), Carpel Tunnel 
syndrome in occupational workers (Burger et al., 2014), as well as complex exercise-
related phenotypes, including range of motion measurements (Brown et al., 
2011;Brown et al., 2011;Collins et al., 2009) and running endurance performance 
(Brown et al., 2011;Posthumus et al., 2010). Although the 3’-UTR of eukaryotic 
genes contain important regulatory elements shown to be involved in the aetiology of 
many diseases (Conne et al., 2000), the biological function of the COL5A1 3’-UTR is 
unknown. This thesis reports novel findings on the role of the COL5A1 3’-UTR and 
its possible involvement in musculoskeletal soft tissue injuries and exercise-related 
phenotypes.  
 
4.1 The tendinopathic phenotype has an overall increase in COL5A1 
mRNA stability and expression. 
 
Expression from both copies of the COL5A1 gene is required for normal 
fibrillogenesis of the heterotypic collagen fibrils which contain, among other proteins, 
types I, III and V collagen (Birk, 2001). Mutations resulting in the loss of function of 





connective tissue disorder, classic Ehlers-Danlos syndrome (Malfait et al., 2010). 
The 50% reduction in the amount of type V collagen produced in these patients 
result in abnormal fibrillogenesis, which is characterised by an increase in the 
average fibre diameter with a greater variability in the width and shape of the fibrils. 
Similar findings have been reported in Col5a1 +/- mice, while Col5a1 -/- mice die in 
utero at E10.5 (Wenstrup et al., 2006), displaying a direct relationship between the 
transcription of the gene, the α1(V) chain synthesis,  type V collagen as well as 
heterotypic fibril organisation. Based on the dosage sensitivity demonstrated in these 
studies, it is speculated that relatively small changes in COL5A1 mRNA stability 
within the normal physiological range could result in inter-individual variation in 
fibrillogenesis. This could lead to altered susceptibility to musculoskeletal soft tissue 
injuries, as well as to variations in flexibility and endurance running performance.  
 
The primary aim of this thesis was therefore to determine whether the COL5A1 3’-
UTR was functional and whether it differed between participants with Achilles 
tendinopathy (TT genotype at rs12722) and asymptomatic controls (CC genotype at 
rs12722). To this end, a well described approach to measuring the effect of the 3’-
UTR on mRNA stability was employed in two fibroblast cell lines (Ogawa et al., 
2010;Ross, 1995;Wang et al., 2008). In this thesis, experiments performed in the 
HT1080 fibroblast cell line show an overall increase in COL5A1 mRNA stability in the 
tendinopathic phenotype. A fold difference was obtained which is consistent with 
reported values for other extracellular matrix genes which range from 1.5 to 4 fold 
(Akhtar et al., 2010;Du et al., 2010;Liu et al., 2009;Ogawa et al., 2010;Thiele et al., 
2004). The HT1080 cells are commonly used for transfection assays with reporter 





constructs in which the 3′-UTR of COL1A1, COL1A2 and COL3A1 were cloned 
downstream of the luciferase reporter (Thiele et al., 2004).  
 
When the above experiments with the COL5A1 3’-UTR were however performed in 
the SV40 transformed WI-38 lung fibroblast cell line, no significant difference was 
observed in mRNA stability between the asymptomatic controls and the 
tendinopathic phenotype. The reason(s) for the different results in the two cells lines 
is currently unknown but it is worth noting that these cells were derived from different 
sources which may account for these differences. While the HT1080 human 
fibroblast cell line was derived from a fibrosarcoma arising adjacent to the 
acetabulum (at the hip joint) of a 35 years old Caucasian male individual (Rasheed 
et al., 1974), the SVWI-38 is a human embryonic lung fibroblast cell line (WI-38) 
transformed with the Simian virus 40 (SV40) (de Haan et al., 1986). It is also worth 
noting that although specific expression of the type V collagen genes have not been 
investigated in this SV40 transformed fibroblast cell line, COL1A2 gene expression is 
transcriptionally repressed in these cells (Parker et al., 1992). To avoid such 
limitations in the future, prospective experiments should be perform in more relevant 
cells such as a primary fibroblast or tenocyte cell line. 
 
Importantly, consistent with the data obtained from in vitro luciferase assays in the 
HT1080 cells, results from an ex vivo assay also showed that there was a higher 
mRNA abundance of COL5A1 in primary fibroblasts from individuals with an ‘at risk’ 
genotype (rs12722, TT) compared to that with a ‘protective’ genotype (rs12722, CC). 
Indeed, a similar fold difference of approximately 2.8-fold mRNA abundance of 





Studies in murine models and EDS patients with haploinsufficiency of COL5A1 
display severe phenotypes such as aberrant skin as well as musculoskeletal soft 
tissue defects (Wenstrup et al., 2000;Wenstrup et al., 2006). Type V collagen as 
mentioned in Chapter 1 is important in the development of the skin and, although the 
skin inherently has a different organisation compared to the tendon, symptoms of 
EDS manifest in the skin as well. Therefore, making use of fibroblasts derived from 
skin explants is relevant as an alternative when examining the possible functional 
effects of genetic variations in the COL5A1 gene. 
 
Of particular interest, was the observation that COL1A1 expression followed a similar 
trend to that seen for COL5A1 in the ex vivo study. While the COL1A1 genotype of 
the donor fibroblasts was not established in the current study, functional variants 
within the first intron of the COL1A1 gene have been shown to alter its expression at 
an inter-individual level in osteoarthritis (Jin et al., 2009;Mann et al., 2001). It would 
therefore be important for future studies to investigate if this is also the case in 
Achilles tendinopathy. The possibility of gene-gene interactions between the 
COL5A1 and COL1A1 genes cannot be excluded since they are both intimately 
involved in fibrillogenesis. Future genetic and ex vivo studies with the functional 
variants of COL1A1 and a larger sample size are necessary to explore whether 
altered COL1A1 gene expression is a possible confounder. 
 
Future experiments should also focus on expanding the current primary fibroblast 
study in order to control for other interacting variants and explore the effect of 
specific genotype combinations on expression of COL5A1 and related genes, both at 





individuals, it is important to repeat these experiments in larger studies to 
compensate for this variation. Furthermore after careful ethical consideration, it 
would be ideal to ascertain COL5A1 mRNA and protein expression in tenocytes from 
tendinopathic and healthy individuals with respect to the 3’-UTR genotype at the 
different loci.  
 
Unfortunately, in vitro mRNA decay assays performed to confirm the above results 
were unsuccessful due to technical reasons (Appendix E) and further work is thus 
required to optimise this assay.  
 
4.2 Identification of C- and T-allelic forms of the COL5A1 3’-UTR  
 
The current study attempted to establish if there were differences in the sequence of 
the COL5A1 3’-UTR in control and Achilles tendinopathic individuals and identified 
two major allelic forms referred to as the C- and T-allelic forms. While the C-allelic 
form corresponds to the wild type sequence and was identified in most of the clones 
generated from asymptomatic controls, the T-allelic form was generally identified in 
the Achilles tendinopathic patients. Importantly, the mRNA stability of the T-allelic 
form was significantly higher than the C-allelic form suggesting that more pro-α1(V) 
chain may be synthesised from the T-allelic form. As mentioned above, the 
preliminary mRNA expression study suggests that the relative mRNA abundance of 
COL5A1 may be increased in the presence of the TT genotype at rs12722 which is a 
contributor of the T-allelic form. Further work is however required to determine 






Although 49 polymorphisms have been identified within the COL5A1 3’-UTR 
(www.ncbi.nlm.nih.gov, accessed on 18 January 2011), the allele frequencies of 36 
of these polymorphisms is currently unknown and most are probably likely to be rare. 
Two of these variants, rs71746744 (-/AGGG) and rs16399 (ATCT/-), nevertheless 
contributed to the major COL5A1 allelic form and, as shown in this thesis, have a 
relatively high minor allele frequency in this population. Only seven of the remaining 
13 polymorphisms, with allele frequency data, had a minor allele frequency of >20%, 
of which five, rs13946 (C/T), rs12722 (C/T), rs3196378 (C/A), rs1134170 (A/T) and 
rs3128575 (T/C), were also identified within the COL5A1 3’-UTR allelic forms. This 
thesis demonstrate that the two major COL5A1 3’-UTR allelic forms were determined 
by seven tightly linked polymorphisms. Based on (1) the available information for the 
identified COL5A1 3’-UTR polymorphisms within the public databases, (2) the limited 
number of clones generated and sequenced within this study, and (3) the strategy of 
only cloning the “extreme” phenotype and specific genotypes for the single 
nucleotide polymorphisms rs13946 and rs12722, it is not surprising that only the wild 
type (C-allelic form) and a single allele (T-allelic form) associated with tendinopathy 
were identified. The sequence of the seven polymorphisms for the C- (wild type) and 
T-allelic form were C-C-C-(AGGG)1-(ATCT)2-A-T and T-T-A-(AGGG)2-(ATCT)1-T-C 
respectively. Sequencing of a larger population would be required to identify other 
potentially functional forms of the 3'-UTR. 
 
Using an in silico approach, it was demonstrated that the C- and T-functional forms 
had clearly different predicted structural differences in their most stable state 
(Abrahams et al., 2013) (Figure 4.1). Furthermore, analyses of the 2.5kb COL5A1 3’-





functional forms were due to the sequence differences within the seven polymorphic 






Figure 4.1 The most stable predicted secondary structures of a region belonging to the C 
(left panel) and T (right panel) functional forms of the COL5A1 3’-UTR modified from 
Abrahams et al., 2013. This region contains both polymorphic miRNA binding sites, single 
nucleotide polymorphism (SNP) rs11103544 (T/C) (in blue) and SNP rs3196378 (C/A) (in 
red), and the AGGG variable nucleotide tandem repeat (STRP) (rs71746744, in purple). The 
region to which Hsa-miR-608 (red box, bottom inserts) and the second unknown miRNA 
(blue box, top inserts) binds are expanded in the boxed inserts. Nucleotide positions within 
the 3’-UTR are also indicated. The secondary structures were generated using the Sfold 





4.3 Variants rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 
(A/T) are also associated with Achilles tendinopathy 
 
A key novel finding of this study was that three additional sequence variants, namely 
rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T) are also 
independently associated with Achilles tendinopathy. Specifically, the AGGG/AGGG, 
-/- and TT genotypes of rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 
(A/T) respectively were significantly over-represented in the tendinopathic 
participants. There was approximately a two-fold increased risk of developing 
chronic Achilles tendinopathy with any one of these three genotypes, which are 
tightly linked (D’ ≥ 0.87) and located within a 256bp region of the COL5A1 3’-UTR. 
All three COL5A1 3’-UTR variants assayed in this study are between nucleotide 
positions 1016 and 1272 downstream of rs12722 and linked to this variant as well (D’ 
≥ 0.55).  
 
In addition, since a MIR608 polymorphism (SNP rs4919510, C/G) was also 
independently associated to Achilles tendinopathy (Abrahams et al., 2013) and the 
COL5A1 3’-UTR contains a functional Hsa-miR-608 binding site, genotype risk score 
frequency distributions were calculated consisting of the independently associated 
MIR608 and the three COL5A1 3’-UTR, rs71746744, rs16399 and rs1134170, 
polymorphisms. The highest risk score, consisting of all the ‘at risk’ genotypes, was 
significantly over-represented in the symptomatic compared to asymptomatic 
participants, with or without MIR608 included in the analysis. This finding supports 
the polygenic nature of musculoskeletal soft tissue injuries and other related 






Allelic interaction of the variants in the COL5A1 3’-UTR was studied and inferred 
haplotypes were constructed with (1) six of the seven polymorphisms and (2) the 
three recently genotyped variants, described above, which distinguished the two 
forms of the 3’-UTR. Interestingly, in both cases, the inferred haplotype representing 
the T-allelic form was significantly over-represented reinforcing what was observed 
when the clones were sequenced. Furthermore, a recent cross-sectional study has 
determined that the COL5A1 rs71746744 was independently associated with pre-
race joint range of motion and running performance during the Two Oceans 56-km 
ultramarathon road race in 2009 and 2011 (Abrahams et al., 2014). The 
AGGG/AGGG genotype was significantly over-represented in the fastest and 
inflexible athletes compared with those with either the -/AGGG or -/- genotype. 
Together, these findings strengthen the associations linking the COL5A1 3’-UTR to 
an involvement in the biomechanical properties of soft tissues. Research has 
primarily focussed on the association of rs12722 (C/T, BstUI RFLP) with various 
musculoskeletal soft tissue injuries and exercise-associated phenotypes in 
Caucasian population groups. The novel independent association of variants 
rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T) with chronic Achilles 
tendinopathy reported in this thesis should be investigated in all the other 





4.4 A 57bp Region of the COL5A1 3’-UTR Confers mRNA Stability 
 
The COL5A1 3’-UTR contains several putative polyadenylation signals (Ross, 1995) 
and miRNA binding sites (Meola et al., 2009) and to begin to identify the regulatory 
elements within the two major COL5A1 3’-UTR allelic forms, deletion constructs 
(Δ488bp and Δ57bp) were generated to include or exclude some of these. These 
constructs were cloned downstream of a luciferase reporter and luciferase activity 
measured as an indication of their impact on COL5A1 mRNA stability. A deletion 
construct (Δ488bp) in which two of the three putative polyadenylation signal sites 
were removed had significantly higher luciferase activity in the T-allelic form compare 
to the C-allelic form. Generally, however there was a significant increase in 
luciferase activity of the Δ488bp constructs for both allelic forms when compared to 
their respective parental full length constructs. This suggests that this deleted region 
of the 3’-UTR contain novel regulatory elements which do not appear to contribute to 
the tendinopathic phenotypes. Further work is required to identify these regulatory 
elements and their role in regulating COL5A1 expression.  
 
When the Δ57bp constructs for the C- and T-allelic forms were compared there were 
no differences in their luciferase activity. This suggests that this region must contain 
regulatory elements responsible for the different impact of the C- and T-allelic forms 
on COL5A1 mRNA stability. The Δ57bp region contains the following 
polymorphisms: (1) rs71698207 which did not contribute to the major T- or C-allelic 
form and was not investigated at the genetic level (Table 3.1), (2) the associated 
rs71746744 which is a contributor to the major allelic forms and (3) one of the 





4.2). Although the putative miRNA binding site within the 57bp region is polymorphic, 
we have previously shown that the SNP within this site (rs11103544) is not 
associated with chronic Achilles tendinopathy (September et al., 2009). In addition, 
this SNP together with rs71698207 was not one of the major sequence variants that 
differentiated between the C- and T-functional forms of the COL5A1 3’-UTR. A site-
directed mutagenesis experiment indicated that this site does not have implications 
in the tendinopathic phenotype and that possibly other regulatory sites in the region 





Figure 4.2 Schematic diagram showing the three polymorphisms present in the 57 bp 
deleted region. The polymorphisms rs71698207, rs71746744 and rs11103544 are 




Moreover, in the current study, the upstream rs12722 (T/C) variant, which has been 
consistently associated with various musculoskeletal soft tissue injuries, and 
rs71746744 (-/AGGG) within the functional Δ57bp deletion region were mutated 
independently using site-directed mutagenesis in order to determine whether the 
variants were individually functional. Although some effect was observed in the 
luciferase activity of the rs12722 mutants, none of the two variants were 





C- and T-allelic forms. These results suggest that there might be complex 
interactions at play in the 3’-UTR where not a single element or region within the 
area is responsible for the observations. It is also possible that the two unexamined 
variants, rs16399 (ATCT/-) and rs1134170 (A/T), may contribute to the phenotype 
but future experiments need to investigate this possibility. Moreover, to study the 
possible coordinated role of different sites within the 3’-UTR on mRNA stability, the 
effect of modifying the untested variants one at a time or combining different variants 
should be examined by site-directed mutagenesis. 
 
4.5 Differential Binding of RNA Binding Proteins (RBPs) to the C- and 
T-allelic forms. 
 
Although we initially focused on the functional polymorphic miRNA binding sites 
within and downstream of the Δ57bp region, they did not appear to significantly 
contribute to the tendinopathic phenotype. In an attempt to explore other regulatory 
units in the deleted 57bp region, putative sites for RNA binding proteins were 
investigated in the region. This study reports differential RNA-RBP complex 
formation within this region between the C- and T-allelic forms of the COL5A1 3′-
UTR. The putative RBPs believed to bind differentially within the 57bp region of the 
3′-UTR are primarily involved in translation initiation, RNA biogenesis and/or in 
shuttling the RNA between the nucleus and cytoplasm (Glisovic et al., 2008;Hogan 
et al., 2008;Ross, 1995). A distinct signal was detected when both the nuclear and 
cytoplasmic extract was assayed with the C-allelic RNA probe but not the T-allelic 
RNA probe. This indicates that a protein(s), present in both the cytoplasm and the 
nucleus, preferentially binds the C-allelic RNA probe i.e. is able to distinguish 
170 
between the two forms, accounting for the tendinopathic phenotype. Further work is 
needed to determine the specificity of the different RBP-RNA binding complexes 
observed and the identity of the RBP(s) responsible for these findings. It is 
imperative that these include competition assays with non-biotinylated RNA probes. 
Further studies should aim at repeating the experiments in a relevant cell line such 
as the primary skin fibroblast cell lines or tenocytes cell lines. In addition, the identity 
of the putative RBP(s) involved in the complex formation should be determined by 
the use of antibodies against the RBPs detected via in silico analysis of the region 
and/or by systematically mutating the putative RBP binding sites. In light of the 
mRNA expression and mRNA stability studies, it would be interesting to determine if 
the RBP complex associated with the C-allelic probe leads to increased COL5A1 
mRNA degradation i.e. whether it is responsible for the decrease in C-allelic mRNA 
stability compared to the T-allelic form.  
4.6 In Perspective 
As reviewed in chapter 1, musculoskeletal soft tissue injuries and other exercise-
associated phenotypes are multi-factorial and multigenic in nature. Numerous 
intrinsic and extrinsic factors interact together to determine the biological variations 
within these phenotypes. Specifically the common C to T rs12722 polymorphism 
(BstUI RFLP) within the COL5A1 3’-UTR has previously been associated with a 
number of sports and occupational injuries as well as, performance-related 
phenotypes (Abrahams et al., 2013;Brown et al., 2011;Brown et al., 2011;Burger et 
al., 2014;Mokone et al., 2006;O'Connell et al., 2013;Posthumus et al., 





these phenotypes are all directly or indirectly associated with the mechanical 
properties of musculoskeletal soft tissue. It has therefore been hypothesised that the 
mechanical properties of musculoskeletal tissue are determined, at least in part, by 
variants within the COL5A1 gene (Collins and Posthumus, 2011). Indeed, the 
reported associations imply that there is an increased type V collagen production 
among individuals with a COL5A1 rs12722 TT genotype, which results in structural 
and architectural changes within the collagen fibril. Furthermore, these changes 
result in altered mechanical properties of musculoskeletal soft tissues, which in turn 
associate with increased risk of specific injuries and muscle damage, as well as, 
reduced joint ROM (flexibility), and increased endurance running ability (Collins and 
Posthumus, 2011). 
 
The novel findings of this thesis supported the hypothesis of Collins and Posthumus 
(2011). The COL5A1 rs12722 TT genotype was associated with increased 
expression of the COL5A1 gene in primary human skin fibroblasts, while the 
COL5A1 rs12722 T allele was associated with increased mRNA stability. In addition 
two major functional forms of the COL5A1 3’-UTR were identified and three 
additional polymorphisms, rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 
(A/T), within the 3’-UTR were shown to be independently associated with chronic 
Achilles tendinopathy. Specifically, the AGGG/AGGG, -/- and TT genotypes of 
rs71746744, rs16399 and rs1134170 respectively, were associated with increased 
risk. As illustrated in figure 4.3, the four independently associated polymorphisms 
appear to alter the predicted secondary structure of the 3'-UTR (Abrahams et al., 
2013). It is proposed that changes in the secondary structure may affect the post-





gene expression of COL5A1; and by implication, type V collagen production. Since 
type V collagen regulates fibrillogenesis, this may in turn affect the mechanical 
properties of connective tissue. As a result, the tissue with reduced risk for specific 
injuries and possibly muscle damage, as well as, increased joint ROM (flexibility), 
and decreased endurance running ability, will contain larger less densely packed 
fibrils. The tissue containing smaller more densely packed fibrils on the other hand 
will be at increased risk of specific injuries and muscle damage, as well as, reduced 
joint ROM (flexibility), and increased endurance running ability (Collins and 
Posthumus, 2011;Ribbans and Collins, 2013) (Figure 4.3).  
 
Although the molecular mechanisms underlying these observations are not yet 
understood this thesis started investigating possible regulatory mechanisms and 
suggests future directions for research. Evidence in mouse skin matrix (Chanut-
Delalande et al., 2004), from Col5a2 targeted deletion experiments, highlights a 
conceivable manner in which this could occur. An increased stability of COL5A1 
mRNA may lead to an overexpression of the α1(V) chain and a resulting increase in 
the α1(V)3 homotrimers. As displayed in their experiments, this may favour the 
assembly of the latter as opposed to the major isoform of type V collagen, 
α1(V)2α2(V), and lead to atypical assembly of heterotypic collagen fibrils. Transgenic 
mouse lines overexpressing the human pro-α1(V) chain in the epidermis (Bonod-
Bidaud et al.,2012) displayed an accumulation of unmasked α1(V)3 fibrils at the 
epidermis–dermis interface. Ultrastructural modifications and changes in 
biomechanical properties were observed, although not statistically significant. To 
examine this possibility further, prospective studies should measure the mRNA 









Figure 4.3 A schematic diagram representing the proposed mechanism of how COL5A1 
may increase (right panel) and decrease (left panel) the risk of chronic Achilles tendinopathy. 
Firstly (1) the four polymorphisms rs12722 (C/T), rs71746744 (-/AGGG), rs16399 (ATCT/-) 
and rs1134170 (A/T) within the 3’-UTR are independently associated with tendinopathy and 
(2) appear to alter the predicted secondary structure of the 3'-UTR. (3) The post-
transcriptional regulation of the mRNA affects the mRNA stability as well as the gene 
expression of COL5A1 and by implication will affect type V collagen production and (4) since 
type V collagen regulates fibrillogenesis, this may affect the mechanical properties of 
tendons. As a result, (5) the tendon with reduced risk of injury will contain larger less densely 
packed fibrils while the tendon with increased risk may contain smaller more densely packed 






In addition, since type V and type XI collagen shares structural and functional 
homologies, Hay et al. (2013) investigated whether functional polymorphisms within 
the genes encoding type XI (COL11A1 and COL11A2) and type V (COL5A1) 
collagens interact with one another to collectively modulate the risk for chronic 
Achilles tendinopathy. Specifically, the authors reported the association of the 
TCT(AGGG) inferred pseudohaplotype, constructed from the COL11A1 (rs3753841 
T/C and rs1676486 C/T) , COL11A2 (rs17999079 T/A) and the COL5A1 rs71746744 
(-/AGGG) genes, respectively, with an increased risk of chronic Achilles 
tendinopathy (Hay et al., 2013). Interestingly, the rs1676486 polymorphism within 
exon 62 of COL11A1, which is associated with lumbar disc herniation in a Japanese 
population, results in an amino acid substitution (Pro1535Ser), which could 
hypothetically cause a conformational change in type XI collagen (Mio et al., 2007). 
More importantly, the T allele of rs1676486 was also associated with increased rate 
of mRNA degradation in their experiments.  
 
Type XI collagen is produced during tendon development but whether it is produced 
in the mature healthy, injured or in the healing tendon is currently unclear (Wenstrup 
et al., 2011). Indeed, Wenstrup et al. (2011) demonstrated coordinate roles for 
collagens V and XI in the regulation of fibril nucleation and assembly during tendon 
development. In light of the findings presented in this thesis, the combined findings 
by Hay et al. (2013) and Mio et al. (2007) as well as the documented homology in 
structure and function of the two collagen types (Fichard et al., 1994;Wenstrup et al., 
2011), it is tempting to speculate, granting the multigenic and multifactorial nature of 
soft tissue injuries, that type V and XI collagen may interact in modulating the risk for 





above (Collins and Posthumus, 2011;Hay et al., 2013) (Figure 4.4). As previously 
mentioned, the COL5A1 rs71746744 (-/AGGG) and COL11A1 rs1676486 (C/T) 
polymorphisms are part of an inferred pseudohaplotype that is associated with 
chronic Achilles tendinopathy. The COL5A1 rs71746744 deletion (-) allele and the 
COL11A1 rs1676486 T allele are associated with increased mRNA degradation as 
described (Figure 4.4; left panel). The altered mRNA stability associated with these 
polymorphisms is believed to result in altered α1(V) and α1(XI) chains and types V 
and XI collagen production. Since types V and XI collagen regulate collagen fibril 
assembly and diameter (fibrillogenesis), this may alter the mechanical properties of 
tendons. Given the inverse relationship between the types V and XI collagen content 
of the fibril and its diameter during tendon development (Wenstrup et al., 2011), 
thinner and more densely packed collagen fibrils, which are associated with chronic 
Achilles tendinopathy (Collins and Posthumus, 2011), are expected due to the 
increased production of types V and XI collagen (right panel). The association of 
these type XI collagen gene polymorphisms, as well as their interaction with the 
COL5A1 3’-UTR polymorphisms, with the other injury and performance-related 










Figure 4.4 A schematic diagram representing the proposed mechanism by which 
polymorphisms within COL5A1 and COL11A1 potentially affect fibrillogenesis (Hay et al., 
2013). (1) The COL5A1 rs71746744 and COL11A1 rs1676486 polymorphisms are part of an 
inferred pseudohaplotype that is associated with chronic Achilles tendinopathy where the 
COL5A1 rs71746744 (-/AGGG) deletion (-) allele and the COL11A1 rs1676486 (C/T) T allele 
are associated with increased mRNA degradation (left panel). The scenario depicting 
decreased mRNA degradation is indicated in the right panel. (2) The altered mRNA stability 
associated with these polymorphisms is believed to result in altered α1(V) and α1(XI) chain 
and types V and XI collagen production (3) Types V and XI collagen regulate collagen fibril 
assembly and diameter (fibrillogenesis), hence altering the mechanical properties of 
tendons. Of note, there is an inverse relationship between the types V and XI collagen 
content of the fibril and its diameter during development as described in Wenstrup et al. 
(2011). Thinner, more densely packed collagen fibrils will be produced due to the increased 
production of types V and XI collagen (right panel) where thinner fibrils are associated with 






As reviewed in chapter 1, the exact biological mechanisms that cause tendinopathies 
are poorly understood. Several theories have however been proposed, which include 
the mechanical theory (Arnoczky et al., 2007;Wren et al., 2003), vascular theory 
(Fenwick et al., 2002;Langberg et al., 1998), the ‘neurogenic’ hypothesis (Alfredson 
et al., 1999;Andersson et al., 2008;Bjur et al., 2005), the iceberg theory (Fredberg 
and Stengaard-Pedersen, 2008) and the pathology continuum theory (Cook and 
Purdam, 2009). Although alterations in the structure and mechanical properties of 
the collagen fibril instinctively appear to support the models that propose that 
mechanical overuse of tendon is the primary inciting event in tendinopathy (the 
mechanical and iceberg theories), biological variation in the structure of the collagen 
fibril is likewise consistent with any of the theories that propose that the cellular 
responses within the tendon are the primary initiating event. Tenocytes and other 
soft tissue cells are able to detect and respond to the mechanical load applied to the 
collagen fibrils in the extracellular matrix of tendons (Arnoczky et al., 2002;Wall and 
Banes, 2005). Due to the physical link of the ECM to the cytoskeletal proteins in the 
tenocytes via integrin and other transmembrane receptors, these cells are able to 
respond appropriately or pathologically to mechanical loading (Khan and Scott, 
2009). Type V collagen has specifically been reported to be involved in cellular 
remodelling in response to mechanical forces (Nakatani et al., 2002) as well as in 
apoptosis and angiogenesis (Luparello and Sirchia, 2005;Merwin et al., 1990;Nardo 
et al., 2014;Souza et al., 2010), demonstrating its importance in the cellular 







Common polymorphisms within COL5A1 3’-UTR are believed to result in alterations 
in type V collagen production. Changes in the expression of type V collagen is 
hypothesised to affect fibrillogenesis and by implication the mechanical properties of 
musculoskeletal soft tissues. Variants within the 3’-UTR have been associated with 
recreational and occupational musculoskeletal soft tissue injuries, as well as other 
exercise-associated phenotypes. Since the function of the COL5A1 3’-UTR is 
unknown and the region contains several putative regulatory elements, the primary 
aim of this thesis was to determine whether the COL5A1 3’-UTR was functional and 
whether this genomic region contains common polymorphisms responsible for 
measurable functional variations that may regulate its gene mRNA stability and 
expression. This is relevant because changes in mRNA expression of COL5A1 may 
lead to changes in the α1(V) chain protein production and the synthesis of type V 
collagen.  
 
Two major functional forms of the COL5A1 3’-UTR were identified in this thesis. In 
addition three additional polymorphisms, namely, rs71746744 (-/AGGG), rs16399 
(ATCT/-) and rs1134170 (A/T), downstream of rs12722 (T/C), were identified within 
the functional forms and shown to independently associate with chronic Achilles 
tendinopathy. The C-functional form, which corresponded to the wild type sequence, 
was predominately identified in asymptomatic controls with the “protective” CC 
rs12722 genotype and was associated with decreased mRNA stability and COL5A1 





chronic Achilles tendinopathic patients with the ‘at risk’ TT genotype and was 
associated with increased mRNA stability and COL5A1 gene expression.  
 
The major functional region of the COL5A1 3’-UTR, responsible for the tendinopathic 
phenotype, was mapped to a 57bp region containing rs71746744 (-/AGGG) and 
several putative RNA binding protein motifs. Preliminary analysis of this region 
showed differential RNA-RBP complex formation within this region between the C- 
and T-allelic forms of the COL5A1 3′-UTR. Finally, this thesis provides molecular 
evidence for the proposed hypothesis that polymorphisms within the COL5A1 3’-
UTR alter fibril architecture and structure and, thereby, mechanical properties of 
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SKIN PUNCH BIOPSY INFORMED CONSENT 
I, the undersigned, h9'Ve been fultyinformed about the UCT/MRC Research Unit for Exercise Science a nd 
Sports Med;cinewithinthe Depsrtment o fHumsn Biology of the Univef'SityofCape Town's s tudyto identify the 
functionsl rro~ of vs riants within the extrscelluisr ms tix (connective tGsue) g eneson muscutoskeJe'lsl soft tissue 
injuries. us ing primsry humsn fibroblsst ceO Jines. A s ingle skin punch biopsy (34 mml., wiD be used to culture 
primsry skin fibroblast oeO lines. A fibroblsst is s type o f ce'D ths t synthesizes the structural framev..'Ork 
(extrs oellu lsr ms trix and ooll&gen) for tissues. The punch biopsywiU be d one bys trs ined medics I practitioner. 
A ll the info rmstion th9t isoolleded during the s tudywiU be tresiedwith the strictest oorrftdentislity s nd will onty 
be used forscientific research purposes. Nsmes s nd persona l particulars will be not re~ased under sny 
circum~tsnces s nd sU d s ts will be snatysed s nonymousty. 
I sgree to p srticipste in the s tudy sndto donsie s s ing6eskin puoch biopsy as d escribed s bove. I hsve been 
informed that I will be free to \\•ithdrsw from the study at any time if 1 so wish. The tissue samples will be 
d estroyed onoompletion ofthestudyto identify the function-s ! role o f varisnts within the exttsceUuls r matrix 
(connective tissue) g enes on muscuklskeletslsofttissue injuries. using primsry humsn fibrcblsst ceO lines. I 
-s lso understsndthstl will be free to req uest thstmytissuessmple be d estroyed before the comp6etion o f the 
study. 
The po terrtislrisksassocis 'ledwiththeskin pund'l biopsy technique from the forearm s re: infection, d elayed 
hesling, phys ic91 pain.ment:91disoomforts ndinjuryto s nerv-e o r s vessel. These risks s re smsll s nd will be 
minimized by the use o f trsined meOICsl prsctitioner. use ofsten1e techniquesand the use of disposable. sing6e 
Ya ms terisfs. 
The tissue sample will be cultured end ans lysed us ing s variety o f molecular techniques to d etermine the 
functio nsl oeffed s o f DNA sequence variations (polymorphisms) w:ithin csndidste g enes for musculoskeletal soft 
tissue injuries. such ss the COL5A1 and COUiA1genes.Arry remsining tissuewlll be discsrded sppropriatefy. 
There is no d irect benefrt to myself !)Q)~Y~( this msy allow b etter prevention s nd treatment options for 
musculosk eletsl soft tissue injuries in the future. I understsnd thst I wiD receive the ow r911 resutts of the study. I 
~ 
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7"-e .,. ·~~Q'IO!)e-t~ "S~'::~ '».X. : !1. 0'!~-:._ C?,».~.- ':! :.·.o e.•..,.,:~ .e~:..:­
~.e..'!: ~s~:. X! :s ....:u?"O"o:>:."""«"'!:C"': ::. ~-~.:.·cs.:-.:>.=.'$-) 




































On average, howtimesa d!;ldoyou performs stretching session? ~ timesldsy 
Q H9mstrings p Qu adriceps 
PJesse tick which musclegroupsdoyou incJude D Cs tf (gastrocnemius) 
in your stretch~ session? D Cstf(soJeus) 
D Groin (inner thigh) p Upper body runbs 
D Other: 
PJease tick when yousi:tetd'l? ~.during aodfor sfter 
bl]Before Exercise 
exercising. You can tick more thsn o ne box) 8 During Exercise 
A fter Exercise 
When you stre~h an :individual muscle group, onawf89e. how - seconds lo!!Qdo~ou holdthe stretch for? D u noe 
p Tw;oe 
When youstre~h an indil.·idual muscle group. on swrsge. how D 3times 
ma~times do~u stretch the muscle for? D 4times 
D 5 times 
D 6 or more times 
D. TENDON INJURY· MEDICAL DETAILS 
Symptoms 
How many t imes haw Tendon Injured 
u ate or __ ,..cute or _ ~uooen or 
Injury Chronic Injury Grsdust Onset 
you had tendoninjuries? 
' 
1Suddenonse1 is wi!hina ,. 
few seconOsor m.inU1e:S 
I" 
~ra.dt.taloBSe1 is over I ' 
days or weeks I " 
Please complete a separate form, Part 0 only, for each Tendon Injury you have had 
Injury Number (1.2-).A..ol-5) o, 02 03 o. Os 0 
Rotstorcufftendon D P-stellartendon D 
• Suprsspinstus D W rist extensor tendons D Which t endon did you injure? 
0 0 • ~o;>.ill3M Achilles t endon 
• ~minor 0 
Which side was injured? D Left D Right 0 Both 
0 Upper1/3 0 MK!dle 1/3 0 Lowe r 1/3 
Which regionofyourtendon 
was injured? Please indicate 













E. HISTORY OF OTHER LIGAMENT ANOTENDON INJURIES IN THE PAST 
Ha\o-e you ever injured a tigannent in fle YesD No D past? 
L " L " 
Knee (ACL) DO Wrist f~gsments DO 
If yes, p)ease specifywh;ch ~aments? Knee (MCL) DO Finger ligaments DO 
f(ou may t ick more thanoneb5ock. 
An Ide lsteral ligaments 0 0 DO pJesse se.lect eiiher l {left) o r R (right}) Knee (PCL) 
Spina l lig9ment~ DO Knee (LCL) DO 
Shoukterligsments DO A.nkJe med is l ligsmerris 0 0 
Elbow f~gsments DO Other ligaments DO 
If Y es. please specify the family member 
0 Mother 
0 Father 
To your knowledge, hsve any other 
YesD NoD 0 S ibling membersofyourfamilysuffered from 
any ligament injury? 0 Son I d aughter 
0 Other fsmity member ... . . ..... . .. .... ...... .. 
3.09. condition: Please choose ligsment 
injury from the frst above 
........................... .............. ..... .... ... 
Ha\o-e you ever injured a tendon in the YesD No D past? 
L R 
Foot a nd s nide: Achilles tendon DO 
~posterior DO 
Plsnts r fssOs DO 
Knee: Pstellsr tendon DO 
If yes, please specifywhich tendon? 
Elbow sndwrist: Wrist extensor tendons 0 0 {You may tick mo-re thano.nebklck. 
















Opers tion Dste 
What surgic:aloperationshaw you 
hsd? (piess-elistandgivedates) 
If female: 
At what age didyoustart 
menstruating? {years) 
Are you currently using any tweof 0 Yes DNo oonttsception? 
If Yes, wbat tweofoonhoeption are D Pill 0 Injection Dtuo you using? 
0 Pre 4 menopaussl (:t12cycles perye9l' s t in'lervalsof2~ 
33 d sys & bJeeding lssts3 4 7 dsys) 
Are you currently? 0 ~r\enopsusal (cyc~ssre irregutsrsnd iess fcequent) 
0 Post 4 menopsussl (noklnger mens1rusting) 
Family History 
If Yes, which t~e lstive? 
0 Mother 
Do any other membersofyour famity 
suffer from elevated bklod chotesteror? YesD NoD 
0 Father 
0 Sibling 
0 Son I d sughter 
0 Other relsti've; ................. 




Is there soy history of arthritis in your YesD NoD 
0 Son I d aughter 
famity? 0 Other relsttve; .. 
&Whsttype of~? 
Rheumstokl D 































Subject N-o: ___ _ 
Section c. Flexibility training history 
Do you perform fle:~aD ility training (regular stretching exe rcises)? I Yes D No D 
If YE S p1ease compSete the rest ofthe flexibility ttsining history section below:-
If NO. continue compSeting the ~uestionnaire from section D. 
On average. how many days a week d o you pe rform a stretching 
d ays/week 
session? 
On s \o-erage, how times .a da~do you p erform a stretching session? times/day 
D Hamstrings 
D Quadriceps 
Please tick which muscle oroupsdo you include in your 
D Catf (gastrocnemius) 
D Csff (soleus) stretching session? D Groin (inner thigh) 
D Upperbodyfunbs 
D Other: 
Please tick when you s tretch? ~.during and/or a fter exercising. 
D Before Exercise 
You can tick more than one box) D During Exercise 
D After Exeroise 
When you stretch an individual muscle group. on ave rag e. how lono do 
seconds 
~u hold the stretch for'? 
D Once 
D Tw jce 
When you stretch an indMclual muscle group. on avetage. how D 3 times 
ma!!l: times do ~u stretch the muscle for? D 4 times 
D 5 times 
D 6 or more times 
Section D. lifestyle and habits history 
Please indicate yoursmokihg status I Current smoker D Ex smoker D I Never smoked D 
If you answe red yes, Number of yesrs of smoking: If stopped. how many yes rss go: 
{past or current 
smoker) please 
complete the section on What is (was) the sversge number of cig-arettes per d ay: 
the right 
glasses beedcider per week 
On aveta_ge. how much alcohol do you d rink per week {tots. g lasses wine per \\'eek 
glasses) o f spirits, wine o r beer? 









Section E. General Personal Medical History 
Do you currently suffer from any of these medical oondftions: 
0 K~gh BJood Pressure 0 Angina/Hesrl Attack 0 A sthms 
D Emphysems 0 Rheumstoid arthritis 0 Osteoarthritis (wear & tear) 
0 Msf~gnsnt disesse (csncer) 0 Elevated Bklod Cho$esterol 0 Adrensldisotders 
If Y es. wh at type? 0 Disbetes melfrtus 0 Thyroid disorders 
0 Renal disesse D Amylo<losis 
Do you currentty suffer from any other 
Connective Tissue. Rheumstobgicsl YesD No D If Y es, plesse select from the list b elow 
Or Musc1e Diseases & Disorders? 
list of some Connective Ttssue -sndfor Rheumatic Diseases and Disorders 
D Ar,kyloiing Spondy~is 0 lipid S1orage Diseases D Ps<Wogou; 
D Aspanylglyeoiamn uri> (AGU) 0 Marfan Syndrome 0 Re3Ctive Anhritis 
D !*.lmU Syndrome 0 Menk:s Kinky Hair Syndrome 0 Reiter's Syndrome 
D ~.lin), Disease 0 MUJCOpotysac:ct.aridoses D Relaps;"S E9!Y9~A 
0 Discoid l u-pus Etyt~...mat0$US 0 Myopathies and Oysuophi:$ 0 Sc?.:roct:rma 
D Ehim.Oanlos synd<ome (EDS) 0 Ooh.rono.sis (Homocystinuria) D ~<A.\ Syndrome 
D Eos;nophooo ~ 0 Osteog.=nesis imp:o..rlecta {01) 0 srs~ ~ E!)~I.IE.'A (SLE} 
0 Giam CeU {Te.mpor.af} Ant.rit ts 0 Polyarteritis No:Sosa 0 Systemic Sc~rosis 
D Gou; 0 fl(t~J!lYA!im Bh.<s:!or!ll~tjsj 0 Weg~ner's Granu!omatosjs 
0 Hyp:rsentive Vasu:la!is D fRilu!ly~ & P.or~~llis- D BJJO.~Wii;. 
0 Musculatdysirophy 0 Myopathy D Ot~r 
Opet9tion Dste 
Whatsutgicsl operations h ave you 
had? (p\ease list and give dates) 
lf~male: 
At what age dM:i you start menstruating? {years) 
Are you currentty us ing any type ofcontrsception? DYes 0 No 
If Y es. what type of contraception are you using? D p;n 0 Injection D IUD 
0 Pre-menopausal (±12 cycles per yest at intervals of23- 33 d sys & 
bleed ing lasts 3-7 d ays) 
Ate you cufl'entty? 0 Menopaussl (cycles sre irregular s nd less frequent) 






















Subject No: ___ _ 
Section H. Muscle Cramping 
Have you ~in your athfeticeeteer suffered from muscle crampina {painful, 
spontaneous, sustained spssrrof a muscle) during or immediately (within 6 hours) Yes D No D 
afte-r exercise (m training or competition) 
If YES please cornpJete the .rest of the musde cramping section beklw:-
If NO, continue completing the questionnaire from section I. 
For how many years have you suffered f rom cramping? (ye•rs) 
Did you suffer from cramping dJring or after exercise in the last 12 months? Yes D No D 
With what tvP' of exercise is )'OUr cramping associsted D Swimming D ~ng D Running (You can tiCk more than one foJm of exercise}? 
In the last 10 races or 
trainina sessions, how many Races: __ 110 
times have you experienced Trsining sessjons: __ 11 0 
cramping? 
D Stretching D Resting 
What treatmenVs have vou hac that D DrinkinR flu id D Ice .sppfiCstion 
successfull:ll rel ieved an acut-e cramp? D Massage D Magnesium 
(can tick: more than one) D Salt (tsblets o r solution) 
D Othe< (Specify: ) 
At what eoint in the race or tnini!!Q run 
~ FtrSt qusrter ~ Second qu-srter 
do you usualty first experience cramping? 
D Third quarter D Fourth quarter 
D After the rsce D No psttem 
In which muscles do you usuelty cramp D C.IYes D Hamstrings 
(pSease Jist t!J..~ by the cne which 
D Ousdriceps (thigh) D Foot muscles cramps most frequently (as 1) and the 
D Othe< (Specify: ' others afte-r that (2-4)? 
Have you ever suffered from ci"EEmpin_g in your whole bodv {arms and-legs)? Yes D No D 
Have you ever been admitled to hose!tal following cramping? Yes D No D 
Have you ever been confused or in a coma during o r after a cramping episode? Yes D No D 
Have you ever hsd "dark urine" in the 3 days following s cramping episode? Yes U No U 
If you cramp, how lo!!Q does tre cramp -ususlty' lsstfor{min)? I (minutes) 
If you cramp. how~ is D Mild: < 5 minutes snd you s re s ble to continue exercising 
the cramp ususly? ~..M: .. D f .. -toders te: 5·15 minutes snd you sre able to continue exercising 
































Subject No: ___ _ 
SECTION K. MEDICAL DETAILS OF TENDON INJURIES 
Symptoms 
How msny times h a't-e Tendon Injured 
Date of Acute or Sudden1 or 
Injury Chronic Injury GtsduajZ Onset you had tendon injuries? 
1 
1Sudden onset is Within s 2 
few seconds or minutes 
3 
~rsduslonset is over • d ays or weeks 
5 
+ 
Please complete a separate form, Part K onty, for e ach Te ndon Injury you hsve had 
Injury Number (1.2.3..A.,.oc 5) 
(i 1 02 0 3 0 4 0 5 (l ---
Rotator cuff tendon 0 Ps tellsr tendon n . Suprsspin-s tus 0 Wrist extensor tendons 0 
Which tendon did you injure? • !nfa.o.plMI!!o 0 Achilles tendon D . ~minor 0 
Which side was injured? 0 l eft 0 R;ght 0 Both 
D Upper 1/3 D MiddSe 1/3 i) lo\\'et 1/3 
Which .region of your tendon was 
ll"'juted? Please indicate on a 
disgf8m. (Onty if applicable) 
To what extent was your Tendon 
OComplete 0 Partial 0 None ruptured? 
How were you injured? 
(e.g. sport. walking) 
0 psin only after exercise 
U psin during exercise. but did notcsuse you to s ttertrsining 
0 p9in during exercise. which csuses you to s ttet tr3ining 
0 psin which csuses you to s top tf9ining 
Grade o f injury at the time of !l no psin 
injury 6 not sure 
!l Other (Specify ) 
0 pain only 9fter exercise 
DR=WJ.during exercise. but did notcsuse you to a lter training. 
D pa in during e xercise. which csuses you to 9iter trsining 
0 p9in which csuses you to stop training 
Grade o f injury currently 
U no psin 
0 not sure 








D Psin ('ess than 1 week) D Stiffness 
Which of the foflowing symptoms 
\\'ere ptesent before the injury D Psin (14 \\<eeks} D S\\>etling 
U Pain (> 4 \\<eeks) 0 None 
0 Pain (less than 1 \\'eek} 0 Stiffness 
Wh;ch of the follo\\.mg symptoms 
we.re present after the injury 0 Psin (14 \\'eeks} 0 S\\-etflng 
0 Pain (> 4 \\>eeks) 0 None 
If you have or had chronic 
tendon pain, what seems to 
alleviate the pain? 
Diagnosis 
Which type of Tendon Disease \\'e.re you I 
d iagnosed with e.g. Rupture, Tendinitis, etc. 
Diagnosed by 0 Doctor 
D Physiotherapist 
{PJease indicate the name and 0 !li9l<ios.~l 
contact numbe-r of the clinician 0 Pod iatrist 
who diagnosed you} OOther 
If you had a tendon rupture. 
0 Surgjcslty f!Non-surgicslty How was it treated? 
If applicab.le, who was the 
Surgeon Phone 
surgeon? 
If applicable, whatd19gnostic 
0 Ultrasound OMRI OCT Other 
ima_ging was performed? 
If appliCable, who did the 




















A.2 Appendix B  














2. Reagents and solutions used for bacterial work and extraction of plasmid 
DNA. 
 
SOB (Super Optimal Broth) (For plating): 
2% w/v Bacto-Tryptone 






H2O to 2L; Autoclaved 
 
SOC (Super Optimal Broth with Catabolic repression) (Growth medium): 
2% w/v Bacto-Tryptone 













2% w/v Difco Bacto-Tryptone 
0.5% w/v Difco Bacto-Yeast Extract 
0.4% MgSO4 
10mM KCl 
H2O to 1L; Autoclaved 
 
TFB 1(Transformation buffer 1) solution 
5ml 1M RbCl 
0.495g MnCl2.4H2O 
0.147g KOAc 
750 mM CaCl2.2H2O 
15 ml of 50% Glycerol 
Adjust to pH 5.8 with glacial Acetic acid 
H2O to 50ml; Filter sterilized 
 
TFB 2 (Transformation buffer 2) solution 
100 mM Mops (pH 7.0 with NaOH) 
1M RbCl 
750 mM CaCl2 
15 ml of 50% Glycerol 






Solution I (GTE) 
50mM Glucose 
25 mM Tris (pH 8.0) 
10mM EDTA 
H2O to 200ml; Filter sterilized 
 
Solution II (Made fresh on the day) 
0.2 M NaOH 
1% SDS 
H2O to 50ml; Filter sterilized  
 
Solution III 
60ml of 5M KOAc (pH 4.8) 
11.5ml of Glacial Acetic acid 
H2O to 100ml; Autoclaved 
 
TE buffer pH 7.5 
10 mM Tris-HCl (pH 7.5) 
1 mM EDTA (pH 8.0) 






DNA extraction from whole blood for the genetic study:
1. Draw 5ml of blood into an EDTA vacutainer tube (Purple top).
2. Blood can be stored at 4°C up to 1 week before the DNA is extracted.
3. Transfer the blood to a sterile 15ml polypropylene tube.
4. Add 2volumes (10ml) of TKM1 buffer containing 2.5% NP40.
5. Mix by inverting several times and incubate at room temperature for 10mins in
order to enhance the haemolysis of the red blood cells.
6. Centrifuge at 3000rpm (1200Xg) at room temperature for 10mins.
7. Decant the supernatant leaving the white pellet at the bottom of the tube.
8. Add 1 volume (5ml) of TKM1 buffer (without NP40) and invert and vortex the
solution.
9. Centrifuge at 3000rpm (1200Xg) at room temperature for 10mins.
10. Decant the supernatant leaving the white pellet at the bottom of the tube.
11. Repeat spteps 7-10 until the pellet in the bottom of the tubes is clean and white.
12. Add 800μl of TKM2 buffer and 50μl of the 10% SDS solution.
13. Vortex and then mix using a blue pipette tip in order to assist in the lyses of the
white blood cells.
14. Incubate for 60mins at 55°C in a water bath.
15. Make sure the pellet is totally dissolved before the next steps.
16. Add 150μl of 5M NaClO4 then 500μl of the molecular biology grade chloroform
and vortex the solution.
17. Transfer the solution to a sterile 1.5ml microfuge tubes.





19. Carefully transfer 500μl of the top aqueous phase to a new sterile microfuge 
tube. 
20. Add 1ml of absolute ethanol and invert until DNA precipitates. 
21. Centrifuge at 1300rpm at room temperature for 5-10mins 
22. Carefully tip off the supernatant leaving the DNA pellet at the bottom of the 
tube. 
23. Allow the DNA pellet to air dry completely and add 200μl of 1X TE buffer. 
24. Incubate the tubes at 65°C for 15 min in a heating block. 









Make up 1 Volume which includes 2.5% NP40 and 1 Volume without NP40 











0.4 M NaCl 
H2O to 200ml; Autoclaved. 
 
10% SDS 
20ml SDS dissolved in autoclaved H2O to 200ml 
Filter sterilised. 
 
1X TE buffer pH 8.0 
10mM Tris-HCL 
1mM EDTA 
H2O to 100ml; Autoclaved. 
 
5M NaClO4 
61.2 grams (5M, MW 122.4) 










A.4 Appendix D 
1. Additional tables of the physiological characteristics per genotype 
groups for the overall South African participants 
 
Physiological characteristics of the three rs71746744 (AGGG/-) genotype groups of the 
South African participants 
 -/- AGGG/- AGGG/AGGG P-value 
Gender  (% Male) 80.00 (10) 57.35 (68) 63.01(73) 0.366 
Age (yrs) a 37.9 ± 12.1 (10) 41.6 ± 13.7 (65) 40.5 ± 12.1 (70) 0.676 
Height (cm) 174.3 ± 7.4 (10) 174.6 ± 10.0 (66) 174.6 ± 9.6(66) 0.996 
Weight (kg) 78.1 ± 13.6 (10) 72.2 ± 12.7 (67) 74.3 ± 12.3 (70) 0.325 
BMI (kg/m2) 25.6 ± 3.8 (10) 23.6 ± 2.8 (64) 24.3 ± 3.1 (66) 0.096 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
 
 
Physiological characteristics of the three rs16399 (ATCT/-) genotype groups of the South 
African participants 
 ATCT/ATCT ATCT/- -/- P-value 
Gender  (% Male) 80.00 (15) 63.33 (90) 70.21 (94) 0.350 
Age (yrs) a 38.6 ± 10.6 (15) 40.1 ± 12.6 (85) 41.2 ± 12.2 (89) 0.696 
Height (cm) 175.4 ± 8.2  (15) 175.3 ± 9.4 (85) 176.2 ± 9.5 (91) 0.817 
Weight (kg) 80.6 ± 13.6 (15) 72.6 ± 12.4 (87) 74.6 ± 13.4 (87) 0.084 
BMI (kg/m2) 25.9 ± 3.1 (14) 23.5 ± 2.9 (83) 23.9 ±  3.0 (86) 0.028 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 







Physiological characteristics of the three rs1134170 (A/T) genotype groups of the South 
African participants 
 AA AT TT P-value 
Gender  (% Male) - 66.34 (101) 69.15 (94) 0.675 
Age (yrs) a - 40.1 ± 12.0 (97) 41.0 ± 11.9 (89) 0.618 
Height (cm) - 175.3 ± 8.9 (97) 176.2 ± 9.5 (87) 0.269 
Weight (kg) - 73.3 ± 12.3 (100) 75.4 ± 13.6 (90) 0.520 
BMI (kg/m2) - 23.7± 3.2 (94) 24.1 ±  3.0 (86) 0.430 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
 
2. Additional tables of the physiological characteristics per genotype 
groups for the overall Australian participants 
 
 
Physiological characteristics of the three rs71746744 (AGGG/-) genotype groups of the 
Australia participants 
 -/- AGGG/- AGGG/AGGG P-value 
Gender  (% Male) 50.00 (18) 42.86 (49) 59.42 (69) 0.203 
Age (yrs) a 41.7 ± 13.4 (18) 39.9 ± 13.6 (49) 43.3 ± 14.1 (68) 0.426 
Height (cm) 173.6 ± 7.4 (17) 170.9 ± 9.7 (49) 173.7 ± 8.7(68) 0.220 
Weight (kg) 75.6 ± 19.7 (17) 74.8 ± 16.5 (49) 77.4 ± 13.2 (70) 0.644 
BMI (kg/m2) 24.9 ± 4.8 (17) 25.6 ± 5.2 (49) 25.6 ± 3.8 (68) 0.822 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 






Physiological characteristics of the three rs16399 (ATCT/-) genotype groups of the Australia 
participants 
 ATCT/ATCT ATCT/- -/- P-value 
Gender  (% Male) 54.55 (22) 42.19 (64) 58.14 (86) 0.148 
Age (yrs) a 44.0 ± 14.1 (22) 39.8 ± 13.7 (64) 42.1 ± 12.6 (85) 0.369 
Height (cm) 171.1 ± 9.7 (21) 171.1 ± 9.5 (64) 173.1 ± 8.6 (86) 0.356 
Weight (kg) 81.33 ± 21.7 (21) 72.0 ± 12.7 (64) 76.3 ± 13.7 (87) 0.027 
BMI (kg/m2) 27.8 ± 7.0 (21) 24.5 ± 3.5 (64) 25.4 ± 3.7 (86) 0.009 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 




Physiological characteristics of the three rs1134170 (A/T) genotype groups of the Australia 
participants 
 AA AT TT P-value 
Gender  (% Male) 50.0 (4) 42.0 (81) 53.8 (65) 0.359 
Age (yrs) a 38.75 ± 13.5 (4) 41.0 ± 13.9 (81) 43.2 ± 13.1 (64) 0.554 
Height (cm) 170.5 ± 10.9 (4) 170.4 ± 9.5 (79) 173.1 ± 8.5 (65) 0.971 
Weight (kg) 75.0 ± 12.5 (4) 75.2 ± 15.4 (80) 75.8 ± 14.2 (66) 0.199 
BMI (kg/m2) 25.7 ± 2.7 (4) 25.2 ± 3.7 (65) 25.8 ±  4.7 (79) 0.657 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 






3. Additional tables of the physiological characteristics per genotype 
groups for the SA tendinopathic participants specifically 
 
 
Physiological characteristics of the three rs71746744 (AGGG/-) genotype groups of the 
South African tendinopathic (SA TEN) participants 
 -/- AGGG/- AGGG/AGGG P-value 
Gender  (% Male) 100 (1) 52.63 (19) 67.74 (31) 0.416 
Age (yrs) a 44.0 (1) 53.1 ± 11.8 (19) 46.6 ± 11.0 (29) 0.153 
Height (cm) 177.0 (1) 174.1 ± 10.1 (18) 174.8 ± 8.9 (26) 0.934 
Weight (kg) 82.0 (1) 73.7 ± 14.6 (18) 78.2 ± 12.3 (28) 0.492 
BMI (kg/m2) 26.2 (1) 24.12 ± 2.9 (18) 25.2 ± 3.0 (26) 0.471 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
 
Physiological characteristics of the three rs16399 (ATCT/-) genotype groups of the South 
African tendinopathic (SA TEN) participants 
 ATCT/ATCT ATCT/- -/- P-value 
Gender  (% Male) 100 (3) 64.29 (28) 77.78 (36) 0.271 
Age (yrs) a 42.7 ± 6.1 (3) 48.7 ± 12.2 (27) 47.8 ± 11.3 (33) 0.687 
Height (cm) 181.83 ± 4.4 (3) 175.3 ± 9.2 (25) 177.8 ± 8.4 (31) 0.340 
Weight (kg) 92.2 ± 11.7 (3) 73.5 ± 14.4 (25) 79.9 ± 13.2 (33) 0.043 
BMI (kg/m2) 27.8 ± 2.4 (3) 23.8 ± 3.5 (25) 24.9 ±  3.3 (31) 0.106 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 







Physiological characteristics of the three rs1134170 (A/T) genotype groups of the South 
African (SA TEN) participants 
 AA AT TT P-value 
Gender  (% Male) - 70.37 (27) 76.32 (38) 0.591 
Age (yrs) a - 48.3 ± 11.0 (27) 47.1 ± 11.8 (35) 0.674 
Height (cm) - 175.9 ± 8.5 (25) 177.6 ± 8.7 (32) 0.441 
Weight (kg) - 73.9 ± 14.0 (26) 80.7 ± 13.7 (34) 0.065 
BMI (kg/m2) - 23.8 ± 3.5 (25) 25.3 ±  3.4 (32) 0.114 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 
yrs, years; kg, kilogram; cm, centimetre. 
 
 
4. Additional tables of the physiological characteristics per genotype 
groups for the AUS tendinopathic participants specifically 
 
 
Physiological characteristics of the three rs71746744 (AGGG/-) genotype groups of the 
Australian (AUS TEN) participants 
 -/- AGGG/- AGGG/AGGG P-value 
Gender  (% Male) 100 (3) 66.67 (12) 75.00 (24) 0.494 
Age (yrs) a 44.7 ± 12.0  (3) 53.4 ± 11.9 (12) 52.0 ± 12.8 (24) 0.561 
Height (cm) 174.0 ± 6.56 (3) 170.6 ± 10.4 (12) 175.5 ± 7.8 (22) 0.305 
Weight (kg) 76.0 ± 16.4 (3) 84.5 ± 19.5 (12) 79.9 ± 11.5 (24) 0.565 
BMI (kg/m2) 25.0 ± 4.4  (3) 28.9 ± 5.2 (12) 26.0 ± 3.8 (22) 0.152 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 





Physiological characteristics of the three rs16399 (ATCT/-) genotype groups of the 
Australian (AUS TEN) participants 
 ATCT/ATCT ATCT/- -/- P-value 
Gender  (% Male) 100 (2) 58.82 (17) 75.76 (33) 0.300 
Age (yrs) a 56.0 ± 5.7 (2) 46.8 ± 14.6 (17) 49.0 ± 11.4 (33) 0.582 
Height (cm) 174.8 ± 0.4 (2) 169.1 ± 11.2 (17) 175.8 ± 6.9 (32) 0.040 
Weight (kg) 107.0 ± 29.7 (2) 76.6 ± 14.6 (17) 81.0 ± 12.1 (33) 0.016 
BMI (kg/m2) 35.0 ± 9.6 (2) 26.7 ± 3.7 (17) 26.3 ±  3.6 (32) 0.012 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 




Physiological characteristics of the three rs1134170 (A/T) genotype groups of the Australian 
(AUS TEN) participants 
 AA AT TT P-value 
Gender  (% Male) - 57.89 (19) 77.27 (22) 0.184 
Age (yrs) a - 49.2 ± 14.5 (19) 49.4 ± 10.8 (22) 0.959 
Height (cm) - 170.6 ± 10.3 (18) 176.1 ± 6.8 (21) 0.053 
Weight (kg) - 83.3 ± 18.1 (19) 81.4 ± 11.0 (22) 0.687 
BMI (kg/m2) - 28.5 ± 5.1 (18) 26.3 ±  3.1 (21) 0.112 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 




Messenger RNA decay assay
Messenger RNA decay assay displaying the fold change of transcripts of the C and T-allelic 
form within the pGL3-COL5A1-3′UTR, as well as that of pRL-TK over time post-treatment. 
The solid black line represents the decay of the T-allelic form; the solid dark grey line 
represents the decay of the C-allelic form while the pale grey solid line represents the decay 
of transcripts of pRL-TK (transfection efficiency control). The broken black lines delimit the 
area used to calculate the area under the curve (AUC). 
